AD	

AWARD NUMBER DAMD17-96-C-6102

TITLE: Phase I Evaluation of Desbutylhalofantrine in Healthy Volunteers

PRINCIPAL INVESTIGATOR: Darrell R. Abernethy, M.D.

CONTRACTING ORGANIZATION: Georgetown University Washington, DC 20057

REPORT DATE: December 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway. Suite 1204. Arignaton. VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 2050-01.

Davis Highway, Suite 1204, Arlington, VA 222	202-4302, and to the Office of Management an	id Budget, Paperwork Reduction Proj	ect (0704-0188), Washington, DC 20503.
1. AGENCY USE ONLY (Leave blar	2. REPORT DATE December 1998	3. REPORT TYPE AND D Annual (14 Sep 97 - 13	
4. TITLE AND SUBTITLE Phase I Evaluation of Desbutylha		5	DAMD17-96-C-6102
6. AUTHOR(S) Darrell R. Abernethy, M.D.			
7. PERFORMING ORGANIZATION N Georgetwon University Washington, DC 20057	IAME(S) AND ADDRESS(ES)	8	PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AND U.S. Army Medical Research and Fort Detrick, MD 21702-5012		S) 1	0. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES			•
12a. DISTRIBUTION / AVAILABILIT Approved for public release; dis		1	2b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 wo	ords)		
		19991	0614 060
14. SUBJECT TERMS Defense omen's Health Research	a program; Halofantrine		15. NUMBER OF PAGES 256 16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICA OF ABSTRACT Unclassified	ATION 20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.
Where copyrighted material is quoted, permission has been obtained to use such material.
Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.
In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).
For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.
In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research involving Recombinant DNA Molecules.
In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature

Date

TABLE OF CONTENTS

DESCRIPTIVE AND SAFETY

Introduction, Text of Report	3 -13
Subject Description	14
Randomization Code	
Study Dates	16
Table 4 (Pharmacokinetic Specimen Times)	17-26
Table 5 (Subject Screening Parameters)	27
Table 6, Figures 1-10 (Subject Vital Signs)	28-54
Table 7, (Female Subject Pregnancy Test)	55
Table 8, Figures 11-22 (Hematological Parameters)	56-79
Table 9, Figures 23-27 (Electrolytes)	80-89
Table 10, Figures 28-45 (Laboratory Profile, Chem 20)	90-125
Table 11, Figures 46-48 (Urinalysis)	126-133
PHARMACOKINETIC AND PHARMACODYNAMIC	
Figure 49 (a-p) Halofantrine Accumulation Kinetics	134-149
Figure 50 Halofantrine Steady State Oral Clearance	150
Table 12, Figures 51-54 (ECG Parameters)	151-177
Table 13, Halofantrine Conc, ECG (Raw Data)	178-207
Figure 55 (a-q) Halofantrine Conc/Time Graphs	208-224
Figures 56-70 Halofantrine Conc vs OTc	225-254

INTRODUCTION:

Halofantrine HCl is an antimalarial drug approved by the FDA for the treatment of mild to moderate malaria caused by *Plasmodium falciparum* or *Plasmodium vivax*(1). The present study was designed to investigate the safety, tolerance and pharmacokinetics of halofantrine HCl given in multiple doses in a Phase I study as part of the overall development of halofantrine as a *prophylactic* antimalarial drug.

RATIONALE FOR STUDY:

Mefloquine HCl and doxycycline hyclate are the only Department of Defense (DOD) pharmaceutical preparations currently approved for prophylaxis against chloroquineresistant Plasmodium falciparum (2). Each of these prophylactic agents has its own spectrum of side-effects that may limit its use in individual patients. In addition, changing development patterns worldwide necessitates the of additional resistance chemoprophylactic agents against this potentially deadly disease. Halofantrine may show promise as an alternative prophylactic therapy, however a number of clinical reports have suggested possible cardiotoxicity of halofantrine in the form of electrocardiographic OT prolongation and associated torsade de pointe arrhythmia(3-6). Therefore careful reevaluation of halofantrine safety when it is being considered for use as prophylaxis in healthy people is necessary.

This Phase I safety and tolerance study was designed to evaluate halofantrine given daily at the maximal dose for which absorption is linear and for which there is limited safety data. The period of dosing for this Phase I safety and tolerance study corresponded to the length of time that dosing would be required for a subsequent Phase IIa experimental sporozoite challenge study, dose-optimization study.

STUDY OBJECTIVES:

The prospectively defined objectives of this Phase I study were as follows:

- 1. To evaluate the safety and tolerance of halofantrine hydrochloride given over time to healthy adults.
- 2. To characterize the variability of multi-dose halofantrine pharmacokinetics over time in healthy adults.
- 3. To correlate pharmacodynamics (electrocardiographic QT intervals) with pharmacokinetics (plasma concentrations of halofantrine/desbutylhalofantrine).

STUDY DESIGN:

The study design was a randomized, double-blind, placebo-controlled Phase I safety and tolerance study. Twenty-one healthy volunteers were randomly assigned to receive

halofantrine or placebo. Initially it was planned to study 16 subjects, with 12 subjects to receive active drug (halofantrine) and 4 subjects to receive placebo, however due to subject drop outs prior to study completion, the number to be enrolled was increased to increase the number of subjects who completed the entire study. The blind was maintained with the increase in sample size accomplished by stratified randomization. Subjects were dosed daily for 42 days with 500 mg halofantrine hydrochloride. Subjects were fasted for at least 2 hours prior to and 2 hours following the oral dose. The initial 21 days of drug administration were done with subjects confined as inpatients to the Georgetown University Medical Center Clinical Research Center and during the remaining 21 days of drug administration the subject reported daily to the Clinical Research Center for medical assessment and supervised drug administration. The subjects were then followed periodically for the next 4 1/2 months with medical assessments and pharmacokinetic sampling at the Clinical Research Center.

CONDUCT OF THE STUDY:

The study was conducted at the Georgetown University Clinical Research Center at Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC. Each subject was an inpatient for 3 weeks during the period between December 21, 1995 and December 27, 1996. The last subject completed the study June 3, 1997. The Principal Investigator was Darrell R. Abernethy, M.D., Ph.D., who is Director of the Georgetown Medical Center Clinical Research Center, Professor of Medicine and Pharmacology, and Director of the Division of Clinical Pharmacology at Georgetown University. Collaborative Investigators included David L. Wesche, M.D., Ph.D. and Brian G. Schuster, M.D., of the Division of Experimental Therapeutics, Walter Reed Army Institute of Research, David Flockhart, M.D., Ph.D., and Jean Barbey, M.D., of the Division of Clinical Pharmacology at Georgetown University Medical Center.

The protocol and informed consent for this study were reviewed and approved by the Georgetown University Institutional Review Board August 1, 1995. Initial recruitment was by word of mouth, however to complete enrollment newspaper advertisement was used. Proposed advertisement for the study was reviewed and approved March 12, 1996. There was also approval of the protocol and informed consent form by the U.S. Army Surgeon General's Human Subjects Research Review Board. Twenty-one healthy male and female subjects were recruited by word of mouth and advertisement in the Washington Post newspaper. All subjects met the protocol inclusion criteria and did not meet the protocol defined exclusion criteria. These were:

Inclusion criteria:

- 1. Aged 18-45 years inclusive
- 2. Male or non-pregnant, non-lactating females
- 3. Weight within 20% of ideal body weight as defined by Metropolitan Life Tables
- 4. Normal history and physical examination
- 5. Normal serum chemistries including Mg++

Halofantrine IND:9847

- 6. Normal CBC
- 7. Negative HIV screen
- 8. Negative hepatitis screen
- 9. Negative serum beta-HCG pregnancy test (females only)
- 10. Normal electrocardiogram
- 11. Normal chest X-ray
- 12. Normal pulmonary function tests with normal DLCO2
- 13. Negative urine drug screen
- 14. Normal urinalysis
- 15. Normal TSH
- 16. Available for the full duration of the study and willing to comply with study procedures
- 17. Provision of written informed consent

Exclusion criteria: Any subject with:

- 1. History of serious medical problems, including any kind of heart disease
- 2. Allergy to halofantrine or related drugs
- 3. Taken any medication one week prior to study
- 4. Donated blood or participated in another investigational drug study within the past 2 months
- 5. History of alcohol or drug abuse
- 6. Cigarette smoking or use of any tobacco product
- 7. Pregnancy, unwillingness to use adequate contraception, or the desire to become pregnant within 6 months of the last dose of study drug
- 8. Prior upper gastrointestinal surgery
- 9. HIV positivity or other clinically significant laboratory abnormalities including hyperlipidemia
- 10. Inability to speak or understand English
- 11. Unusual dietary habits

Each of the subject volunteers also had a screening physical examination and laboratory study as outlined in the protocol. Any candidate with significant clinical or laboratory abnormality was excluded from participation and referred for appropriate health care follow-up.

Demographics of the 21 subject participants are outlined in Table 1. In summary, they ranged in age for 21-44 years, there were 18 males and 3 females, 8 Caucasian and 13 Black, their weight range was 63-96 kg, and their height range was 62-73 inches.

Subjects were randomized to receive either active or placebo halofantrine in a 4:1 ratio with the randomization blinded and maintained by Dr. Mark Sale, a member of the Division of Clinical Pharmacology at Georgetown Medical Center. The randomization allocation of subject participants is outlined in Table 2. The test material was halofantrine hydrochloride 250 mg tablets. The material was provided by the US Army, however the

original source was noted to be SmithKline Beecham Pharmaceuticals, Welwyn Garden City, Herts, U.K. The tablets were noted to be lot #G1905/V001.

All drug doses were administered in the morning following at least 2 hours fast, with fasting continued for 2 hours following the drug administration. The first 21 daily doses were administered while the subjects were confined the inpatient unit. On day 22 the subjects were discharged from the inpatient unit and they returned daily for their morning observed dose from day 22 to day 41. At that time they were readmitted to the inpatient unit to receive the last dose of halofantrine and have clinical evaluation, safety laboratory determinations, and blood sampling for pharmacokinetic evaluation. On day 43 the subjects were discharged from the inpatient unit to return to the outpatient area on study days 44, 45, 48, 51, 54,57,72, and 180.

Subjects 001, 003, 006, 007, 009, 012, 013, 015, 019, 020, and 021 completed the entire 180 days of the study. Subject 017 received only 2 doses of drug, therefore safety information was collected, however this subject was not included as one of the 20 with sufficient data for some evaluation. The other subjects, 002, 004, 005, 008, 010, 011, 014, 016, and 018 completed various proportions of the study before dropping out (Table 3). No subjects were discontinued for adverse events, however 3 adverse events, gastroenteritis (subject 002), skin rash (subject 006), and headaches (subject 011) were noted. The gastroenteritis was associated in time with a food ingestion (about 6 hours later) that seemed the most likely cause, although drug exposure could not be ruled out. The skin rash disappeared while the subject remained on drug and the subject completed the study, therefore it was deemed unlikely to be related to drug exposure. The headaches were temporally related to drug exposure for several days and were deemed to be likely related to drug exposure. An outline of study participation by the subjects is noted in Table 3.

Blood sampling for pharmacokinetic analysis and electrocardiograms for QTc analysis were obtained as follows:

<u>Day</u>	Time after dose (hr
1	predose (1/2 hr)
1	0.5
1	1
1	2
1	3
1	4
1	6
1	8
1	10
1	12
2	predose
	predose
3 4	predose
4	2
4	4
4	6
4	8
4	12
5	predose
6	predose
7	predose
7	2
7	4
7	6
7	8
7	12
8	predose
9	predose
10	predose
11	predose
12	predose
13	predose
14	predose
14	2
14	4
14	6
14	8
14	12

<u>Day</u>	Time after dose (hr)
15	predose
16	predose
17	predose
18	predose
19	predose
20	predose
21	predose
21	2
21	4
21	6
21	8
21	12
25	predose
29	predose
32	predose
36	predose
39	predose
42	predose
42	0.5
42	1
42	2
42	3
42	4
42	6
42	8
42	10
42	12
43	am
44	am
45	am
48 51	am
51	am
54 57	am
37 72	am
180	am am
100	am

Each sampling time point, scheduled and actual, is listed in Table 4. As can be seen, the inpatient samples were obtained within a few minutes of the scheduled time, with outpatient samples for the most part within 1-2 hours of the scheduled time. For pharmacokinetic samples that deviate significantly from the scheduled time, the analysis uses the actual time of collection for purposes of calculation. All blood samples were

centrifuged in a refrigerated centrifuge promptly, the plasma separated, and stored at -70 C until time of shipment. All samples were shipped on dry ice.

Analysis of electrocardiographic data was as follows. All ECGs were 12 lead with a 15 second 3-lead rhythm strip (I, aVF, V2). The chart speed for recording the 12 lead ECG was 25 mm/sec, the speed for the rhythm strip was 50 mm/sec. Two copies of each ECG were recorded, one for the chart and one for interpretation. For each ECG the RR interval and QT interval were measured for the first 3 consecutive normal and technically acceptable complexes and the results were averaged. If the RR interval was greater than 500 msec, QTc was calculated according to the Bazett formula(7). If the RR interval was less than 500 msec, the Fridericia correction was used(8). QT interval measurement was based on a modification of the method of Lepeschkin et al(9). The ECG tracings were placed on a digitizing pad and a cross-hair type pointing device was used to mark the beginning and the end of each interval. The data were transmitted to and stored on computer. The QT duration was measured on the rhythm strips from three leads simultaneously with use of the earliest beginning of the QRS complex to the end of the longest T wave in any of the three simultaneous leads. The end of each T wave was determined by drawing a tangent to the steepest portion of the downsloping T wave. The point at which this tangent intersected with the isoelectric line was used to designate the end of the T wave.

In addition to the above mentioned procedures, questioning regarding adverse reactions and subjective symptomatology, vital sign determinations and determination of laboratory safety parameters were performed as outlined in the study protocol. Deviations have been noted in the specific case report forms. These data are recorded for each subject in the subject's case report form. Copies of case report forms have been appropriately completed for each subject and have been periodically reviewed by the USAMMDA monitor. These forms are on file and available at the Georgetown University Clinical Research Center.

Periodically, according to the protocol-defined procedure, plasma samples were shipped on dry ice to Dr. Emil Lin at the Drug Studies Unit, School of Pharmacy, University of California at San Francisco. Quality control and reporting of plasma concentration data was monitored separately from clinical site monitoring.

RESULTS:

The study findings will be separated into 5 sections as follows: (1) Clinical Adverse Experiences, (2) Laboratory Safety Parameters, (3) Pharmacokinetic Results, (4) Pharmacodynamic [Electrocardiographic] Results, and (5) Pharmacokinetic / Pharmacodynamic Concentration Effect Relationships.

1. Clinical Adverse Experiences. Subject 002 (21 year old Black male) experienced stomach cramping, diarrhea, and fever for 4 days starting day 31 of the study. This began a few hours after ingestion of some possibly contaminated food. The subject stated he had

eaten salmon with a friend and the friend had become ill with similar symptoms. Evaluation on day 32 revealed mild abdominal tenderness and no other significant findings. At that time CBC showed 8000 WBC, Hb 14.2 and Hct 42.3. Symptoms subsided spontaneously on day 35. This subject was receiving halofantrine. He discontinued study on day 36 for personal reasons. Subject 006 (26 year old White male) developed a localized skin rash on day 11. Local care was administered and by day 15, while the subject remained on study the rash resolved. This subject was receiving placebo. Subject 011 (43 year old Black Hispanic female) complained of a throbbing headache on day 7. This was considerably relieved by a 650 mg dose of acetaminophen. The headache recurred on days 10, 12, 19, 21, and 22. Physical examination was unrevealing at the various evaluations during this series of headaches. This subject was receiving halofantrine. The subject did not subsequently complain of headache. Based on the history and examination, I deemed the subject 002 and subject 006 events to be unlikely to be related to halofantrine, and the subject 011 event to be probably related to halofantrine.

2. Laboratory Safety Parameters. Screening laboratory parameters for inclusion into the study are shown in Table 5 and include Drug Screen, Chest X-ray, Pulmonary function tests (screen and day 42), TSH, HIV, Hepatitis Surface Antigen (HBsAg), Hepatitis C (HbC), and Hepatitis C antibody (HbC antibody).

Vital signs during the course of the study are shown in Table 6(a-e) and include systolic blood pressure, diastolic blood pressure, heart rate, temperature, and weight. Each of these parameters is followed by 2 figures that plot the values and variance. This first figure shows the data in a linear array and includes maximum and minimum values, while the second figure shows the data with standard deviation plotted on a true time scale (Figures 1-10). Of interest, systolic and diastolic blood pressure and heart rate tended to be less during the inpatient part of the protocol (days 1-22). Early in the study weight was not measured daily, therefore missing data appear as empty cells in this table.

Beta HCG for female subjects (003, 010, 011) is shown in Table 7 and data are included for the duration of their participation (only 003 completed the study).

Hematological profile during the course of the study is shown in Table 8(a-l) and includes WBC, hemoglobin, hematocrit, RBC, red cell indices (MCV, MCHC, MCH), reticulocyte count, and white cell differential (eosinophils, segmented neutrophils, monocytes, lymphocytes. Values outside of the laboratory normal range are bolded. Each table is followed by a figure which plots the mean, standard deviation, and extreme values for the respective parameter (Figures 11-22). No trend for change in hematological parameters could be discerned during and following drug exposure. Missing data and data not obtained due to subject dropout are shown as empty cells.

Electrolytes during the course of the study are show in Table 9(a-e) and include sodium, chloride, potassium, carbon dioxide, and glucose. Values outside of the laboratory normal range are bolded. Each table is followed by a figure which plots the mean, standard

deviation, and extreme values for the respective parameter (Figures 23-27). No trend for change in electrolytes, CO2, or glucose could be discerned during the course of the study. Missing data and data not obtained due to subject dropout are shown as empty cells.

Other chemistries during the course of the study are shown in Table 10(a-s) and include alkaline phosphatase, albumin, total bilirubin, blood urea nitrogen, calcium, total cholesterol, HDL cholesterol, triglycerides, creatinine, gGT, LDH, magnesium, phosphate, total protein, AST, ALT, and uric acid. Each table is followed by a figure which plots the mean, standard deviation, and extreme values for the respective parameter (Figures 28-45). No trend for change in other chemistries could be discerned during the course of the study. Missing data and data not obtained due to subject dropout are shown as empty cells.

Urinalysis with microscopic examination is shown in Table 11(a-e) and includes casts, occult blood, RBC, WBC, and specific gravity. Each table is followed by a figure which plots the mean, standard deviation, and extreme values for the respective parameter (Figures 46-48). Occult blood noted for subjects 003 and 010 was observed during menses for these female subjects. No trend for change in urinalysis parameters was noted throughout the course of the study.

- 3. Pharmacokinetics: The pharmacokinetic parameters which could be evaluated with a degree of reliability were accumulation rate constant and accumulation half-life for each of the halofantrine stereoisomers (+Halofantrine and -Halofantrine) and steady state oral clearance for each of the isomers. Accumulation rate constants were determined from all trough (prior to the next dose) concentrations for days 1-45, the time of daily oral dosing of 500 mg/day racemic Halofantrine hydrochloride. Steady state oral clearance was determined from the mean of the measured trough concentrations from dosing days 23-45, which on visual inspection provided a reasonable description of steady state. Fitted functions for each subject, calculated accumulation rate constants and half lives are shown on Figure 49 (a-p). Calculated values were: +Halofantrine; 0.161±0.120 days-1 and 7.01+4.80 days respectively and -Halofantrine; 0.184±0.191 days-1 and 7.25±4.82 days respectively. Similarly steady state concentrations and oral clearance are shown on Figure 50. Observed and calculated values were: +Halofantrine; 88.8±46.2 ng/ml and 139±73.0 L/hr respectively and -Halofantrine; 43.7±17.3 ng/ml and 265.2±135.4 L/hr respectively. It is worth noting that +Halofantrine has markedly higher steady state concentrations across the group and this is reflected in the oral clearance calculation, which is about ½ that seen for -Halofantrine.
- 4. Pharmacodynamics (Electrocardiographic Effects): Electrocardiographic parameters during the course of the study are shown in Table 12 (a-d) including heart rate, PR interval, QRS duration, and QTc calculated as described above. Following each table is a plot of mean, standard deviation, and extreme values for each ECG (Figures 51-54). No trend for change in heart rate, PR interval, or QRS duration could be discerned. In contrast, QTc interval tended to be prolonged from baseline in subjects 002, 007, 009,

010, 011, 014, 016, 018, and 021. These subjects were all receiving halofantrine, and none of the subjects receiving placebo had an appreciable change in QTc.

5. Concentration Effect (Pharmacokinetic/Pharmacodynamic) Relationships: Raw data depicting measured ECG QTc and concentrations of the stereoisomers of halofantrine and its major metabolite, desbutylhalofantrine are shown in Table 13 (a-o). Subjects who received placebo of course are not represented as they have no halofantrine concentration determinations. Concentration time plots for isomers of halofantrine and desbutylhalofantrine are show in Figure 55 (a-o). Linear regressions of +halofantrine and ECG QTc and -halofantrine and ECG QTc are depicted in figures 56-70. It is clear that in most subjects a strong relationship between halofantrine concentration and lengthening QTc exists (Subjects 1,2,4,8,9,10,11,14,15,16,18, and 20) and that there is little relationship for others (Subjects 5,7,19).

CONCLUSIONS:

This halofantrine regimen of 500 mg per os once daily administered in the fasting state for a period of 6 weeks was well tolerated by the subject participants. Clinical adverse effects were few and minor. Laboratory safety profiles showed no evidence of abnormality associated with drug exposure. Electrocardiographic QTc prolongation in the range of 5-15% occurred in most subjects who received halofantrine, and did not occur in subjects who received placebo. In most instances a linear relationship between increasing concentrations of each of the halofantrine stereoisomers and lengthening of the ECG QTc could be demonstrated. Since racemic halofantrine was administered concentrations of each of the isomers covaried, therefore no conclusion can be reached from this study about the relative contribution to QTc prolongation from the respective isomers.

Darrell R. Abernethy, M.D., Ph.D.

Principal Investigator

17 December, 1998
Date

REFERENCES:

- 1. Bryson HM, Goa KL: Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 43: 236-258.
- 2. Bradley D: Prophylaxis against malaria for travellers from the United Kingdom. Malaria Reference Laboratory and the Ross Institute. Brit Med J. 1993; 306: 1247-1252.
- 3. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ: Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-1056.
- 4. Monlun E, Pillet O, Cochard JF, Favarel Garrigues JC, le Bras M: Prolonged QT interval with halofantrine. Lancet 1993; 341: 1541-1542.
- 5. Castot A, Rapoport P, Le Coz P: Prolonged QT interval with halofantrine. Lancet 1993; 341: 1541.
- 6. Drug altert: Halofantrine. Weekly Epidemiol. Rec. 1993; 68(37): 269-270.
- 7. Bazett HC: An analysis of the times relations of electrocardiograms. Heart 1920; 7: 353-370.
- 8. Fridericia LS: Die systolendauer im elektrokardiogramm bei normalen menchen und bei Herzkranken. Acta Med Scand. 1920; 53: 469-486.
- 9. Lepeschkin E, Surawicz B: The measurement of the Q-T interval of the electrocardiogram. Circulation, 51:378, 1952,

		HA	LOFANTRI	NE SUBJE	HALOFANTRINE SUBJECT DEMOGRAPHICS	RAPHICS			
4001410					Moight	Hoicht	Hoop	Date	Study
Number	Initials	Race	Gender	Age	(kg)	(in)	Day 0	Dropped	Completed
	JKS	*	Σ	23	64	67	12/21/95		06/18/96
2	BSH	a	Σ	21	96	89	12/21/95	01/25/96	
*	EJW	M	L	23	68	70	12/21/95		06/18/96
4	WPS	В	Σ	27	68	7.1	01/10/96	02/16/96	
5	SGA	В	Σ	35	68	70	01/10/96	02/07/96	
* 9	JBC	8	Σ	26	77		01/25/96		07/23/96
7	DAN	3	Σ	33	73	89	02/15/96		08/13/96
8	AYB	m	Σ	28	64	29	02/15/96	02/25/96	
6	GRL	8	Σ	38	75	71	02/15/96		08/13/96
10	EYJ	Ω	ш	39	75	65	02/15/96	04/09/96	
11	C-E	B (Hispanic)	L	43	99	52	02/23/96	04/08/96	
12 *	궆	m	Σ	37	82	71	03/14/96		09/10/96
13 *	GLG	Μ	Σ	35	63	29	03/28/96		10/08/96
4-	DLS	В	Σ	43	75	89	03/28/96	96/20/90	
15	DMK	۵	Σ	28	7.1	63	03/28/96		09/24/96
16	L-W	m	Σ	44	11	73	03/28/96	05/11/96	
17	PDC	Ω	Σ	21	89	70	08/01/96	08/05/96	
18	KLS	В	Σ	36	89	69	08/01/96	10/02/96	
19	WSB	>	Σ	43	82	71	08/22/96	-	02/18/97
20	K-P	m	Σ	22	75	70	10/31/96		04/28/97
21 *	CAE	M	Σ	38	92	69	12/05/96		26/03/90
* denotes Placebo	Sebo					voice of the second sec			

RANDOMIZ/	RANDOMIZATION CODE
Subject No.	Assignment
-	Halofantrine
2	Halofantrine
3	Placebo
4	Halofantrine
5	Halofantrine
9	Placebo
7	Halofantrine
8	Halofantrine
6	Halofantrine
10	Halofantrine
11	Halofantrine
12	Placebo
13	Placebo
14	Halofantrine
15	Halofantrine
16	Halofantrine
17	Halofantrine
18	Halofantrine
19	Halofantrine
20	Halofantrine
21	Placebo

Subject Initials Number Initials 1 JKS 2 BSH 3 EJW 4 WPS 5 SGA 6 JBC 7 DAN 9 GRL 4 AYB 9 GRL 6 GRL	Hospital		
	ביומיסב	OteC	Study
	Day 0	Dropped	Completed
	12/21/95		06/18/96
	12/21/95	01/25/96	
	12/21/95		06/18/96
	01/10/96	02/16/96	
	01/10/96	02/01/96	
	01/25/96		07/23/96
	02/15/96		08/13/96
	02/15/96	02/25/96	
	02/15/96		08/13/96
	02/15/96	04/09/96	
11 C-E	02/23/96	04/08/96	
12 HLL	03/14/96		09/10/96
13 GLG	03/28/96		10/08/96
14 DLS	03/28/96	96/20/90	
15 DMK	03/28/96		09/24/96
16 L-W	03/28/96	05/11/96	
17 LDG	08/01/96	08/05/96	
18 KLS	08/01/96	10/02/96	
19 WSB	08/22/96		02/18/97
20 K-P	10/31/96		04/28/97
21 CAE	12/05/96		26/03/90

Blank	Blank = Not Obtained	Obtaine	ס			**		Bloc	Table 4-1 Blood Specimen PK Times	Table 4-1 ecimen P	K Time	ຜູ			•				
Subj	Date Time	Day 1 Pre	Day 1 .5hr	Day 1 1hr	Day 1 2hr	Day 1 3hr	Day 1 4hr	Day 1 6hr	Day 1 8hr	Day 1 10hr	Day 1 1	Day 2	r. 3	Day 4 Pre	Day 4 2hr	Day 4 4hr	Day 4 6hr	Day 4 8hr	Day 4 12hr
01	Act:	7:40	8:37	8:57	10:02	11:00	11:57	13:59	16:00	18:03	20:00	07:40	08:05	07:45	10:00	12:02	14:07	15:46	20:00
01	oiff:	10	7	-3	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	. 0	-3	-1	3		200	10	35	15	,))	7	-14	0
02	Act:	8:00	8:43	9:13	10:13	11:12	12:20	14:15	16:15		20:15	08:18	08:18	08:03	m	~	14:18	16:03	20:05
0.5	Schd:	7:45	8:45	9:15	10:15	!	12:15	4	6:1	15	20:15	7:45	7:45	7:45	15	15	14:15	16:15	20:15
02	Diff:	15	-2	-2	-2	۳,	2	0	0	ഗ	0	33	33	18	m	м	m	-12	-10
03	Act:	8:17	9:24	9:50	10:56	11:47	12:52	14:50			20:50	08:30	08:25	08:13	w	m	14:50	16:42	20:50
03	Schd:	8:20	9:20	10:50	11:50	12:50	13:50	15:50	0	:50	21:50	8:20	8:20	8:20	10:50	12:50	14:50	16:50	20:50
03	Diff:	m 1	4	-60	-54	-63	851	09-	09-	04-	0 9 -	O H	n	-	5 *	7	>		>
40	Act:	8:34	9:15	9:45	10:40	11:40	12:40	14:40				08:36	00:60	09:45		ហ	15:55	18:00	20:00
40	Schd:	8:00	9:00	9:30	10:30	11:30	12:30	14:30	0	30	20:30	8:00	8:00	8:00	30	12:30	14:30	16:30	20:30
4	Diff:	34	15	12	0 H	10	10	10	20	10	0 1	5 9	0	105	n n	ری	n œ	0	0
0.5	Act:	8:20	9:05	9:25	10:25	11:30	12:25	14:25	16:25	18:25	20:20		08:35	08:35	11:15	13:07	14:55	7:0	19:00
0.5	Schd:	8:00	9:00	9:30	10:30	11:30	12:30	14:30	16:30		20:30	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30
02	Diff:	20	ın	ا ا	ω	0	ហ	5	ហ	- 5	-10	30	35	35	45	3.)	57	30	ا ا
90	Act:	8:45	9:21	9:50	10:50	11:50	13:00	15:00	16:50	19:00	20:45	08:20	00:60	08:58	11:00	12:55	14:55	17:05	21:00
90	Schd:	8:20	9:20	9:50	10:50	11:50	12:50	14:50	16:50	18:50	20:50	8:20	8:20	8:20	10:50	12:50	14:50	16:50	20:50
90	Diff:	25	П	0	0	0	10	10	0	10	ហ	0	40	38	10	ro.	ഗ	15	10
07	Act:	9:25	10:00	10:31	11:35	••	13:30	15:30	17:30	19:32	21:30	08:52	05:50	08:58	11:06	13:06	15:10	17:12	21:28
0.7	Schd:	9:00	10:00	10:30	11:30	12:30	13:30	15:30	17:30	19:30	21:30	9:00	9:00	9:00	11:30	13:30	15:30	17:30	21:30
0.7	Diff:	25	0	п	S	0	0	0	0	7	0	80 1	20	-2	-24	-24	-20	-18	-2
0.8	Act:	7:53	8:32	9:18	9:56	11:00	12:05	14:00	16:00	18:05	20:10		08:07	07:55	10:00	12:00	14:00	16:05	20:45
0.8	Schd:	7:30	8:30	9:00	10:00	11:00	12:00	14:00	16:00	18:00	20:00	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00
80	Diff:	23	73	80	- 4	0	ς.	0	0	ഗ	10	23	37	25	0	0	0	Ŋ	45
60	Act:	8:14	90:6	9:28	10:15	11:19	12:20	14:20	16:20	: 20	20:26	08:15	08:28	08:15	10:20		14:20	6:2	20:30
60	Schd:	7:50	8:50	9:20	10:20	11:20	12:20	14:20	16:20	18:20	20:20	7:50	7:50	7:50	10:20	12:20	14:20	16:20	20:20
60	Diff:	24	16	ω	5	٦-	0	0	0	0	9	25	38	25	0	0	0	7	10
10	Act:	8:30	9:25	9:45	10:50	11:44	12:40	14:30	16:40	18:40	21:00	08:34	08:55	08:25	10:45		14:50	16:50	23:40
10	Schd:	8:10	9:10	9:40	10:40	11:40	12:40	14:40	16:40	18:40	20:40	8:10	8:10	8:10	10:40	12:40	14:40	16:40	20:40
10	Diff:	20	15	ហ	10	4	0	-10	0	0	20	24	45	15	2	10	٦0	10	180
11	Act:	9:20	9:50	10:20	11:30	12:20	13:20	15:35	17:25	19:20	21:33	09:51	90:60	09:20	11:20	13:05	15:05	17:05	21:10
11	Schd:	8:50	9:50	10:20	11:20	12:20	13:20	15:20	7:20	9:20	21:20	8:50	8:50	8:50	:20		15:20	17:20	21:20
11	Diff:	30	0	0	10	0	0	15	ហ		13	61	15	30	0	-15	-15	-15	-10

									12	Table 4-2									
Blan	Blank = Not Obtained	Obtaine	þ					Blo	Blood Specimen PK Times	cimen l	PK Tim	es							
Subj	Date j Time	Day 1 Pre	Day 1 .5hr	Day 1 1hr	Day 1 2hr	Day 1 3hr	Day 1 4hr	Day 1 6hr	Day 1 8hr	Day 1 10hr	Day 1 12hr	Day 2 Pre	Day 3 Pre	Day 4 Pre	Day 4 2hr	Day 4 4hr	Day 4 6hr	Day 4 8hr	Day 4 12hr
12	Act:	8:18	9:55	9:30	10:30	11:25	12:35	14:30	16:30	18:35	20:10	08:12	08:40	07:50	10:00	12:21	14:20	16:24	20:25
12	Schd:		8:45	9:15	10:15	11:15	12:15	14:15	16:15	18:15	20:15	7:45	7:45	7:45	10:15	12:15	14:15	16:15	20:15
12	Diff:		70	15	15	10	20	15	15	20	2	27	55	S.	-15	9	٠.	σ	10
13	Act:	8:55	9:30	10:00	11:00	12:00	13:00	15:04	17:02	19:03	21:00	08:55	09:20	08:55	11:05	13:05	14:55	16:55	21:05
13	Schd:		9:30	10:00	11:00	12:00	13:00	15:00	17:00	19:00	21:00	8:30	8:30	8:30	11:00	13:00	15:00	17:00	21:00
13	Diff:		0	0	0	0	0	4	7	м	0	25	20	25	S	LO	5	r,	Ŋ
14	Act:	8:00	8:50	9:20	10:20	11:20	12:20	14:20	16:20	18:20	20:20	08:25	00:60	08:10	10:28	12:21	14:04	16:09	20:29
14	Schd:		9:00	9:30	11:30	12:30	13:30	15:30	17:30	19:30	21:30	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30
14	Diff:		-10	-10	-70	-70	- 70	-70	-70	-70	- 70	25	09	10	-2	6-	- 26	-21	-1
15	Act:	8:30	9:14	9:50	10:45	11:48	12:50	14:44	16:45	18:35	20:36	08:40	08:41	08:50	10:55	12:55	14:55	16:55	20:45
15	Schd:	8:10	9:10	9:40	10:40	11:40	12:40	14:40	16:40	18:40	20:40	8:10	8:10	8:10	10:55	12:55	14:55	16:55	20:55
15	Diff:	20	4	10	S	89	10	4	2	-5	4 -	30	31	40	0	0	0	0	-10
16	Act:	7:58	8:40	9:07	10:05	11:05	12:05	14:05	16:10	18:05	20:00	07:55	08:00	08:04	10:04	12:04	14:30	16:30	20:12
16	Schd:	7:30	8:30	9:00	10:00	11:00	12:00	14:00	16:00	18:00	20:00	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00
16	Diff:		10	7	ហៈ	Ŋ	ഹ	Ŋ	10	ស	0	25	30	34	4	4	30	30	12
17	Act:	8:29	9:15	9:31	10:31	11:30	12:32	14:30											
17	Schd:	8:00	9:00	9:30	11:30	М	13:30	15:30	17:30	19:30	21:30	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30
17	Diff:		15	н	- 59	09-	- 58	09-				,							
18	Act:	8:05	9:05	9:37	10:35	11:32	12:34	14:33	16:31	18:35	20:35	08:25	08:40	08:05	10:32	12:35	14:30	16:30	20:55
18	Schd:		9:00	9:30		11:30	12:30	14:30	16:30	18:30	20:30	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30
18	Diff:	ស	Ŋ	7	S	7	4	т	н	Ŋ	2	25	40	Ŋ	77	ù	0	0	25
19	Act:	8:26	9:02	9:35	10:30	11:32	12:30	14:30	16:55	18:37	20:20	08:35	08:33	08:28	10:43	12:41	14:32	17:00	20:38
19	Schd:		9:00	9:30	10:30	11:30		14:30	16:30	18:30	20:30	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30
19	Diff:	26	7	гo	0	7		0	25	7	-10	35	33	28	13	11	(1)	30	ω
20	٠ + ٢	7.38	8.35	9.05	10:00	11:00	12:00	14:00	16:00	18:03	19:55	08:00	07:47	08:00	10:13	12:08	14:19	16:15	20:20
20	Scho.		8.30	00.6	10:00	11:00	12:00	14:00	16:00	18:00	20:00	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00
20	Diff:	. ω	2	. 2	0	0	0	0	0	м	-5	30	17	30	13	80	19	15	20
;		,		,				•	((L C	0	6		0	. 0	6	6		2.
5 57	Act:		8:44	9:17	10:16	11:15	12:17	14:16	26:15	18:35	20:02	7.45	7.45	7.45	10:02	12:06	14:00	50:01	24:02
21	Schd: Diff:	7:45	8:45 -1	9: L5	10:15	0	12:13	14:15	0	20	-15	35	30	15	-13	6-	-15	-10	25

Blank = Not Obtained

Date Day 5 Time PRE	Day 5 PRE		Day 6 Pre	Day 7 Pre	Day 7 2hr	Day 7 4hr	Day 7 6hr	Day 7 8hr	Day 7 12hr	Day 8 Pre	Day 9 Pre	Day 10 Pre	Day 11 Pre	Day 12 Pre	Day 13 Pre	Day 14 Pre	Day 14 2hr	Day 14 4hr
Act: 07:55 07:49 07:56	07:49		07:56		09:20	11:52	13:58	15:51	20:05	08:03	07:55	07:51	07:58	07:45	07:40	07:58	09:55	12:00
7:30 7:30	7:30		7:30		10:00	12:00		16:00	20:00	7:30	7:30	7:30	7:30	7:30	7:30	7:30	10:00	12:00
25 19	19		26		-10	8	- 2	9	w	33	25	21	28	1.5	10	28	ις	0
Act: 08:05 08:20 08:18	08:20	08:20	08:18		10:02	12:05	14:20	16:07	20:25	08:10	08:17	08:16	08:20	08:07	08:05	08:09	10:08	12:10
7:45 7:45	7:45	7:45	7:45		10:15	12:15	14:15	16:15	20:15	7:45	7:45	7:45	7:45	7:45	7:45	7:45	10:15	12:15
20 35	35		33		-13	-10	'n	8 -	10	25	32	31	35	22	20	24	-7	5
Act: 08:42 08:40 08:38	08:40		08:38		10:45	12:43	14:42	16:40	20:55	08:45	08:53	08:49	08:55	08:25	08:34	08:45	10:45	12:43
	8:20		8:20		10:50	12:50	14:50	16:50	20:50	8:20	8:20	8:20	8:20	8:20	8:20	8:20	10:50	12:50
22	20		18		r N	-7	8	-10	ß	25	33	29	35	Ŋ	7.4	25	5	-7
Act: 08:45 08:40 08:40	08:40	08:40	08:40		10:45	12:45	14:45	16:45	20:46	08:40	08:40	08:50	08:47	08:43	08:41	08:37	10:40	12:40
8:00 8:00	8:00	8:00	8:00		10:30	12:30	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30	12:30
45 40	40		40		15	15	15	15	16	40	40	20	47	43	41	37	10	10
Act: 08:25 08:20 08:25	08:20		08:25		10:25	12:25	14:25	16:21	20:25	08:29	08:25	08:29	08:20	08:25	08:20	08:16	10:25	12:25
20:30 8:00	8:00	8:00	8:00		10:30	12:30	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30	12:30
-725	20	20	25		ن ا	5-	-5	6-	-5	29	25	29	20	25	20	16	.5	د
Act: 08:55 08:50 09:10	08:20		09:10		11:10	13:15	15:10	17:10	21:20	08:51	09:10	08:59	08:48	08:48	08:46	08:38	10:50	12:50
	8:20		8:20		10:50\ 12:50	12:50	14:50	16:50	20:50	8:20	8:20	8:20	8:20	8:20	8:20	8:20	10:50	12:50
Diff: 35 30 50	30		20		20	25	20	20	30	31	20	39	28	28	26	18	0	0
Act: 09:00 08:54 08:54	08:54	08:54	08:54		11:10	13:04	15:02	17:03	21:30	01:60	00:60	09:25	08:45	09:10	09:14	09:02	11:07	13:07
Schd: 9:00 9:00 9:00	9:00		9:00		11:30	13:30	15:30	17:30	21:30	9:00	9:00	9:00	9:00	9:00	9:00	9:00	11:30	14:30
Diff: 0 -6 -6	9 -		9-		-20	-26	-28	-27	0	10	0	25	-15	10	14	73	-23	- 83
Act: 08:03 08:07 07:55	08:07		07:55		10:00	12:00	14:00	16:00	20:00	08:03	07:55	08:05						
Schd: 7:30 7:30 7:30	7:30 7:30		7:30		10:00	12:00	14:00	16:00	20:00	7:30	7:30	7:30	7:30	7:30	7:30	7:30	10:00	12:00
Diff: 33 37 25	37		25		0	0	0	0	0	33	25	35				٠		
Act: 08:24 08:15 08:15	08:15		08:15		10:20	12:20	14:15	16:20	20:30	08:18	08:20	08:30	08:13	08:17	08:20	08:19	10:35	12:34
Schd: 7:50 7:50 7:50	7:50		7:50		10:20	12:20	14:20	16:20	20:20	7:50	7:50	7:50	7:50	7:50	7:50	7:50	10:20	12:20
Diff: 34 25 25	25		25		0	0	5-	0	10	28	30	40	23	27	30	53	15	14
Act: 08:38 08:38 08:35	08:38		08:35		10:42	12:45	14:45	16:42	22:10	08:45	08:45	50:60	08:30	08:55	08:55	08:36	10:34	12:45
8:10 8:10	8:10		8:10		10:40	12:40	14:40	16:40	20:40	8:10	8:10	8:10	8:10	8:10	8:10	8:10	10:40	12:40
: 28	28		25		7	Ŋ	S	7	90	32	35	55	20	45	45	26	9-	S.
Act: 09:30 09:35 09:15	09:35		1:60	N	11:20	13:25	15:10	17:10	21:24	09:38	09:14	08:30	09:59	09:20	00:60	09:25	11:30	13:31
8	8:50		8:50		11:20	13:20	15:20	17:20	21:20	8:50	8:50	8:50	8:50	8:50	8:50	8:50	11:20	13:20
Diff: 40 45 25	4.5		25		0	ഹ	-10	-10	4	48	2 4	4 0	6.9	30	0	J C	0	-1

13:00 13:00 0

12:30 12:15 15 12:20 12:30 -10 12:40 12:40 0 12:00 12:00 0 12:35 12:30 5

12:30

12:34 12:30 4 12:03 12:00 3

Day 14 4hr

Blank	= Not (Blank = Not Obtained	ed Day 6	Day 7	Day 7	Day 7	Day 7	Blc	<u> </u>	Table 4-4 secimen F	PK Tirr Day 9	Day 10	Day 11	Day 12	Day 13	Day 14	Day 14 E
Subj	Time	PRE	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre	Pre	Pre	Pre	Pre	2hr
12	Act:	08:13	08:20	08:18	10:12	12:13	14:13	16:15	22:20	08:12	08:17	08:25	08:20	08:30	08:20	08:15	10:25
12	Schd:	7:45	7:45	7:45	10:15	12:15	14:15	16:15	20:15	7:45	7:45	7:45	7:45	7:45	7:45	7:45	10:15
12	Diff:	28	35	33	-3	-2	. 2	0	125	27	32	40	35	45	35	30	10
13	Act:	08:56	08:55	00:60	11:20	13:15	15:15	17:12	21:17	00:60	09:23	10:05	09:05	00:60	08:59	08:55	11:10
13	Schd:	8:30	8:30	8:30	11:00	13:00	15:00	17:00	21:00	8:30	8:30	8:30	8:30	8:30	8:30	8:30	11:00
13	Diff:	26	25	30	20	15	15	12	17	30	53	95	35	30	29	25	10
Ţ	1	0	t .	. 00		36.61	7.0.7	01.31	20.00	80.80	21.80	. BO	08.17	21.80	06.80	08.20	10.28
1 T	ACL:	04:80	00:10	#7:00 8.00	10:20	12:30	14:20	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30
1.4	Diff:	10	15	24	9-	-14	-3	-11	13	28	15	65	17	15	20	20	-2
	,	i.	0				00.31	16.35	9.00	7. 80	08.50	00.05	86.80	78.45	08.40	08.28	10:41
C T T	ACL:	00:00	8.10	##:00 01.8	10.40	12.40	14.40	16.40	20.30	8:10	8:10	8:10	8:10	8:10	8:10	8:10	10:40
15	Diff:	25	28	34.5	20	15	20	-5	18	35	40	75	28	35	30	18	н
16	Act:	07:36	07:55	08:02	10:06	12:02	14:08	16:02	20:05	08:10	07:45	08:35	07:55	07:50	07:58	08:00	10:05
16	Schd:	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00	7:30	7:30	7:30	7:30	7:30	7:30	7:30	00:01
16	Diff:	v	25	32	ω.·	71	ω	7	Ω	40	15	65	25	20	28	30	Ŋ
17	Act:									ı							
17	Schd:	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30
17	Diff:					,									•		
18	Act:	08:15	08:11	07:45	10:33	12:34	14:30	16:32	20:28	08:20	08:35	07:45	07:58	08:02	08:25	08:20	10:30
18	Schd:	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30
18	Diff:	15	11	-15	ю	4	0	7	-2	20	35	-15	-2	2	25	20	0
19	Act:	08:23	08:02	08:25	12:11	12:35	14:35	16:25	20:45	08:32	08:30	08:25	08:20	08:20	08:23	08:10	10:32
19	Schd:	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30
19	Diff:	23	2	25	101	ß	Ŋ	-5	15	32	30	25	20	20	23	10	2
20	Act:	08:00	07:58	07:56	09:58	12:08	14:07	16:10	20:05	07:59	08:10	08:12	07:58	07:55	07:55	07:50	10:10
20	Schd:	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00	7:30	7:30	7:30	7:30	7:30	7:30	7:30	10:00
20	Diff:	30	28	26	-2	ω	7	10	ហ	29	40	42	28	25	25	20	10
2.1	بار	07:50	07:40	07:56	55:60	12:00	13:58	15:56	20:00	08:01	08:10	08:28	08:10	07:50	07:40	07:47	10:10
2.1	Schd:	7:45	7:45	7:45	10:15	12:15	14:15	16:15	20:15	7:45	7:45	7:45	7:45	7:45	7:45	7:45	10:15
21	Diff:	S.	5.	11	-20	-15	-17	-19	-15	16	25	43	25	Ŋ	- 5	7	rv.

Blank	c = Not (Blank = Not Obtained			٠.		Blo	Tal od Spec	Table 4-5 Blood Specimen PK Times	Times			•					
Subj	Date Time	Day 14 6hr	Day 14 8hr	Day 14 12hr	Day 15 Pre	Day 16 Pre	Day 17 Pre	Day 18 Pre	Day 19 Pre	Day 20 Pre	Day 21 Pre	Day 21 2hr	Day 21 4hr	Day 21 6hr	Day 21 8hr	Day 21 12hr	Day 22 Pre	
01	Act: Schd:	14:00 14:00	16:07 16:00	20:10 20:00	07:55 7:30	07:50 7:30	07:53 7:30	07:40	07:50	07:57	07:56 7:30	10:00	12:00	14:00	16:00	19:40	07:50	
01	Diff:	0	7	10	25	20	23	10	20	27	26	0	0	0	0	-20	20	
02	Act:	14:23	16:20	20:35	08:13	08:13	08:20	08:20	08:05	08:10	08:12	10:15	12:15	14:15	16:15	20:00	08:10	
0 0	Schd:	14:15	16:15	20:15	7:45	7:45	7:45	7:45	7:45	7:45	7:45	10:15	12:15	14:15	16:15	20:15	7:45	
7		œ	n	0.7	87	87	35	32	70	25	27	0	0	0	0	-15	25	
03	Act:	14:56	16:43	20:55	08:52	08:47	08:51	08:50	08:13	08:50	08:50	10:53	12:53	14:53	16:59	21:07	09:15	
03	Schd:	14:50	16:50	20:20	8:20	8:20	8:20	8:20	8:20	8:20	8:20	10:50	12:50	14:50	16:50	20:50	8:20	
5	DILL	٥	<i>(</i> -	ئ د	32	27	31	30	- 7	30	30	ю	m	m	σı	17	55	
04	Act:	14:40	16:40	20:40	08:35	08:44	08:45	10:05	08:57	08:45	08:39	10:40	12:40	14:55	16:45	20:42	08:45	
0.4	Schd:	14:30	16:30	20:30	8:00		8:00	8:00	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00	
4,	Diff:	10	10	10	32	44	45	125	57	5.	9 9	10	10	25	15	12	45	
0.5	Act:	14:25	16:31	20:30	08:20	08:33	09:15	09:43	08:22	08:25	08:17	12:25	12:25	14:25	16:25	20:20	08:24	
50	Schd:	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	12:30	12:30	14:30	16:30	20:30	8:00	
c c	DILL	ر د	п	0	20	33	75	103	22	25	17	ភ	5-	ភ	ហ	-10	24	
90	Act:	14:58	16:57	20:47	08:39	00:60	08:59	08:39	08:55	08:35	08:50	12:55	12:55	14:55	16:55	21:43	08:56	
90	Schd:	14:50	16:50	20:50	8:20	8:20	8:20	8:20	8:20	8:20	8:20	10:50	12:50	14:50	16:50	20:50	8:20	
90	Diff:	æ		m I	6 . ·	40	39	19	32	15	30	125	Ŋ	ſΩ	Ŋ	53	36	
0.7	Act:	15:07	17:10	21:00	10:10	09:07	08:60	60:05	09:41	01:60	09:12	11:20	13:15	14:22	16:47	21:40	09:03	
0.7	Schd:	15:30	17:30	21:30	9:00	9:00	9:00	00:6	9:00	9:00	9:00	11:30	13:30	15:30	17:30	21:30	9:00	
03	Diff:	-23	-20	-30	70	7	30	ហ	41	10	12	-10	-15	-68	-43	10	ю	
08	Act:																	
08	Schd:	14:00	16:00	20:00	7:30	7:30	7:30	7:30	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00	7:30	
80	Diff:																	
60	Act:	14:30	16:27	20:00	08:18	08:09	08:19	08:19	08:30	08:25	08:10	10:30	12:30	14:25	16:21	20:25	08:10	
60	Schd:	14:20	16:20	20:20	7:50	7:50	7:50	7:50	7:50	7:50	7:50	10:20	12:20	14:20	16:20	20:20	7:50	
60	Diff:	10	7	-20	28	13	29	29	40	35	20	10	10	52	н	ស	20	
10	Act:	14:45	16:45	20:30	08:48	08:30	08:41	08:39	80:60	08:50	08:25	10:58	12:45	14:58	16:45	20:41	08:38	
10	Schd:	14:40	16:40	20:40	8:10	8:10	8:10	8:10	8:10	8:10	8:10	10:40	12:40	14:40	16:40	20:40	8:10	
10	Diff:	വ	ស	-10	38	20	31	29	28	40	15	18	S	18	Ŋ	ч	28	
11	Act:	15:25	17:28	21:20	09:19	08:30	09:28	09:13	09:21	09:20	80:60	11:20	13:15	15:15	17:20	21:15	09:12	
11	Schd:	15:20	17:20	21:20	8:50	8:50	8:50	8:50	8:50	8:50	8:50	11:20	13:20	15:20	17:20	21:20	8:50	
11	Diff:	ហ	œ	0	29	-20	38	23	31	30	18	0	-5	- 5	0	2	22	

Blank	= Not (Blank = Not Obtained	~		٠.		Bloc	Tak od Speci	Table 4-6 Blood Specimen PK Times	Times			,				
Subj	Date Time	Day 14 6hr	Day 14 8hr	Day 14 12hr	Day 15 Pre	Day 16 Pre	Day 17 Pre	Day 18 Pre	Day 19 Pre	Day 20 Pre	Day 21 Pre	Day 21 2hr	Day 21 4hr	Day 21 6hr	Day 21 8hr	Day 21 12hr	Day 22 Pre
12	Act:	14:30	16:25	20:20	08:22	01:60	08:15	08:14	08:05	08:13	08:00	10:13	12:16	14:22	16:58	20:22	08:13
12	Schd:	14:15	16:15	20:15	7:45	7:45	7:45	7:45	7:45	7:45	7:45	10:15	12:15	14:15	16:15	20:15	7:45
12	Diff:	15	10	Ŋ	37	85	30	29	20	28	15	- 2	г	7	43	7	. 28
13	Act:	15:10	17:04	21:12	08:52	08:10	09:35	08:60	08:57	09:12	50:60	11:20	13:15	15:19	17:10	21:12	08:50
13	Schd:	15:00	17:00	21:00	8:30	8:30	8:30	8:30	8:30	8:30	8:30	11:00	13:00	15:00	17:00	21:00	8:30
13	Diff:	10	4	12	22	-20	65	09	27	42	35	20	15	19	10	12	20
14	Act:	14:20	16:20	20:23	08:25	08:40	08:14	08:22	08:34	08:16	08:50	11:59	12:57	14:55	16:46	21:05	08:18
14	Schd:	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00
14	Diff:	-10	-10	L-7	25	40	14	22	34	16	20	89	27	25	16	35	18
15	Act:	14:42	16:40	21:00	08:36	07:45	09:04	08:55	08:35	08:45	08:37	10:45	12:45	14:45	16:45	20:47	08:37
15	Schd:	14:40	16:40	20:40	8:10	8:10	8:10	8:10	8:10	8:10	8:10	10:40	12:40	14:40	16:40	20:40	8:10
15	Diff:	7	0	20	26	-25	54	45	25	35	27	Ŋ	2	5	ស	7	27
16	Act:	14:00	16:00	19:55	07:55	07:45	08:10	08:04	08:04	07:58	07:56	10:10	12:06	14:02	16:05	20:01	07:58
16	Schd:	14:00	16:00	20:00	7:30	7:30	7:30	7:30	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00	7:30
16	Diff:	0	0	r L	25	15	40	34	34	28	26	10	9	73	S	1	28
17	Act:																
17	Schd:	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00
17	Diff:				, e st												
18	Act:	14:35	16:35	20:30	08:20	08:45	08:55	08:17	08:25	08:20	08:15	10:32	12:30	14:30	16:30	20:50	08:30
18	Schd:	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00
18	Diff:	Ŋ	2	0	20	45	55	17	25	20	15	7	0	0	0	20	30
19	Act:	14:34	16:33	20:25	08:20	08:23	08:10	08:20	08:25	07:30	08:04	10:30	12:30	14:30	16:36	20:49	08:20
19	Schd:	14:30	16:30	20:30	8:00	8:00	8:00	8:00	8:00	8:00	8:00	10:30	12:30	14:30	16:30	20:30	8:00
19	Diff:	4	м	1	20	23	10	20	25	-30	4	0	0	0	9	19	20
20	Act:	14:00	16:02	20:15	07:55	07:36	07:37	07:58	07:55	07:58	07:55	10:02	12:05	13:55	15:50	20:10	07:50
20	Schd:	14:00	16:00	20:00	7:30	7:30	7:30	7:30	7:30	7:30	7:30	10:00	12:00	14:00	16:00	20:00	7:30
20	Diff:	0	2	15	25	9	7	28	25	28	25	7	ડ	ភ	-10	10	20
21	Act:	14:05	16:08	20:20	07:50	08:00	07:57	08:00	07:55	07:58	07:45	10:00	12:00	14:00	16:00	20:00	08:10
21	Schd:	14:15	16:15	20:15	7:45	7:45	7:45	7:45	7:45	7:45	7:45	10:15	12:15	14:15	16:15	20:15	7:45
21	Diff:	-10	-7	5	ស	15	12	15	10	13	0	-15	-15	-15	-15	-15	25

Table 4-7	d Specimen PK Times
	Blood S

Blank = Not Obtained

Subj	Date Time	Day 25 Pre	Day 29 Pre	Day 32 Pre	Day 36 Pre	Day 39 Pre	Day 42 Pre	Day 42 .5hr	Day 42 1hr	Day 42 2hr	Day 42 3hr	Day 42 4hr	Day 42 6hr	Day 42 8hr	Day 42 10hr	Day 42 12hr	Day 43 AM
,		,	•		6	i.		i i		0	,		30.61		01.71	31.35	00.00
01	Act:	09:05	00:80	08:07	02:80	TO:02	,	06:/0	08:14	07:60	07:07	12:40	13:03	13:00		1 0	20.75
01	Schd:	7:30	7:30	7:30	7:30	7:30	7:30	8:30	00:6	00:01	00:17	00:27	T4:00	16:00	00:8T	00:02	06:7
01	Diff:	95	30	37	20	155		-40	-46	-50	-50	40	- 55	09-	- 50	95	-30
02	Act	08:20	07:10	08:55													
02	Schd:	7:45	7:45	7:45	7:45	7:45	7:45	8:45	9:15	10:15	11:15	12:15	14:15	16:15	18:15	20:15	7:45
02	Diff:	35	-35	7.0											•		
6	٠ + ۲	08.40	08:30	08:27	08:25	08:45	09:10	09:45	10:15	11:15	12:15	13:20	15:15	17:15	19:15	21:15	08:45
3 6		8.20	8:20	8:20	8:20	8:20	8:20	9:20	10:50	11:50	12:50	13:50	14:50	16:50	18:50	20:50	8:20
03	Diff:	20	0	7	, G	25	20	25	-35	-35	-35	-30	25	25	25	25	25
40	A TT	09:35	08:50	08:33	08:30												
. 6	Schd:	8:00	8:00	8:00	8:00	8:00	8:00	9:00	9:30	10:30	11:30	12:30	14:30	16:30	18:30	20:30	8:00
0.4	Diff:	95	20	33	30										٠		
0.5	Act:	09:18															
, u	gobd.	00.8	00.8	0	00.8	00.8	8:00	00:6	9:30	10:30	11:30	12:30	14:30	16:30	18:30	20:30	8:00
50	Diff:	78)	· ·	· ·											
)		2															٠
90	Act:	08:40	08:45	08:36	08:37	08:45	08:45	08:60	10:10	11:10	11:50	12:56	15:09	18:05	19:18	21:00	08:30
90	Schd:	8:20	8:20	8:20	8:20	8:20	8:20	9:20	9:50	10:50	11:50	12:50	14:50	16:50	18:50	20:50	8:20
90	Diff:	20	25	16	17	25	25	10	20	20	′ 0	9	19	75	28	10	10
				;	ا مسترمی ا		6		,		0			61.71	90.0	30.10	07.30
0.2	Act:	09:38	19:10	09:20	09:48	10:00	00:60	09:43	10:13	77:77	10:21	13:06	15:03	51:/1	19:00	64:03	66:10
07	Schd:	9:00	9:00	9:00	9:00	9:00	00:6	10:00	10:30	11:30	12:30	13:30	15:30	17:30	19:30	21:30	00:6
07	Diff:	38	610	20	48	09	0	-17	-17	-18	-29	-24	-27	-17	-22	- 25	-81
80	Act:																
90	Schd:	7:30	7:30	7:30	7:30	7:30	7:30	8:30	9:00	10:00	11:00	12:00	14:00	16:00	18:00	20:00	7:30
80	Diff:																
60	Act:	08:52	09:20	09:20	10:43	08:35	08:05	08:50	09:50	10:20	11:33	12:20	14:20	16:20	18:20	20:20	07:40
60	Schd:	7:50	7:50	7:50	7:50	7:50	7:50	8:50	9:20	10:20	11:20	12:20	14:20	16:20	18:20	20:20	7:50
60	Diff:	62	120	120	173	45	15	0	0	0	13	0	0	0	0	0	-10
7	1	0		0		0.00	08.40	08.30	26.80	10.50	11:45	12:55	14:55	16:57	18:45	20:48	08:30
9 6	#CL:	70:00	0.10	01.00	01.4	01.0	8.10	9.10	9:40	10:40	11:40	12:40	14:40	16:40	18:40	20:40	8:10
0 0	scuo:) ; ; o	01.0		0) - (24.0				بر	۲.	17	ហ	83	80
10	Dift:	χο 	155	ر 8	1/5	0 9	05	0	C +	9	า	7) 1))	;
11	Act:	12:35	13:46	08:20		11:53	90:60	09:40	10:10	11:29	12:15	13:10	15:10	17:16	19:17	21:20	00:60
11	Schd:	8:50	8:50	8:50	8:50	8:50	8:50	9:50	10:20	11:20	12:20	13:20	15:20	17:20	19:20	21:20	8:50
11	Diff:	225	296	-30		183	15	-10	-10	σ	-5	-10	-10	-4	۳-	0	10

Table 4-8	Blood Specimen PK Times
	٠.
	Blank = Not Obtained

	пан	91 A	1111	11110	HIN	ν.	70 4	,																							
Day 43	.	09:45	7:45	120	00:60	8:30	30	,	8:00		09:07	8:10	57	07:59	7:30	29	08:30	8:00	0	08:30	8:00	30	00:00	8:00	-60	08:00	7:30	30	07:45	7:45	0
Day 42	Tant	20:15	20:15	5	21:40	21:00	40		20:30		21:20	20:40	40	20:00	20:00	0		20:30		20:41	20:30	11	20:38	20:30	œ	20:05	20:00	ഗ	20:40	20:15	25
Day 42	TOUE	18:20	18:15	ഹ	19:31	19:00	31		18:30		19:08	18:40	28	18:08	18:00	83		18:30		18:55	18:30	25	18:38	18:30	ω	18:05	18:00	ហ	18:33	18:15	18
Day 42	ans	16:20	16:15	ω	17:35	17:00	35		16:30		17:07	16:40	27	16:00	16:00	0		16:30		16:36	16:30	9	16:38	16:30	ω	16:05	16:00	ស	16:41	16:15	26
Day 42	6 hr	15:08	14:15	23	15:45	15:00	45		14:30		15:10	14:40	30	14:02	14:00	73		14:30		19:36	14:30	306	14:40	14:30	10	14:05	14:00	Ŋ	14:32	14:15	17
Day 42	4hr	12:26	12:15	11	13:37	13:00	37		12:30		13:04	12:40	24	17:08	12:00	308		12:30		12:30	12:30	0	12:35	12:30	Ŋ	12:05	12:00	S	12:39	12:15	24
Day 42	3hr	11:20	11:15	ហ	12:38	12:00	38		11:30		12:14	11:40	34	11:05	11:00	ហ		11:30		11:37	11:30	7	11:30	11:30	0	11:05	11:00	Ŋ	11:32	11:15	17
Day 42	2hr	10:17	10:15	7	11:32	11:00	32		10:30		11:07	10:40	27	10:00	10:00	0		10:30		10:30	10:30	0	10:32	10:30	7	10:05	10:00	5	10:28	10:15	13
Day 42	1hr	09:19	9:15	4	10:30	10:00	30		9:30		10:15	9:40	35	00:60	00:6	0		9:30		08:30	9:30	0	08:60	9:30	0	90:60	9:00	ហ	08:60	9:15	15
Day 42	.5hr	08:48	8:45	m	09:31	9:30	1		9:00		09:14	9:10	4	08:40	8:30	10		9:00		09:01	9:00	ਜ	90:60	9:00	r.	08:35	8:30	ហ	08:55	8:45	10
Day 42	Pre	08:10	7:45	25	08:57	8:30	27		8:00		08:45	8:10	35	07:55	7:30	25		8:00		08:05	8:00	Ŋ	08:10	8:00	10	07:58	7:30	28	07:50	7:45	ß
Day 39	Pre	08:21	7:45	36	09:30	8:30	09	07:30	8:00	-30	09:20	8:10	100	07:10	7:30	-20		8:00			8:00		08:20	8:00	20	08:47	7:30	77	09:12	7:45	87
Day 36	Pre	08:36	7:45	51	09:25	8:30	55	07:08	8:00	-52	10:40	8:10	150	01:18	7:30	-372		8:00	•		8:00		00:60	8:00	09		7:30		09:10	7:45	85
Day 32	Pre	08:29	7:45	44	09:50	8:30	20	07:20	8:00	-40	10:10	8:10	120	07:40	7:30	10		8:00		18:30	8:00	630	09:05	8:00	65	09:15	7:30	105	09:04	7:45	79
Day 29	Pre	08:20	7:45	35	09:01	8:30	31	07:37	8:00	-23	09:48	8:10	86	07:25	7.30	5 5		8:00		18:42	8:00	642	08:36	8:00	36	12:12	7:30	282	09:14	7:45	8 9
Day 25	Pre	08:25	7:45	40	08:35	8:30	S	07:55	8:00	-5	00:00	8:10	20	07:32	7.30	2 2		8:00		09.48	8:00	108	08:35	8:00	35	08:51	7:30	81	08:42	7:45	57
Date	Time	Act:	Schd:	Diff:	Acts	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	↑	2000	Diff:	Act:	Schd:	Diff:	۲. ۲.	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:
	Subj	12	12	12	13	13	13	14	14	14	15	15	15	7	1 6	16	17	17	17	2,0	7 6	18	19	19	19	70	20	20	21	21	21

	•		\																/																
Table 4-9		Day 180 AM	10:00	7:30	150		7:45		00:60	8:20	40		8:00			8:00		08:55	8:20	35	00:44	00:6	-496		7:30		15:30	7:50	460		8:10			8:50	
Ta Spot	ade noc	Day 72 AM	09:55	7:30	145		7:45		13:54	8:20	334		8:00			8:00		08:55	8:20	35	18:20	9:00	260		7:30		11:32	7:50	222		8:10			8:50	
à	ğ	Day 57 AM	08:50	7:30	80		7:45		08:28	8:20	œ		8:00			8:00		08:40	8:20	20	19:00	9:00	009		7:30		15:05	7:50	435		8:10			8:50	
		Day 54 AM	08:33	7:30	63		7:45		08:10	8:20	-10		8:00			8:00		08:55	8:20	35	23:40	9:00	880		7:30		14:20	7:50	390	13:35	8:10	325		8:50	
**		Day 51 AM	08:50	7:30	80		7:45		08:10	8:20	-10		8:00			8:00	ت.	08:55	8:20	3.5	12:00	9:00	180		7:30		12:20	7:50	270	10:30	8:10	140		8:50	
		Day 48 AM	09:18	7:30	108		7:45		00:60	8:20	40		8:00			8:00		08:48	8:20	28		9:00			7:30		10:25	7:50	155		8:10			8:50	
		Day 45 AM	08:38	7:30	68		7:45		09:57	8:20	76		8:00			8:00		09:25	8:20	65		9:00			7:30			7:50			8:10		14:03	8:50	313
7	Blank = Not Obtained	Day 44 AM	08:45	7:30	75		7:45		15:45	8:20	445		8:00			8:00		09:20	8:20	06		9:00			7:30		11:30	7:50	220	15:20	8:10	430	09:40	8:50	20
1	≡ Not ∟	Date Time	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:	Act:	Schd:	Diff:
ī	Blank	Subj	01	01	01	02	02	02	03	03	03	40	04	04	0.5	0.5	0.5	90	90	90	07	0.7	07	08	80	08	60	60	60	10	10	10	11	11	11

	Blank	: = Not (Blank = Not Obtained	75		٠.		<u>α</u>	Ta lood Spe	Table 4-10 Blood Specimen PK Times	
n.	Subj	Date Time	Day 44 AM	Day 45 AM	Day 48 AM	Day 51 AM	Day 54 AM	Day 57	Day 72 AM	Day 180 AM	*
ec ·	12	Act:	08:34	09:05	08:22	08:40	08:28	78.15	73.80	0	
17	12	Schd:	7:45	7:45	7:45	7:45	7:45	7.45	27.45	09:10 7:45	
10	12	Diff:	49	80	37	55	4.3	30	71	/ : 4 5 8 5	
90	13	40.4	08.90			((1			ł	
	7	, , , , , , , , , , , , , , , , , , ,	4.00	24:42	44:TT	10:57	17:00	13:09	13:55	11:50	
	7 ;	: u	8:30	0 F : B	8:30	8:30	8:30	8:30	8:30	8:30	
	7	DIEE:	70	72	205	147	510	279	325	200	
	14	Act:									
	14	Schd:	8:00	8:00	8:00	8:00	8:00	8.00	ο.	00.	
	14	Diff:					•)		0	
	15	Act:	13:55	16:18	10:30	10.40	71.45	. 6	i.		
	15	Schd:	8:10	8:10	8:10	8:10	01.8	70:47	10:05	11:05	
	15	Diff:	345	488	140	150	215	357	8:10	8:10 175	
	,) ! !	7	
	9 ,	Act:	09:15							08:30	
	91	Schd:	7:30	7:30	7:30	7:30	7:30	7:30	7:30	7:30	
	97	Diff:	105							120	
	17	Act:		18:00	09:42	08:45	15:15	17.25	07.11		
		Schd:	8:00	8:00	8:00	8:00	8:00	8.00	04.11	0	
	17	Diff:		009	102	45	435	565	220	00:8	,
	18	٨ ٢		0	0		,				
		Schdi	0.00	00:07	24:42	α:45* β.00°	15:15	17:25*	11:40		
		Diff:))	600	102	0:00 1485	8:00 435	8:00	8:00	8:00	
					*	~	drawn on	_	יים איני		
		Act:	08:40	09:07	09:20		09:30		19 day		
		Schd:	8:00	8:00	8:00	8:00	8:00	8:00	8:00	8.00	
	19	Diff:	40	29	110	105	06	75	90))	
		Act:	08:35	10:58	11:20	13:30					
		Schd:	7:30	7:30	7:30	7:30	7:30	7.30	7.30	000	
	20	Diff:	65	208	230	360		})	25.	
	21	Act:	08:56	10:50	70.17	00.71	7.00	0	6		
	21 5		7:45	7:45	7.45	7.75	07:40	00:00	30:60	!	
	21	Diff:	71	185	152	375	120	/:45 75	7:45 80	7:45	

Verteen X-Ray Function pill/ml HIV HBsAG Serology 01	Subject	Drug	Chest	Pulme	Pulmonary	TSH			HPC	
Screen S	Number	Screen	X-Ray	Fund	tion	µIU/mI	≥Ħ	HBsAG	Serology	HbCAb
01	Time>	Screen	Screen	Screen	Day 42	Screen	Screen	Screen	Screen	Screen
01 Normal Normal 2.10 .										
02 Normal Normal 1.70 .	10	1	•	Normal	Normal	2.10	f	ı		
03 Normal Normal 0.11	02	1	ı	Normal		79.0	ı	4		1
04 . Normal Normal 0.11 . Normal 06 - Normal 0.70 - O.7 - O.7 07 - Normal Normal 0.30 - O.7 - O.7 08 - Normal Normal 0.80 - O.7 - O.7 - O.7 10 - Normal Normal Normal 1.70 - O.7	03	•	•	Normal	Normal	1.70	ı	5	1	1
05 Normal Normal 0.70	04		*	Normal	Normal	0.11	*		1	
06 Normal Normal 0.94 Normal Normal 0.90 Normal Normal 0.90 Normal Normal 0.90 Normal Normal 0.80 Normal Normal 1.90 Normal Normal 1.90 Normal Normal 1.27 Normal Normal 2.01 Normal Normal 1.27 Normal Normal 1.67	05	ŧ	•	Normal		0.70	1	•		1
07 - Normal Normal 0.90 -	90	•	F	Normal	Normal	0.44		,	E	1
08 . Normal Normal Normal O.60	07	1	ı	Normal	Normal	0.90	1		1	
09 . Normal Normal 1.70 .	80	1	•	Normal		09.0	ŧ		1	
10 - Normal Normal Normal 0.80	60	1	ı	Normal	Normal	1.70		1		
11 - Normal Normal 1.90 - - 13 - - Normal Normal - - - 14 - - Normal 1.27 - - 15 - - Normal 2.01 - - 16 - - Normal 0.29 - - + 17 - - Normal 1.40 - - + 19 - - Normal Normal 1.67 - - - 20 - - Normal Normal 1.67 - - - 21 - - Normal Normal 1.37 - - - 21 - - Normal Normal 1.34 - - - 21 - - Normal Normal 0.92 - - - 21 - - Normal Normal - - - - 21 - - Normal Normal - - - - 20 - - Normal	10	1	t	Normal	Normal	0.80	ı	1		1
12 - Normal Normal 1.45 -	11	1		Normal	Normal	1.90	ı	•		1
13 - - Normal Normal Normal -	12	•	ı	Normal	Normal	1.45	ı	•		1
14 - - Normal 1.27 - + -	13	•	f	Normal	Normal		ı	-		
15 - Normal Normal 2.01 -	14	•	1	Normal		1.27	-	*	•	8
16 - Normal	15	•	ır"	Normal	Normal	2.01	-	*		
17 - Normal 4.08 - + + 18 - - Normal 1.40 - - - 19 - - Normal 0.70 - - - 20 - - - - - - - - 21 - - Normal Normal 2.36 - - - - nk Cell = Not Obtained - - - - - - - - rage - <td< td=""><td>16</td><td>•</td><td>1</td><td>Normal</td><td>Normal</td><td>0.29</td><td>, '</td><td>•</td><td>-</td><td>+</td></td<>	16	•	1	Normal	Normal	0.29	, '	•	-	+
18 - Normal Normal Normal 1.40 -	17	1	1	Normal		4.08	-	1	+	-
19 - - Normal Normal Normal 0.70 -	18	•		Normal	Normal	1.40	1	•	The state of the s	1
20 - - Normal 1.67 -	19	ı		Normal		0.70		•		,
21 - - Normal 2.36 - - nk Cell = Not Obtained - - - - rage 1.34 - - Dev 0.92 - - C 4.08 - - C - - - C - - - C - - - - C - - - - C - - - - C - - - - C - - - - C - - - - D - - - - C - - - - C - - - - C - - - - C - - - - C - - - - C - - - - C - - - - C - - - - C - - - <td>20</td> <td>ı</td> <td>1</td> <td>Normal</td> <td>Normal</td> <td>1.67</td> <td>1</td> <td>1</td> <td></td> <td>1</td>	20	ı	1	Normal	Normal	1.67	1	1		1
nk Cell = Not Obtained rage Dev	21	1	ı	Normal	Normal	2.36	1		The state of the s	ı
rage Dev		lot Obtained								
Dev								-		
Dev	Average					1.34				
	Std Dev					0.92				
	Max					4.08		770		
	Min					0.11				

Subj / Day	8	_	2	က	4	2	9	7	8	6	10	17	12	13	14	15	16
2		400		7,	901	007	4	90	7	0,1	400	4	124	100	121	106	778
10		771	711	711	2	00	2	2	± 9	0 !	67	2 :	1 9	071	2	041	
05	132	128	117	122	125	132	112	116	136	137	129	124	130	128	149	132	134
03	132	100	116	107	92	100	101	96	96	92	95	95	118	94	130	106	90
04	. 112	128	112	108	118	124	138	118	123	122	122	132	132	126	140	126	118
05	139	114	102	114	120	118	104	98	114	108	113	108	110	114	110	104	114
90	124	148	108	127	122	122	122	135	116	114	125	124	124	122	133	126	114
07	154	123	144	118	132	134	136	146	134	133	137	128	140	139	128	158	140
80	122	134	118	106	104	114	108	112	126	115	106						
60	120	126	128	120	128	126	126	112	118	116	108	104	122	122	112	122	108
10	128	124	122	114	118	124	124	136	97	125	114	138	124	119	122	127	128
11	130	116	106	86	97	97	106	110	102	93	89	104	100	06	108	108	113
12	134	104	132	118	116	112	115	121	122	122	116	120	134	129	128	102	130
13	132	112	115	109	108	122	108	120	118	106	92	104	110	108	114	110	116
14	112	106	104	114	116	118	122	118	124	107	100	116	128	109	100	108	102
15	140	110	117	116	106	112	122	114	116	107	110	122	104	114	102	117	106
16	117	92	104	06	06	105	102	96	102	108	94	100	106	104	105	102	98
17	100	128	119														
18		108	114	108	116	106	106	124	94	112	103	106	104	96	110	107	105
19	131	108	128	134	110	115	96	120	125	104	118	96	118	86	127	120	98
20	125	122	125	132	116	122	122	110	122	118	114	104	114	118	126	110	112
21	112	95	83	06	94	82	94	105	106	92	96	66	102	100	92	06	88
Summary:	Systolic BP, mmHg	BP, mn	nHg					,		į							
Average	126.1	116.6	115.5	112.9	111.7	114.7	114.0	115.7	115.3	112.6	110.2	112.6	118.6	112.9	119.3	115.8	111.8
Std Dev	12.4	13.7	12.7	11.8	11.9	12.5	12.4	13.1	12.2	12.1	13.3	12.9	12.4	14.9	14.9	15.1	15.0
Max	154	148	144	134	132	134	138	146	136	137	137	138	140	139	149	158	140
Min	100	92	83	06	06	82	94	96	94	92	89	92	100	98	92	06	80

Subj \ Day	17	18	19	20	21	22	23	24	25	26	27	78	29	90	3	32	
0.1	132	122	120			134	136	120	118	138	120	130	126	120	130	128	
02	122	112	116	120	134	122	113	136	145	138	142	138	124	136	134	142	
03	92	92	06	06	06	96	136	86	06	106	106	91	116	106	98	86	i .
40	132	123	110	134	8	140	134	132	124	128	122	132	117	124	132	132	
05	118	108	109	107	110	122	113	123	120		148	124					
90	108	118	120	122	130	-	124	120	133	116	112	140	122	128	134	132	
	128	148	126	136	164	140	138	136	139	144	135	126	122	126	120	120	
80																	
60	108	110	118	116	124	108	132	125	116	114	127	116	140	120	125	116	110
9	120	136	132	119	112	116	125	112	122	135	152	120	132	126	132	124	108
11	86	110	114	127	106	128	110	110	124	116	127	124	130	140	128	126	113
12	100	126	130	124	112	116	116	116	120	134	122	142	135	112	118	132	143
13	114	112	124	107	116	122	122	114	120	122	112	124	122	116	113	124	146
14	122	118	116	118	118	138	135	114	118	123	119	126	114	136	131	124	136
15	98	110	114	116	116	127	143	122	128	130	134	110	133	102	136	124	138
16	92	98	110	110	106	104		98	06	117	129	128	108		116	134	118
17	:																
18	96	100	98	114	107	118			108	130	124		142	137		126	124
19	106	106	119	118	100	112	108	124	120	103	116	120	130	146	. 118	118	
20	119	116	120	114	114	104	136		116	112	125	124	120	124	124	115	117
21	86	103	105	91	96	103			97	117		113	118			120	
Summary:																	
Average	110.1	114.1	115.3	115.7	113.6	119.2	126.3	118.8	118.3	123.5	126.2	123.8	125.1	124.9	124.3	124.2	122.1
Std Dev	14.3	13.3	10.3	12.1	17.4	13.1	4.11	11.3	14.4	11.7	12.3	11.9	9.2	12.3	10.1	9.5	13.6
Max	132	148	132	136	164	140	143	136	145	144	152	142	142	146	136	142	146
Min	86	92	06	06	90	96	108	86	06	103	106	91	108	102	86	98	

Subj \ Day	34	35	36	37	38	39	40	41	42	43	44	45	48	21	54	22	72
01	100	108	108	116	118	116	132	112	116	110	122	126	122	124	128	116	130
02	126	136															
03	94	108	114	110	102	112	100	106	98	98	116	124	106	96	114	113	106
04	134	132	134	118													
05																	
90	130	134	132	124	116	125	120	130	114	130	115	132	134	124	120	132	122
07		126	140	132	108	136	117		142	121				122	108	152	134
90			_														
60	112		117	120	115	104	126	108	112	109	114	132	126	115	116	120	115
10	152	119	122	120	115	122	116	104	116	132	128	120		130	124		
7	138	116	130	119	134	125	134	108	94	112	104	118					
12	128	118	106	123	116	126	123	102	134	126	126	106	126	131	128	126	147
13	120	120	120	120	128	112	131	106	106	120	106	122	128	132	118	112	120
14	124	138	154	124	125	144	127						_				
15	112	123	114	136	130	122	128	122	108	139	110	125	116	124	132	114	138
16	120	111	110	131	115	108	106	97	104	112	116						114
17											/						
18	124	138		120	126		130	132	119	128		122	138	112	134	134	136
19	114	119	126	112	123	124	131	119	128	98	122	Q.	136	116	116	105	113
20	124	118				130	118	119	92	116	121	126	124	112	132	108	
21	121	124	116			120	134	115	100	107	102	96	134	112	100	123	100
Summary:																	
Average	121.9	122.8	122.9	121.7	119.4	121.7	123.3	112.9	112.2	117.2	115.5	120.8	126.4	119.2	120.8	121.3	122.9
Std Dev	13.6	9.9	13.2	7.1	8.8	10.5	10.0	10.4	14.4	12.2	8.3	10.3	9.5	10.1	10.2	13.2	14.2
Max	152	138	154	136	134	144	134	132	142	139	128	132	138	132	134	152	147
Min	94	108	106	110	102	104	100	97	92	86	102	96	106	96	100	105	100

Subj \ Day	180
10	114
02	
03	112
04	
05	
90	144
07	125
80	
60	116
10	
11	
12	126
13	117
14	
15	140
16	123
17	
18	
19	
20	
21	
Summary:	
Average	124.1
Std Dev	11.3
Max	144
Min	112

Figure 1: SD & Range Charts for Systolic BP, mmHg




Figure 2: Systolic BP, mmHg




Table 6b-1 Vital Signs: Diastolic BP

01 64 74 74 60 68 64 68 60 68 61 62 64 74 74 02 72 68 99 68 70 58 56 69 64 60 68 64 60 72 66 64 70 58 60 72 66 68 70 70 70 68 68 69 70 68 68 69 70 68 68 70 68 69 70 68 68 70 68 68 70 68 68 70 68 68 70 68 70 68 70 68 70 68 70 68 70 68 70 68 70 68 70 68 69 69 70 68 69 70 68 69 70 68 69 70 68 69 70 68 69 </th <th>Subi / Day</th> <th>00</th> <th>-</th> <th>2</th> <th>c</th> <th>4</th> <th>2</th> <th>9</th> <th>/</th> <th>8</th> <th>6</th> <th>10</th> <th>11</th> <th>12</th> <th>13</th> <th>14</th> <th>15</th> <th>16</th> <th>17</th> <th>18</th> <th>19</th> <th>20</th>	Subi / Day	00	-	2	c	4	2	9	/	8	6	10	11	12	13	14	15	16	17	18	19	20
1 64 74 74 60 68 64 68 65 61 62 64 74 74 74 74 74 60 68 60 68 65 64 68 60 64 67 64 68 63 64 60 74 62 68 70 64 68 69 64 60 72 66 69 72 66 68 60 72 66 68 70 70 68 69 69 72 66 68 60 68 60 72 66 68 60 68 70 68 69 69 70 68 80 60 68 70 68 69 </th <th></th> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td> </td> <td></td> <td></td> <td> `</td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									-					 `		-						
2. 2 7.2 6.8 9.9 6.8 7.0 5.8 5.6 4.4 6.8 6.3 6.4 6.0 7.4 6.2 6.3 6.4 6.0 7.4 6.2 6.0 6.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 7.4 6.0 </th <th>01</th> <td>64</td> <td>74</td> <td>74</td> <td>09</td> <td>89</td> <td>64</td> <td>89</td> <td>09</td> <td>89</td> <td>65</td> <td>61</td> <td>62</td> <td>64</td> <td>74</td> <td>20</td> <td>7.1</td> <td>74</td> <td>20</td> <td>89</td> <td>20</td> <td>63</td>	01	64	74	74	09	89	64	89	09	89	65	61	62	64	74	20	7.1	74	20	89	20	63
33 56 66 54 69 50 46 52 50 52 58 52 42 50 52 14 80 72 66 68 58 60 58 60 72 66 68 76 60 64 80 72 66 68 76 60 64 78 60 66 58 60 62 58 60 72 66 68 76 60 64 78 71 80 70 66 68 78 71 80 70 66 68 78 71 80 70 66 68 70 66 68 78 71 68 70 66 69 70 69 60 69 70 60 66 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60 60 </th <th>02</th> <td>72</td> <td>89</td> <td>66</td> <td>89</td> <td>20</td> <td>58</td> <td>99</td> <td>44</td> <td>89</td> <td>63</td> <td>64</td> <td>09</td> <td>74</td> <td>62</td> <td>98</td> <td>84</td> <td>29</td> <td>09</td> <td>20</td> <td>09</td> <td>61</td>	02	72	89	66	89	20	58	99	44	89	63	64	09	74	62	98	84	29	09	20	09	61
44 80 72 66 58 66 58 60 72 66 68 76 76 68 76 78 79 66 64 78 71 80 70 68 61 62 58 70 56 60 64 78 71 80 70 68 61 62 84 68 78<	03	56	99	54	69	50	46	52	20	52	28	52	42	20	52	46	99	48	46	48	46	56
15 68 64 54 58 60 66 56 56 62 58 70 56 60 64 16 90 96 74 58 78 71 80 70 68 61 62 84 68 76 18 70 80 72 68 62 77 58 68 76 78 70 <th>04</th> <td>8</td> <td>72</td> <td>09</td> <td>99</td> <td>28</td> <td>99</td> <td>58</td> <td>09</td> <td>72</td> <td>99</td> <td>89</td> <td>9/</td> <td>98</td> <td>82</td> <td>70</td> <td>89</td> <td>64</td> <td>9/</td> <td>29</td> <td>9/</td> <td>72</td>	04	8	72	09	99	28	99	58	09	72	99	89	9/	98	82	70	89	64	9/	29	9/	72
66 90 96 74 58 78 71 80 70 68 61 62 77 58 68 76 78 18 70 84 60 78 60 64 76 72 68 62 77 58 68 76 78 76 78 70 64 52 59 62 64 53 57 70 70 70 64 52 69 60 70 64 52 66 60 70 64 52 69 60 </th <th>05</th> <td>89</td> <td>64</td> <td>54</td> <td>58</td> <td>09</td> <td>99</td> <td>56</td> <td>54</td> <td>62</td> <td>58</td> <td>70</td> <td>99</td> <td>09</td> <td>64</td> <td>52</td> <td>28</td> <td>62</td> <td>99</td> <td>09</td> <td>99</td> <td>62</td>	05	89	64	54	58	09	99	56	54	62	58	70	99	09	64	52	28	62	99	09	99	62
77 84 60 78 60 64 76 72 68 62 77 58 68 76 78 79 70 78 79 70 70 70 70 70 70 70 70 70 70 70 70<	90	90	96	74	28	78		80	70	89	61	62	84	89	78	2	72	20	20	99	70	68
88 70 80 70 64 52 62 69 60 72 55 60 56 50 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 56 50 50 56 50 50 56 50<	07	84	09	78	09	64	76	72	89	62	77	28	89	9/	78	09	74	64	72	64	72	99
19 66 68 68 72 65 60 72 55 60 56 50 60 50 50 60 50 50 60 50 50 60 50 50 60 60 50 60 60 50 60 60 60 50 60<	80	70	8	70	64	52	62	59	62	64	53	22										
0 68 72 70 68 56 73 72 58 69 69 69 1 88 74 59 60 56 56 60 58 72 78 56 60 60 54 78 78 56 60 60 54 78 76 60 60 54 78 78 60 60 54 78 78 60 60 54 78 78 60 60 60 54 78 78 60 60 64 78 78 78 60 60 64 78 78 78 78 78 78 78 78 78 78 78 78 78 79 70 80 68 60 68 69 68 69 68 69 68 89 69 79 70 80 80 80 70 70 80 80 <th>60</th> <td>99</td> <td>68</td> <td>99</td> <td>64</td> <td>72</td> <td>29</td> <td>62</td> <td>99</td> <td>09</td> <td>72</td> <td>55</td> <td>09</td> <td>26</td> <td>20</td> <td>26</td> <td>74</td> <td>52</td> <td>62</td> <td>09</td> <td>62</td> <td>64</td>	60	99	68	99	64	72	29	62	99	09	72	55	09	26	20	26	74	52	62	09	62	64
1 88 74 59 60 56 60 58 72 78 56 60 60 76 72 72 67 85 72 76 66 76 76 76 72 72 67 86 76 76 76 76 76 76 76 76 76 76 66 77 76 76 76 77 70 70 70 70 70 70 70 70 70 70 70 70 70 </th <th>10</th> <td>- 68</td> <td>72</td> <td>70</td> <td>62</td> <td>99</td> <td>99</td> <td>70</td> <td>89</td> <td>56</td> <td>73</td> <td>72</td> <td>28</td> <td>69</td> <td>69</td> <td>28</td> <td>72</td> <td>99</td> <td>75</td> <td>70</td> <td>75</td> <td>64</td>	10	- 68	72	70	62	99	99	70	89	56	73	72	28	69	69	28	72	99	75	70	75	64
2 78 78 72 72 67 85 72 66 66 76 78 79 79 79 79 70 </th <th>11</th> <td>88</td> <td>74</td> <td>59</td> <td>09</td> <td>56</td> <td>56</td> <td>09</td> <td>28</td> <td>72</td> <td>78</td> <td>26</td> <td>09</td> <td>09</td> <td>54</td> <td>9/</td> <td>28</td> <td>64</td> <td>62</td> <td>64</td> <td>62</td> <td>74</td>	11	88	74	59	09	56	56	09	28	72	78	26	09	09	54	9/	28	64	62	64	62	74
13 64 62 56 62 46 60 54 56 44 50 48 52 14 84 68 66 67 62 64 74 72 70 80 56 64 74 68 15 71 68 67 62 64 74 72 70 80 56 64 74 76 68 64 74 72 70 80 56 64 74 74 68 67 66 68 64 68 60 56 68 64 48 60 58 64 58 64 48 60 58 64 48 60 58 64 58 64 48 60 58 64 68 69 58 64 68 74 72 74 68 74 72 74 74 72 74 74 74 72 <th>12</th> <td>78</td> <td>78</td> <td>82</td> <td>76</td> <td>72</td> <td>72</td> <td>29</td> <td>85</td> <td>72</td> <td>99</td> <td>99</td> <td>9/</td> <td>84</td> <td>78</td> <td>82</td> <td>89</td> <td>80</td> <td>7.1</td> <td>82</td> <td>71</td> <td>72</td>	12	78	78	82	76	72	72	29	85	72	99	99	9/	84	78	82	89	80	7.1	82	71	72
4	13	64	62	56	57	56	62	46	09	54	56	44	20	48	52	28	52	48	62	09	62	58
5	14	84	89	99	67	62	64	74	72	22	80	56	64	74	89	54	28	52	72	64	72	75
6	15	71	89	47	58	64	74	09	63	56	52	20	64	56	54	52	99	46	61	29	61	62
7 76 65 68 64 60 58 64 48 60 54 64 58 50 9	16	9	62	64	09	28	68	09	56	99	89	52	59	64	52	99	09	62	29	09	29	74
8 73 61 66 68 64 60 58 64 48 60 54 64 58 50 70 70 77 90 71 56 58 80 76 66 74 72 66 76 66 74 72 66 76 66 74 72 66 76 76 66 74 72 66 76 76 66 72 71 64 60 76 76 76 77 71 64 66 76 76 77 71 64 66 76 77 71 64 76 76 77 71 74 75 77 70 71 70 </th <th>17</th> <td>76</td> <td>65</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>:</td> <td></td> <td>!</td>	17	76	65						:													!
19 80 60 70 77 90 71 56 58 80 76 66 72 71 64 72 66 72 71 64 60 76 77 76 76 77 76 76 76 76 76 76 76 76 76 76 76 76 77 76 77 76 77 77 78<	81	73	61	99	68	64	09	28	64	48	09	54	64	28	20	09	26	09	52	65	52	65
20 70 71 80 68 88 88 60 66 72 71 64 60 76 21 60 54 44 52 56 54 49 57 57 60 58 56 54 55 nary: Diastolic BP, mmHg ge 72.5 68.7 66.2 64.2 65.6 62.6 61.8 63.7 65.7 59.6 63.9 63.9 63.9 64.9 63.7 64.9 67.7 97.7 10.8 11.3 10.3 12.6 67.3 67.9 68.7 68.7 68.7 69.6 63.9 63.9 64.9 63.7 65.7 69.7 69.6 63.9 63.9 63.9 69.0 88 88 85 80 80 72 84 80 80	19	80	9	70	77	90	71	56	28	80	9/	99	74	72	99	09	64	52	47	99	47	99
21 60 54 44 52 56 54 49 57 57 60 58 56 54 55 arry: Diastolic BP, mmHg ge 72.5 68.7 66.2 64.2 65.6 62.6 61.8 63.7 65.7 59.6 63.9 63.9 63.9 63.9 64.9 63.9 64.9 63.9 64.9 63.9 63.9 64.9 64.9 63.9 64.9 63.9 64.9 63.9 64.9 64.9 63.9 64.9 64.9 64.9 64.9 63.9 64.9 64.9 64.9 63.9 64.9 64.9 64.9 63.9 64.9	20	20	70	7.1	80	68	88	88	09	99	72	71	64	09	92	64	28	62	99	64	99	72
ge 72.5 68.7 66.2 64.2 65.6 62.6 61.8 63.7 65.7 59.6 63.0 64.9 63.9 63.9 90 96 99 80 90 88 85 80 80 72 84 86 82	21	09	54	44	52	56	54	49	22	22	09	28	26	54	55	64	54	48	51	64	28	52
ge 72.5 68.7 66.2 64.2 65.6 62.6 61.8 63.7 65.7 59.6 63.9 64.9 63.9 63.9 64.9 64.9 64.9 64.9 63.9 64.9 64.9 63.9 64.9 63.9 64.9 63.0 64.9 63.9 64.9 63.9 64.9 6																						
ge 72.5 68.7 66.2 64.2 65.6 62.6 61.8 63.7 65.7 59.6 63.0 64.9 63.9 63.9 65.9 9.5 8.9 12.6 7.3 9.4 8.9 10.4 8.7 8.1 8.5 7.7 9.7 10.8 11.3 10 90 96 99 80 88 85 80 80 72 84 86 82 50 50 50 50 50 50 60 <t< th=""><th>Summary:</th><td>Diasto</td><td>olic BF</td><td>, mm</td><td>₽ 1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Summary:	Diasto	olic BF	, mm	₽ 1																	
9.5 8.9 12.6 7.3 9.4 8.9 10.4 8.7 8.1 8.5 7.7 9.7 10.8 11.3 10 90 96 99 80 90 88 88 85 80 72 84 86 82 50 54 44 50 50 46 46 46 47 48 50 44 40 48 50	average	72.5		66.2	64.2	64.2		62.6		63.7	65.7	9.69	63.0	64.9			64.5	60.2	63.6	63.2	63.9	65.6
90 96 99 80 90 88 88 85 80 72 84 86 82 82 E2 E4 44 E2 E0 46 46 48 E2 44 48 E0	stdev	9.5	8.9	12.6	7.3	9.4	8.9	10.4	8.7	8.1	8.5	7.7	9.7	10.8		10.4	8.7	9.7	9.1	7.2	8.7	6.5
	max	90		66	80	06	88	88	85	80	80	72	84	98	82	98	84	80	92	82	9/	75
26 34 44 32 30 40 40 44 40 37 44 45 30	min	56	:	44	52	20	46	46	44	48	52	44	42	48	20	46	52	46	46	48	46	52

Subj / Day	21	22	23	47	3	2	77	2	2	3	5	5	3	5	3	3					1
3	70	63	72	86	89	64	09	99	70	64	99	72	102	56	54	64	54	64	62	74	1
	74	1 7	57	72	74	64	74	78	61	89	29	73		70	63						. !
<u>.</u>	56	28	54	20	54	20	09	47	52	78	52	58	56	46	89	26	44	26	64	52	
04	69	98	20	84	84	82	9/	84	54	92	92	74	82	82	20	99	89	,			
0.5	949	20	92	84	74		72	98												84	
9	70	64	92	82	72	70	72	78	88	73	88	99	79	78	88	80	78	72	9/	22	1
07	72	70	99	84	65	62	89	2	54	89	09	99			64	70	64	20	78		
200	-)																		7.1	
3 2	25	909	2	69	89	80	9/	97	98	63	56	64	26	54		99	28	64	26	80	
40	64	71	98	80	74	85	78	70	72	89	55	89	64	74	64	68	72	9/	99	78	
1	64	72	64	9/	2	74	79	80	80	80	98	82	20	89	72	78	71	78	20	80	
12	72	82	99	78	2	74	74	80	80	99	99	79	75	77	80	09	73	99	78	69	
13	09	28	65	99	99	09	99	64	29	62	22	63	9/	28	61	53	99	64	62	71	
14	68	85	89	99	89	80	85	72	65	80	84	72	83	9/	65	80	99	29	99	29	
<u>د</u>	200	9	84	68	72	99	73	70	64	62	26	74	86	2	72	09	09	71	99	64	1
16	02	72		99	28	71	92	98	22		70	84	7.1	72	65	68	75	65	74		
17				99																	
000	61	62			54	62	80		6	82		89	80	72	82	-	28	78		29	ļ
19	56	70	62	74	72	64	09	70	77	83	72	92	72	72	99	78	84	78	90	87	
20	76	48	8		62	64	9/	78	72	74	89	20	7.1	74	70				78	2	
21	63	68			64	61		71	99			63	29	77	26	64			22	89	
Summary:																					
averade	65.6	68.1	70.9	73.6	67.8	68.5	73.4	74.8	2.69	72.1	67.4	7.07	72.6	69.2	68.4	67.4	66.1	67.8	69.7	71.2	63.9
stdev	6.2	9.7	9.9	9.5	7.4	9.2	8.5	10.8	11.9	8.2	11.4	6.9	10.9	9.8	8.8	8.6	10.2	8.4	9.3	9.3	10.9
	76	98	88	98	84	85	92	97	6	88	88	84	86	82	88	80	84	78	8	87	
-	C	,	1	1	i	9	6	7	C	0	C	Ĺ	Ü	(7	72	~	2	ע	ST.	

180	64		09			84	82	99	9/			74	64		78	8							72.8	8.6	84	09
72	99		99			62	64		74			78	73		84			82	68		84		72.0	8.5	84	909
57	54		54			70	80		99			72	56		9			68	65	58	61		63.8	8.1	80	54
54	62		26			80	56		62	72		72	09		99			80	78	72	63		9.79	8.6	80	56
51	72		9			78	64		62	09		77	70		09			52	74	99	89		66.4	7.7	78	52
48	64		26			98			62			78	09		09			98	88	89	64		70.2	12.0	88	56
45	70	28			88				62	74	80	73	63		99			62	80	9/	99		9.07	8.8	88	58
44	64		28			62			89	74	89	64	09		20	64			72	74	64		64.8	6.7	74	50
43	56		89			78	74		28	9/	65	98	09		89	99		79	46	64	09		6.99	10.4	98	46
42	78		20	 		70	72		09	99	48	85	52		55	99		78	74	36	62		63.5	13.4	85	36
Subj \ Day	01	05	03	04	05	90	20	80	60	10	7	12	13	14	15	16	17	18	19	20	21	Summary:	average	stdev	max	nin.

Dec. 17, 1998

Figure 3: SD & Range Charts for Diastolic BP, mmHg





Figure 4: Diastolic BP, mmHg



01 89 02 87 03 77 04 80 05 54 06 87 07 62 08 46 09 52 10 83 11 107 12 60	1					-							-	_	_				-	
	7															-				
	_	70	61	62	52	63	7.1	74	09	22	26	7.1	22	98	28	62	82	9/	99	99
	53	86	56	29	28	65	54	63	53	7.1	28	26	20	99	92	61	26	20	22	61
	64	73	69	51	57	52	61	61	55	26	89	92	87	69	29	29	59	58	22	91
	65	65	64	9/	64	64	69	69	29	69	99	84	84	9/	9/	73	83	98	89	83
	54	20	65	48	59	22	29	54	53	53	62	53	24	48	22	53	20	99	22	9
	69	57	53	64	20	61	59	29	28	61	99	09	29	61	69	22	65	29	99	69
	47	42	47	54	47	29	63	54	99	99	29	61	20	73	26	77	64	69	29	79
\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \	61	62	56	53	22	51	21	54	55	22										•
	52	20	53	51	53	47	25	52	52	22	20	46	20	48	22	48	22	47	49	47
	74	71	74	83	74	9/	69	83	74	20	74	64	63	93	99	99	29	91	83	99
	93	75	64	99	65	64	29	63	73	61	65	61	28	61	09	63	29	65	71	86
	89	29	09	61	99	65	64	65	79	99	09	63	29	09	81	67	71	69	69	2
13 64	43	42	46	43	46	49	46	48	48	44	45	44	42	43	46	20	43	45	44	41
	45	28	48	46	48	48	46	45	20	46	48	48	20	45	46	54	48	20	46	48
15 70	65	77	64	58	69	59	29	29	28	62	29	64	09	22	48	53	54	71	09	9
16 82	85	70	71	74	69	65	70	71	73	02	69	63	79	70	29	79	29	69	70	29
	9/																			
18 70	64	09	73	64	63	61	79	62	64	28	78	9	99	09	09	99	62	99	99	29
	56	29	65	70	9/	29	74	29	8	09	77	69	73	99	87	64	63	69	2	59
	54	65	64	52	63	63	63	22	92	06	29	09	29	99	9	61	59	09	62	69
21 71	20	59	70	56	69	63	61	70	99	57	63	9	22	78	29	59	99	29	58	1/2
Summary Heart Rate,	te, BPM	5																		
71.5	64.0 6	64.2 6	60.7	59.7	60.7	60.2	62.3	6.09	63.7	61.7	62.6	2.09	63.6	63.8	64.4	62.3	61.6	65.3	64.1	66.1
14.6	13.9	12.9	8.6	10.5	9.0	7.5	9.0	9.3	11.8	10.0	9.0	9.5	12.0	13.4	17.8	8.6	10.2	13.6	12.0	13.0
:	93	86	74	83	9/	92	79	83	95	06	78	84	87	93	87	79	83	98	83	91
Min 46	43	42	46	43	46	47	46	45	48	44	45	44	42	43	46	48	43	45	44	4

Subj \ Day	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	4
04	7.1	7.1	77	96	80	9	91	71	67	09	99	20	62	65	65	62	73	73	69	93	62
02	65	84	52	99	71	69	85	77	79	87	88	114		107	85						
03	09	22	70	48	25	09	29	71	63	28	28	69	64	63	29	62	62	61	73	82	64
04	83	92	110	83	93	93	91	100	7.1	83	74	85	81	83			78				
02	57	53	99	73	53		9/	63													
90	64	69	83	87	87	83	69	88	89	73	17	70	9/	83	73	20	9/	85	74	69	96
07	88	20	91	68	20	93	85	74	09	77	61	69			99	53	99	49	9/	20	
80		<u> </u>																			
60	46	20	63	09	74	96	09	83	63	61	9	62	22	63		26	62	54	20	09 .	29
10	70	85	81	83	20	104	107	9/	83	91	91	73	81	91	93	63	8	79	54	87	9
11	63	109	71	83	73	87	79	29	77	74	7.1	74	29	79	92	74	74	74	9/	83	74
12	99	22	71	83	83	83	77	82	74	20	64	81	99	81	71	65	69	70	83	9/	93
13	45	48	69	74	62	65	44	20	53	74	48	63	81	29	99	26	62	52	54	63	20
14	20	22	83	57	09	64	59	56	62	26	23	53	22	70	52	79	20	22	53	53	
15	52	61	81	85	74	71	79	64	74	79	92	81	94	73	92	79	69	83	83	85	83
16	74	85		104	85	101	81	81	87		79	70	11	20	73	8.1	83	77	7.1	83	91
17																					. !
28	73	77	:		85	83	83		96	87		81	91	83	104		85	89		79	87
19	56	79	29	70	70	99	74	64	79	89	99	22	70	79	69	73	73	69	81	64	64
20	70	63	99		58	62	63	09	63	61				61	53				61	21	54
21	09	62			61	28		55	28			62	69	22	61	62		+	27	65	61
Summary																					
Average	64.1	70.9	75.1	77.9	72.5	81.7	74.3	72.4	73.3	73.8	69.1	75.1	73.0	75.6	73.0	67.2	6.07	69.5	68.9	72.5	72.1
Std Dev	11.7	15.7	13.4	15.0	11.4	15.5	15.0	13.0	12.3	11.8	12.0	13.0	11.6	12.3	14.9	9.5	9.4	12.8	12.4	14.4	15.7
Max	89	109	110	104	93	104	107	100	96	9	91	114	94	107	104	81	85	83	83	93	96
Min	45	48	52	48	53	09	44	20	53	26	48	53	55	59	52	53	20	49	20	20	50

03		5	44	45	48	51	54	27	72	180
03 03										
03	63	64	29	61	64	53	69	69	77	76
03										
04	87	6/	74	74	81	81	99	99	73	62
_										
05										
90	29	52	29	7.1	77	29	77	29	61	77
07	69	46				71	20	83	73	20
80										
60	20	45	69	52	51	90	22	89	53	69
10	99	65	79	87		79	93			
-	9	62	73	89			!	İ		-
12	74	74	99	62	9/	85	99	82	69	20
13	45	20	09	69	53	61	61	25	61	65
14										
15	09	7.1	65	9/	9/	70	73	28	107	93
16	63	73	91							
17						!				
18	29	59	83	83	9/	83	91	82	68	
19	9/	9/	69		85	81	79	9/	59	
20	57	62	61	61	58	73	56	29		
21	61	74	77	69	77	91	74	20	62	
Average	63.7	62.7	69.4	71.4	69.7	72.0	71.5	9.69	72.2	70.3
Std Dev	10.3	11.2	10.1	11.3	11.7	11.1	11.4	12.0	15.5	12.6
Max	87	79	91	89	85	85	93	68	107	93
Min	45	45	59	52	51	53	56	52	53	20

Dec. 17, 1998

SD & Range Charts for Heart Rate, BPM Figure 5:




Figure 6: Heart Rate, BPM




Table 6d-1 Vital Signs: Body Temperature

73
ě
ä∶
þ
0
₫
z
<u>"</u>
an
丽

Subj \ Day	00	1	2	က	4	2	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20
	-																				
01	37.0	35.8	36.1	35.6	35.3	35.7	36.2	36.2	35.6	36.1	36.2	35.7	35.6	35.5	36.1	35.5	36.1	36.5	36.0	35.9	36.4
02		36.4	36.2	35.8	38.7	35.5	36.2	36.3	36.6	36.8	37.1	36.7	36.3	36.2	35.4	36.2	35.5	35.5	35.6	36.2	35.5
03	36.6	36.6	36.6	36.1	36.4	36.7	36.6	36.4	37.0	36.8	37.1	36.7	36.3	36.6	36.1	36.7	36.7	37.0	37.0	36.7	36.8
04	36.9	36.7	36.7	36.4	36.7	36.7	36.5	36.8	36.7	36.8	36.5	36.7	36.8	36.9	36.9	36.7	36.9	36.5	37.8	37.7	36.6
90	36.3	36.1	36.2	36.7	35.8	35.9	36.2	36.4	36.1	36.2	36.2	36.0	36.3	36.3	36.3	36.0	36.0	35.9	36.5	35.9	36.4
90	37.0	36.6	36.0	35.9	34.4	36.0	36.0	36.2	35.8	36.3	35.8	36.3	35.9	35.9	35.9	36.0	36.3	36.8	36.6	36.7	36.3
20	36.2	36.3	35.4	35.9	36.7	35.9	36.0	36.2	35.8	36.3	35.8	36.3	35.9	35.9	35.9	36.0	36.3	36.8	36.6	36.7	36.3
80	36.6	36.0	36.3	36.1	35.9	36.1	36.1	36.0	36.0	36.4	36.2										
60	36.6	36.1	36.6	36.0	36.1	36.0	36.0	36.2	36.2	36.2	36.4	36.1	35.8	36.2	36.1	36.2	36.3	36.3	35.9	36.1	36.1
10	37.0	36.7	36.9	36.7	36.9	36.9	37.4	37.1	36.3	36.4	36.9	36.8	36.8	36.7	35.5	36.7	36.9	36.9	36.9	38.1	36.5
11	36.8	37.6	37.3	36.6	36.6	36.0	36.7	36.4	36.6	36.7	36.7	36.3	36.4	36.2	36.3	36.3	36.0	36.2	35.8	36.4	36.2
12	35.6	35.6	35.5	35.6	35.6	35.8	35.0	35.6	36.0	36.3	35.9	35.7	36.0	35.6	35.5	36.4	35.6	36.2	36.4	36.1	35.5
13	36.9	36.2	36.0	35.9	36.1	36.0	35.9	36.0	36.2	36.2	35.5	35.9	35.7	35.7	36.1	35.6	35.0	36.2	35.5	35.8	35.8
14	36.5	36.6	36.4	36.3	36.4	36.4	36.3	36.3	36.2	36.4	36.5	36.5	36.5	36.1	36.5	36.6	36.4	36.6	36.5	36.5	36.5
15	35.6	35.6	36.2	35.8	36.0	35.6	35.4	36.0	36.2	36.1	35.7	35.5	35.7	35.7	35.7	35.3	36.0	36.0	36.0	36.0	35.5
16	36.5	36.7	36.2	36.0	36.4	36.3	35.9	36.4	36.3	36.4	36.2	36.0	36.5	36.5	36.2	36.0	36.0	36.5	36.1	36.3	36.2
17	37.0	36.1								<u> </u>											
18	36.4	36.0	36.2	36.1	36.0	36.2	36.7	36.1	36.1	36.0	36.0	36.1	36.1	36.1	36.4	36.2	36.4	36.1	36.4	36.6	36.1
19	37.0	36.5	36.3	36.2	36.3	36.3	36.3	36.3	36.0	36.4	35.6	36.4	36.1	36.0	36.2	36.5	37.0	35.2	35.8		36.2
20	36.8	36.2	36.2	36.2	36.3	36.1	36.1	36.3	36.4	36.4	36.2	36.4	36.0	36.0	36.4	36.4	36.0	36.1	36.4	37.1	36.4
21	36.7	35.8	36.5	36.3	36.1	36.3	35.9	36.4	35.8	36.1	36.4	36.1	35.9	36.1	35.8	35.9	35.8	36.4	36.6	35.9	36.0

Summary	Body Temperature	mpera		၁																	
Average	36.6	36.3	36.3	36.1	36.2	36.1	36.2	36.3	36.2	36.4	36.2	36.2	36.1	36.1	36.1	36.2	36.2	36.3	36.3	36.5	36.2
Std Dev	0.4	0.5	0.4	0.3	0.8	0.4	0.5	0.3	0.3	0.2	0.5	0.4	0.4	0.4	0.4	0.4	0.5	0.5	9.0	9.0	0.4
Max	37.0	37.6	37.3	36.7	38.7	36.9	37.4	37.1	37.0	36.8	37.1	36.8	36.8	36.9	36.9	36.7	37.0	37.0	37.8	38.1	36.8
Min	35.6	35.6	35.4	35.6	34.4	35.5	35.0	35.6	35.6	36.0	35.5	35.5	35.6	35.5	35.4	35.3	35.0	35.2	35.5	35.8	35.5

Dec. 17, 1998

Table 6d-2 Vital Signs: Body Temperature

Subi / Day	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	4
10	36.1	35.6	36.7	36.2	36.3	35.9	36.1	36.5	36.0	35.2	36.7	36.3	36.0	35.4	34.6	36.0	36.3	35.2	36.6	35.6	35.3
02	35.1	35.3	35.7	36.0	35.9	36.1	36.3	36.7	36.5	36.5	36.4	38.2		38.3	36.9						
03	36.8	36.6	36.7	36.4	36.7	35.8	36.5	36.6	36.7	36.4	36.2	36.7	36.2	36.8	36.5	36.6	36.5	36.7	35.7	36.6	36.1
04	37.0	36.7	37.1	36.7	37.2	37.0	36.7	37.2	36.8	36.9	36.7	36.8	37.0	36.9	36.6	36.6	36.8				
05	36.1	36.1	34.8	35.3	35.0	-	35.7	35.8													
90	36.6	36.4	36.4	36.7	36.1	37.0	37.0	36.5	37.0	36.6	36.7	36.7	37.0	37.1	36.0	35.9	36.9	36.9	36.4	36.0	36.9
70	36.6	36.7	36.4	35.5	36.2	36.6	36.9	39.9	36.7	35.5	36.3	36.7			36.6	36.5	36.6	35.6	36.2	35.6	
80																					
60	36.3	36.0	36.3	37.0	36.4	35.8	36.0	36.4	36.2	36.2	36.4	36.1	36.5		36.3	36.7	36.5	36.2	36.2	36.2	36.1
10	36.9	36.5	36.2	36.1	36.0	35.9	37.0	36.8	36.9	35.8	36.4	36.9	36.6	36.4	35.5	36.4	36.6	36.3	36.6	36.9	36.7
11	36.3	36.1	35.3	1	35.7	35.8	36.1	36.0	36.0	36.3	36.4	36.1	36.7	36.9	36.1	36.4	36.6	35.5	36.2	36.6	36.7
12	36.0	36.2	36.3	35.7	36.4	36.7	35.7	35.8	36.1	36.0	36.4	35.5	36.6	35.8	36.0	35.8	35.4	35.6	36.2	35.4	35.2
13	35.9	36.3	35.0	36.3	34.8	35.6	35.0	39.7	34.8	34.8	35.3	39.5	35.0	33.2	35.5	35.1	36.2	36.0	35.5	34.8	35.2
14	36.5	36.0	37.2	36.1	36.2	36.5	35.9	36.4	35.5	35.8	36.1	36.9	36.4	35.4	36.5	36.7	36.3	35.7	36.1	36.6	
15	35.3	35.0	35.7	35.8	35.3	36.0	36.0	35.8	36.0	34.7	34.6	36.1	35.3	34.1	35.1	35.1	35.4	36.0	35.0	35.4	36.0
16	36.3	36.0		36.7	36.7	36.8	35.8	36.2	36.3		36.1	36.2	36.9	36.1	35.9	36.1	36.2	36.0	36.1	35.8	36.3
17				:	: 	,		;				: :									
18	36.2	36.5	:		35.8	36.6	36.8		36.5	35.8	:	36.7	36.6	36.1	36.7		36.5	35.3		36.8	36.3
19	36.0	35.4	35.7	35.4	34.4	က		35.5	36.3	36.5	36.7	36.3	36.7	36.1	36.1	36.7	36.4	36.2	36.3	36.3	36.4
20	36.3	-	36.6		36.3	36.5	35.5	36.7	36.8	36.0	36.6	36.5	36.1	36.0	36.0				36.2	36.4	36.1
21	36.0	36.2			36.1	36.0	36.1	36.3				36.1	36.3		36.0	36.3			35.7	35.6	35.8
Summary																					
Average	36.2	36.1	36.1	36.1	36.0	36.3	36.2	36.7	36.3	35.9	36.3	36.7	36.4	36.0	36.1	36.2	36.3	35.9	36.1	36.0	36.1
Std Dev	0.5	0.5	0.7	0.5	0.7	0.4	0.5	1.2	9.0	9.0	9.0	0.9	9.0	1.2	9.0	0.5	0.4	0.5	0.4	9.0	0.5
Max	37.0	36.7	37.2	37.0	37.2	37.0	37.0	39.9	37.0	36.9	36.7	39.5	37.0	38.3	36.9	36.7	36.9	36.9	36.6	36.9	36.9
Min	35.1	35.0	34.8	35.3	34.4	35.6	35.0	35.5	34.8	34.7	34.6	35.5	35.0	33.2	34.6	35.1	35.4	35.2	35.0	34.8	35.2

Blank = Not Obtained

Page 45

Table 6d-3 Vital Signs: Body Temperature

		l


Blank = Not Obtained

Subj \ Day	42	43	44	45	48	51	54	57	72	180
10	36.0	36.1	35.4	35.1	36.0	35.8	36.1	36.3	35.8	36.0
02					_,,,,					
03	36.9	37.0	35.7	35.9	36.5	37.0	36.6	36.0	36.2	36.7
04										
05										
90		36.2	36.4	36.4	36.6	36.3	36.6	36.4	36.7	36.7
07	37.2	35.8				36.4	36.1	37.1	36.7	36.4
80										
60		36.1	36.3	36.5	36.2	36.7	36.2	36.5	36.2	36.8
10	36.7	36.6	36.4	36.6		36.7	36.1		ļ	
1	36.4	36.5	36.4	36.6						
12	35.8	35.8	35.6	35.8	36.0	35.0	35.5	35.0	36.0	35.3
13	36.0	35.0	35.5	36.0	36.6	35.9	35.8	36.6	36.6	35.4
14	:	i		,						
15	36.1	36.0	36.4	35.2	35.8	35.5	36.5	36.2	36.7	35.1
16	36.2	36.6	36.9						36.5	36.7
17										
18		36.1		36.1	36.7	36.1	36.4	36.7	35.7	
19		36.3	36.4		37.0	36.1	36.4	35.9	36.6	
20	36.4	36.6	36.3	36.0	36.5	36.8	36.8	36.1		
21	36.0	36.6	36.4	36.3	36.5	37.2	36.2	36.4	36.2	
Summary										
Average	36.3	36.2	36.2	36.0	36.4	36.3	36.3	36.3	36.3	36.1
Std Dev	0.4	0.5	0.5	0.5	0.4	0.6	0.4	0.5	0.4	0.7
Мах	37.2	37.0	36.9	36.6	37.0	37.0	36.8	37.1	36.7	36.8
Min	35.8	35.0	35.4	35.1	35.8	35.0	35.5	35.0	35.7	35.1

Dec. 17, 1998

Page 46

Figure 7: SD & Range Charts for Body Temperature, °C



200 180 160 140 Figure 8: Body Temperature, °C 120 Day of Protocol 100 80 9 40 20 00 34.5 37.5 36.5 36.0 35.5 Body Temperature, °C

Page 48

Table 6e-1 Body Weight

Subj \ Day	00	-	7	က	4	2	9	7	8	6	10	13	12	13	4	15	
				1													- 1
01																	-
02																	
03								-									ļ
04									154	155	156	157	158	159	159	159.5	
05									148	147	148	147	145	147	146	146	
90		169	166	166	169	170	170	170	169	170	169	168	170	170	169.5	170	
07		160	160	164	167	164	171	170	169	172	174	172	173	173	173	179	
80		127	125	125	125	125	126	125	125	125	125						
60		167	166	166	164	164	166	164	165	165.5	169	165	167	175	164	164	
10		167	161	163	161	161	161	162	164	164	164	164	165	166	165	165	•
11		148	148	148	146	146	145	146	146	146	146	146	146	146	148	149	148.5
12		181	180	182	182	182	182	182	185	184	183	184	184	184	182	182	
13		137	139	139	139	140	139	139	140	140	140	140	140	141	141	141	
14			163	161	161	161	162	162	162	163	163	162	162	162	162	164	
15		154	153	153	154	153	153	154	152	152	152	152	153	152	152	152	
16		166	163	163	162	165	165	163.5	165	165	165	165	165	167	166	166	167.5
17		168															
18	-	145	145	145	145	145	145	144	148	148	150	144	150	150	152	151	
19		178	176	176	175	174	174	174	173	177	173	171	172	172	172	172	
20		170	170	172.5		175	175	172	173	174	173	174	174.5	175	176.	175	
21	206	202	200	200	199	200	200	200	202	203	200	203	204	202	202	202	
Summary:	Body Weight, Lb	ight, Lk															
Average	206.0	162.6	161.0	161.6	160.6	161.7	162.3	161.8	161.2	161.8	161.8	163.4	164.3	165.1	164.3	164.8	164.8
Std Dev		18.6	18.0	18.2	18.6	18.4	18.5	18.4	17.9	18.4	17.6	16.2	16.2	15.9	15.3	15.5	15.8
Max	206		200	200	199	200	200	200	202	203	200	203	204	202	202	202	202
Min	206	127	125	125	125	125	126	125	125	125	125	140	140	141	141	141	

Subj \ Day	17	18	19	20	21	22	23	24	25	76	27	28	29	90	31	1
01													150	148	151	
02												221	214	214	216	
03							:					-	148	148	148	148
04	160	159	159	159	159	159	163.5	169	169	163	162	163	163	148	148	148
05	146	146	144	145	144	145	148	150	150			150				
90	170	170	170.5	172	173.5	171	171	172	175	174	173.5	173	172	172	172	172
07	179	178.5	178.5	181.5	179	178	179	181.5	182	180	176	177	178	180	180	178
08																
60	164	166	165	167	166	166	169	166	163	162	164	164	164	167	167.5	168
10	165	168	166	168	169	168	168	168	168	168	168	168	168	167	170	169
11	147	147	147	147	148	147	150	148	150	148	150	150	154	152	149	150
12	183.7	185	183	182	183	180	185	185	184	184	184	184	182	182	184	183
13	140	140	141	140	140	142	140	141	141	142	142	140	141	142	140	139.5
14	166	165	163	164	164	167	168	167	167	167	165	165	165	166	165	167
15	152	152	152	153	153	153	154	154	154	156	157	154	158	156	156	151
16	167	167	167	168	168	168	:	168	168	170	170	170	171		170	171
17						!										ļ
18	152	151	152	152	152	153			152	152	151		151.5	151		152.5
19	171	172	173	173	172	171	172	179	176	178	175	178	177	180	176	178
20	175	178	178	177	179	180		180	182.5	181	181	180	177	180	181	179
21	201	202	204	200	202	202			204	204			204	202		205
Summary:																
Average	164.9	165.4	165.2	165.5	165.7	165.6	164.0	166.3	167.8	168.6	165.6	169.1	168.8	168.1	167.1	165.4
Std Dev	15.7	16.2	16.4	15.8	16.2	15.6	13.4	13.5	16.2	15.9	12.3	19.0	18.7	20.5	18.9	16.9
Мах	201	202	204	200	202	202	185	185	204	204	184	221	214	214	216	205
Min	140	140	141	140	140	142	140	141	141	142	142	140	141	142	140	140


Units: Pounds

Table 6e-3 Body Weight

Subj \ Day	33	34	35	36	37	38	39	40	41	42	43	44	45	48	51	54	57
10	150	150	149.5	150	150	151	149.5	150	149	149	148	149	152	149	148	147	147
02	206	206															
03	151	150	150	150	149.7	151	152	151.5	151	146	144	150	150	150	148	150	150
94	151	150	163	164	162				-								
05																	
90	173	171	170	171	172	172.5	172	172	169	169	172	172	172.5	172	171	170	173
07																	
80																	
60	168	166				:											
10	169	168	168	165	168	167	165	165	165	167	167	169	168	:	170	169	
1	153	151	151	151	149	150	150	148	144	148	150	144	151				
12	184	183	183	183	182	183	183	182	184	184	182	183	184	183	184.5	183	184
13	139	139	141	141	140	139	145	139	139	136	137	136	136	141	141	137	138
14	165	165	164	167	168	168	168	166	168								
15	151	156	156	160	159	155	158	156	159	156	158	161	158	158	158	164	160
16		174	172		171	170	171	171	171	169	168	169					
17										1						***************************************	
18	153	155	153		151	145		152	150	150			154	152	150	150	152
19	176	175		1771	178	176	179	178	175	173	173	177	181	174	179	174	178
20	177	178				182	180	180		179	179	181	180	181	182	180	
21	207	208	208	206			205	206	204	204		204	204	205	204	208	210
Summary:																	
Average	167.1	167.4	163.7	165.4	161.5	162.3	167.5	165.5	163.7	163.8	161.6	166.2	165.9	166.5	166.9	166.5	165.8
Std Dev	19.8	19.2	17.6	17.7	12.9	14.5	16.9	17.7	17.9	18.7	12.1	19.3	19.1	19.9	19.6	20.1	22.6
Max	207	208	208	206	182	183	205	206	204	204	182	204	204	205	204	208	210
Min	139	139	141	141	140	139	145	139	139	136	137	136	136	141	141	137	138

Subj / Day	72	180
10	150	152
02		
03	152	147
40		
05		
90	174	172
07		
80		
60		
10		
11		
12	183	192
13	137	134
14		
15	155	
16		٠
17		
18		
19	178	
20		
21	204	
Summary:		
Average	166.6	159.4
Std Dev	21.9	22.8
Max	204	192
Min	137	134

SD & Range Charts for Body Weight, Lb Figure 9:



200 180 160 140 Figure 10: Body Weight, Lb 120 100 80 90 40 20 8 0.0 100.0 150.0 Body Weight, Lb

Dec. 17, 1998

$\boldsymbol{\sigma}$
Φ
:=
72
≍
=
О
$\overline{}$
\simeq
Z
11
11
¥
_
~
\mathbf{m}
_

DAY 168			
Subject SCR DAY O DAY 28 DAY 54 DAY 84 DAY 112 DAY 140 DAY 168			
DAY 112	`		
DAY 84	1		
DAY 54	1	1	
DAY 28	i	1	
DAY O	1	ı	-
SCR	-	ı	ı
Subject	03	10	11

		>	>	ΛV	DAY	DAY	DAY	DAY	DAY	DAT	ב ב ב	- - -	
400	2	Ę -	<u> </u>	4	7	4	77	28	35	42	54	72	180
Subject	2011	>	-	•									
1	8.1	8.5	6.4	6.2	7.0	7.0	5.1	5.6	5.1	7.4	5.7	6.8	0.9
- 6	4.5	5.0	3.3	4.6	4.9	5.5	2.5	5.2	3.2				
1 6		5.2	5.2	4.1	5.7	4.5	3.5	3.5	3.4	4.0	3.7	5.9	3.0
2		7.2	6.2	6.8	0.9	7.1	7.0	6.3	9.9	6.4			
t u	5. A	3.7	3.2	3.0	3.1	3.5	3.8	3.4	3.1				
ی د	4.3	4 1	4.0	4.9	4.0	4.2	4.4	4.4	3.9	4.0	3.7	6.4	5.8
· ·		5.0	3.9	4.3	4.5	5.7	0.9	4.5	-	5.0	6.1		
. ∞	3.7	3.6	2.0	5.4	4.3					1	C L		
6	5.5	6.4	9.9	8.0	7.2	6.7	6.2	5.7	6.8	7.0	5.8		
5	5.3	4.4	4.7	4.5	4.8	4.5	5.2	5.2	4.6	4.4	2.0		
2 -	888	5.6	4.1	4.5	5.4	0.9	7.9	6.3		6.3			
12	6	4.5	3.8	4.1	4.1	4.0	4.2	3.7	4.3	3.9	4.3		
1 2	. נכ	0.9	5.0	5.1	5.8	5.5	5.3	4.0	4.6	3.7	0.9		
2 7	117	8	7.7	7.7	9.3	6.7	7.0	8.2					,
45	6.4	0.9	6.1	6.1	5.4	5.4	2.0	6.4	6.9	6.1	5.8		8.
16	5.7	6.5	5.6	5.8	5.3	5.6	5.7	5.9	6.0	5.5			
2 1	6.7	4	0.9	1	:	:				1			-
- 0	- 'c	4.6	4	5.1	5.7	6.5	0.9	5.0	4.9	3.8	4.6		
2 5	י ע ר	7.3	5.7	10.8	8.8	10.8	7.0	6.2	5.2	6.4	5.6		
200	47	110	3.6	4.4	5.1	4.8	5.2	5.8	3.6	3.3	6.1		
21	6.7	6.9	6.3	9.9	9.9	7.6	6.2	5.4	5.4	5.4	5.4	5.2	
	F												
Summary:	WBC,	I nousands/cu min	יבח וווווו	u	5.7	20	2.	5.3	4.9	5.2	5.2	6.1	5.9
Average	0.9	5.8	0.0	0.0	2 2	5 4	1.0	12	L. C.	13	0.9	0.7	2.3
Std Dev	1.9	1.5	1.2	8.	C. C.	- 0	4 0 7	1 c	0 0	7.4	6.1	6.8	8.7
Мах	11.7	8.5		10.8	9.3	0.0	. C	2.0	5 6		3.7	5.2	3.0
Min	3.7	3.6	3.2	3.0	3.1	3.5	3.5	ე 1.	- -	3	;	!	

Figure 11: SD & Range Charts for WBC, Thousands/cu mm Box = Mean ±1 SD; Line = Min to Max Scrn ∞ WBC, Thousands/cu mm

Page 57

Day of Protocol

∞	C
Φ	7
0	C
ď	ε
-	đ
	I


Figure 12: SD & Range Charts for Hemoglobin, g/dL Box = Mean ±1 SD; Line = Min to Max Scrn Hemoglobin, g/dL

Dec. 17, 1998

Day of Protocol


		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	1	4	7	14	21	28	35	42	54	72	180
-			10,	, L	0		7	000	6	0.07	0 77	777	42.0
-	46.5	48.0	49.7	43.5	43.0	41.0	45.4	38.8	40.3	40.9	41.8	44.0	43.0
7	45.3	46.0	41.9	45.2	44.3	48.7	44.4	43.3	43.4	43.3			
3	41.8	40.1	44.6	37.6	39.7	42.2	37.6	38.7	34.5	37.0	36.8	36.8	35.5
4	47.4	42.9	45.2	43.2	42.1	41.0	39.8	41.8	40.5				
5	41.6	42.2	41.2	40.6	39.5	39.0	41.4	43.2					
9	42.0	41.2	41.7	40.5	39.4	39.9	37.8	38.9	39.7	40.0	39.7	39.3	41.0
7	43.0	38.3	37.9	39.3	36.8	37.0	38.7	38.9		36.8	39.1		
8	42.9	41.8	40.8	41.3	39.5								
6	42.9	42.8	41.7	44.5	36.4	39.9	39.3	42.5	36.2	42.2	40.3		
10	35.4	35.3	35.8	34.3	32.0	33.5	31.2	33.4	33.5	34.6	34.4		
11	36.5	35.2	34.5	34.0	36.2	33.6	35.4	31.9		32.5			
12	47.9	40.0	43.4	43.0	42.9	39.4	40.0	40.0	40.5	40.6	40.4		
13	44.9	42.5	43.2	40.9	40.0	37.8	39.4	38.6	40.6	42.5	40.2		
14	44.5	41.7	41.4	43.9	44.3	44.1	44.1	42.4	44.2	-			
15	53.3	46.8	43.9	46.0	43.9	42.2	37.0	45.0	47.0	43.5	41.8		
16	43.5	42.6	43.0	42.8	42.3	38.4	39.0	39.7	41.3	37.6			
17	48.3	48.4	47.4										
18	38.9	40.2	40.4	40.8	40.5	40.8	37.0	37.4	38.4	39.6	39.6		
19	45.5	44.1	44.0	45.3	44.8	45.0	44.1	43.0	43.9	42.9	42.7		
20	45.5	42.4	43.6	45.5	44.3	43.3	43.5	56.3	44.0	43.5	46.0	47.6	
21	42.9	43.8	42.8	41.9	43.3	42.8	38.9	41.4	41.0	44.5	43.8	43.3	
Summary:	Hematocrit, %	rit, %											
Average	43.8	42.2	42.3	41.7	40.8	40.5	39.7	40.8	40.6	40.1	40.5	42.3	39.8
Std Dev	4.0	3.5	3.4	3.4	3.4	3.7	3.5	5.0	3.6	3.5	2.9	4.3	3.9
Max	53.3	48.4	49.7	46.0	44.8	48.7	45.4	56.3	47.0	44.5	46.0	47.6	43.0
Min	25.4	35.2	34.5	34.0	32.0	33.5	31.2	319	33.5	32.5	34 4	36.8	35.5

SD & Range Charts for Hematocrit, % Figure 13:



		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
-	5.29	5.49	5.66	4.93	4.94	4.71	5.14	4.42	4.60	4.63	4.74	5.08	5.09
2	4.99	5.18	4.67	5.01	4.92	5.39	4.92	4.90	4.94	4.87			
3	4.76	4.57	5.12	4.31	4.49	4.90	4.33	4.50	3.03	4.37	4.28	4.39	4.42
4	5.30	4.76	4.99	4.84	4.63	4.58	4.43	4.61	4.50				
20	4.78	4.85	4.72	4.67	4.59	4.56	4.74	4.98					
9	4.86	4.80	4.81	4.69	4.85	4.65	4.35	4.48	4.58	4.64	4.59	4.54	4.86
7	4.77	4.32	4.18	4.36	3.98	4.15	4.16	4.31		4.21	4.47		
8	5.01	4.94	4.83	4.85	4.71								
6	4.88	4.90	4.81	5.03	4.15	4.57	4.46	4.84	4.15	4.79	4.55		
10	4.01	4.01	4.07	3.91	3.66	3.82	3.55	3.82	3.85	3.99	3.97		
11	4.18	4.01	4.01	3.89	4.15	3.80	3.98	3.60		3.66			-
12	4.99	4.18	4.54	4.50	4.47	4.15	4.16	4.22	4.34	4.28	4.27		
13	5.01	4.76	4.82	4.52	4.42	4.25	4.39	4.30	4.48	4.71	4.42		
14	4.71	4.51	4.51	4.75	4.68	4.72	4.72	4.56	4.75				
15	6.36	5.68	5.37	5.49	5.22	5.08	4.51	5.10	5.60	5.19	5.01		
16	4.91	4.75	4,82	4.79	4.65	4.32	4.46	4.44	4.63	4.25			
17	5.61	5.65	5.54										
18	4.49	4.70	4.73	4.73	4.70	4.73	4.43	4.40	4.45	4.51	4.64		
19	5.27	5.01	5.09	5.28	5.23	5.18	5.12	4.99	2.08	4.97	4.97		i en
20	4.47	4.19	4.31	4.62	4.34	4.22	4.27	5.54	4.35	4.30	4.57	4.77	
21	4.76	4.79	4.72	4.61	4.76	4.66	4.20	4.49	4.57	4.90	4.74	4.74	
										1			
Summary:	RBC, Mil	RBC, Millions/cu mm	mu										
Average	4.92	4.76	4.78	4.69	4.58	4.55	4.44	4.55	4.49	4.52	4.56	4.70	4.79
Std Dev	0.49	0.48	0.44	0.39	0.39	0.43	0.38	0.45	0.55	0.40	0.29	0.26	0.34
Max	6.36	5.68	5.66	5.49	5.23	5.39	5.14	5.54	5.60	5.19	5.01	5.08	5.09
Min	4.01	4.01	4.01	3.89	3.66	3.80	3.55	3.60	3.03	3.66	3.97	4.39	4.42

Figure 14: SD & Range Charts for RBC, Millions/cu mm




		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	4	21	28	35	42	54	72	180
01	88.0	87.0	87.8	88.2	87.0	86.9	88.2	87.5	87.6	88.2	88.1	87.5	84.0
02	90.7	89.0	89.7	90.1	90.0	90.3	90.2	88.3	87.8	88.9			
03	87.8	87.8	86.9	87.2	88.4	86.0	86.9	85.8	85.6	84.8	85.9	83.8	80.0
40	89.3	90.0	9.06	89.5	6.06	89.0	89.9	2.06	90.0				
05	87.0	86.8	87.2	86.8	86.0	85.0	87.3	9.98					ļ
90	86.4	85.8	86.7	86.0	86.0	85.7	87.0	86.8	86.7	86.3	9.98	80.4	84.0
20	90.0	90.3	2.06	90.1	90.0	9.88	89.0	2.68		87.4	87.4		
90	85.6	84.6	84.5	85.1	84.0								
60	87.9	87.2	86.7	88.3	83.5	87.1	88.2	87.7	87.3	88.0	88.6		
10	88.3	88.0	88.0	87.7	87.6	87.5	87.7	87.4	6.98	9.98	86.5		
7	87.3	87.6	86.0	87.4	87.2	88.5	88.8	88.5		88.8	-		
12	95.9	95.4	92.6	92.6	96.0	95.8	96.2	94.2	94.7	93.0	94.7	94.6	
13	89.5	89.3	9.68	90.3	90.3	88.9	9.68	89.9	9.06	90.2	91.0		
14	94.0	92.4	91.2	92.4	94.7	93.2	93.4	92.8	92.8				
15	83.8	82.3	81.8	83.7	83.9	83.1	81.8	83.1	84.0	83.7	83.5		
16	89.0	89.7	89.3	89.3	91.0	89.0	0.78	89.4	89.1	88.4			
17	85.9	85.6	85.6									-	
18	9.98	85.5	85.2	86.1	86.1		83.0	85.1	86.1	86.5	85.4		
19	86.3	87.9	86.0	85.8	85.6	86.7	86.2	85.9	86.4	86.2	85.8		
20	101.7	101.1	101.2	99.0	102.1	102.4	101.9	101.6	101.0	101.1	100.5	99.7	
21	90.0	91.4	2.06	8.06	8.06	91.7	92.7	92.1	90.0	90.7	92.4	91.4	
Summary:	MCV, fL		0	0	7 00	0	000	4 00	000	7 00	0.08	808	82.7
Average	89.1	88.8	88.0	03.0	- 66	2.80	2.60	03.1	2.60	2.00	03.0	2,7	02.2
Std Dev	04.0	04.0	04.1	03.6	04.6	04.5	04.5	04.1	04.2	0.40	04.0	07.1	02.3
Мах	101.7	101.1	101.2	99.0	102.1	102.4	101.9	101.6	101.0	101.1	100.5	99.7	84.0
Min	83.8	82.3	81.8	83.7	83.5	83.1	81.8	83.1	84.0	83.7	83.5	80.4	80.0

SD & Range Charts for MCV, fL Day of Protocol Box = Mean ±1 SD; Line = Min to Max Figure 15: Scrn MC√, ₹L

	·····	DAY	DA	L									
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	
5	0 00	7 FC	000		0								
5 8	23.3	51.3	30.0	30.1	30.2	30.1	30.1	29.8	30.3	30.1	29.6	29.0	
02	30.6	31.5	30.1	30.8	30.8	30.3	30.4	30.6	30.1	29.8			<u> </u>
03	29.6	29.1	29.6	29.9	29.4	29.6	28.9	29.5	28.8	28.7	28.9	27.7	27.7
04	28.2	31.0	31.0	30.6	30.6	30.8	30.7	30.2	30.2				
02	28.9	28.9	29.0	28.9	28.5	28.9	28.6	28.3	71.6				
90	29.3	29.7	29.5	29.4	29.4	29.7	30.1	30.0	30.6	29.4	28.9	29.4	29.8
07	29.8	30.1	29.7	29.8	33.4	30.8	30.8	28.3		28.4	28.4		1
08	27.9	27.8	28.3	27.9	28.0								
60	29.5	29.3	29.6	29.3	33.2	29.9	28.8	28.6	28.8	29.0	29.8		
10	29.8	29.5	29.5	29.4	31.3	29.9	28.7	28.2	28.6	28.5	29.5		
11	28.8	29.6	29.9	30.0	29.1	28.6	28.5	29.0		29.3			
12	31.2	31.2	31.3	30.8	31.3	31.5	31.8	32.7	32.5	32.5	32.3		
13	29.8	30.2	30.5	31.0	30.8	39.6	31.5	31.5	31.1	31.2	30.4		
4	32.7	31.1	31.5	31.8	31.7	32.4	31.8	31.5	31.2				
15	27.7	28.0	28.7	28.9	27.6	29.4	28.8	29.9	28.8	28.5	29.0		
16	29.9	29.0	28.9	30.1	29.6	29.9	29.6	29.9	29.3	29.0			
17	28.9	28.4	28.9										
18	28.9	28.5	28.6	28.5	28.5	27.8	28.4	28.3	28.4	28.3			
19	28.6	29.0	29.5	29.5	29.4	29.5	28.9	29.4	29.1	29.6	29.1		
20	35.5	34.4	34.7	36.6	34.4	34.7	35.4	34.9	34.6	34.6	33.9	33.8	
24	31.9	31.6	31.4	31.5	31.4	31.3	32.0	31.6	31.7	31.2	31.1	34.9	
Summary:	MCHC, g/dl	/dL									-		
Average	29.9	30.0	30.0	30.2	30.4	30.8	30.2	30.1	30.3	29.9	30.1	31.0	29.2
Std Dev	01.8	01.6	01.4	01.8	01.8	02.6	01.8	01.7	01.7	01.7	01.6	03.2	01.3
Max	35.5	34.7	36.6	36.6	39.6	39.6	35.4	34.9	34.6	34.6	34.9	34.9	30.1
Min	27.7	27.8	28.3	27.9	27.6	27.8	28.4	28.2	28.4	28.3	28.4	27.7	27.7

Figure 16: SD & Range Charts for MCHC, g/dL




Units: Picograms

Table 8g MCH

	Subject Scrn	01 34.1			04 31.5			07 33.3	08 32.5		10 . 33.7			13 33.3	14 43.8	15 33.1	16 33.1		18 33.3	19 33.1	20 34.9	21 35.4	Summary: MCH, pg			
DAY	0	36.3	35.3	33.2	34.4	33.3	34.6	33.3	32.9	33.5	33.5	33.8	32.6	33.8	33.6	33.9	32.4	33.2	33.2	32.9	34.0	34.5	ס	33.7	6.00	
DAY	-	34.2	33.6	34.1	34.2	33.3	34.0	32.7	33.4	34.1	33.2	34.7	32.7	34.0	34.5	35.0	32.4	33.7	33.6	34.4	34.3	34.5		33.8	2.00	
DAY	4	34.1	34.1	34.3	34.1	33.2	34.3	33.1	32.8	33.2	33.5	34.3	32.2	34.3	34.4	34.5	33.7		33.0	34.3	36.8	34.6		33.9	6.00	-
DAY	7	34.7	34.2	33.2	33.6	33.3	34.2	37.1	33.3	37.9	33.4	33.3	32.6	34.1	33.5	32.9	32.5		33.1	34.3	33.6	34.5		34.0	01.4	
DAY	14	34.6	33.6	34.4	34.5	33.9	34.7	34.8		34.4	34.1	32.3	33.1	35.5	34.7	35.3	33.6		32.3	34.0	33.8	34.1		34.1	6.00	1
DAY	21	34.1	33.7	33.3	34.2	32.8	34.8	34.8		32.7	32.7	32.0	33.1	35.2	34.0	35.1	34.1		34.3	33.6	34.7	34.5		33.9	6.00	1
DAY	28	34.0	34.7	34.3	33.3	32.7	34.5	31.5		32.6	32.3	32.7	34.5	35.1	33.9	35.2	33,4		33.2	34.2	34.4	34.3		33.7	0.10	C
DAY	35	43.6	34.3	33.6	33.6		35.3			33.0	32.9		35.0	34.4	33.6	34.3	32.8		33.0	33.7	34.2	35.2		34.5	02.5	0
DAY	42	34.1	33.5	33.8			34.0	32.5		33.0	32.9	33.0	34.3	34.5		34.1	32.8		32.3	34.4	34.2	34.4		33.6	7.00	1 70
DAY	54	33.6		33.6			33.3	32.5		33.6	34.0		34.2	33.4		34.1			33.1	33.9	33.5	33.7		33.6	00.5	0.70
DAY	72	33.2		33.1			34.0									34.6					33.9	31.9		33.5	6.00	0 7 0
DAY	180	35.9		34.3			35.4											ļ						35.2	00.8	25.0

Figure 17: SD & Range Charts for MCH, pg




	- 70
	=
	≂
	ب
_	C
윤	_
œ	Q.
4s	t
	•
Ω	Q
╦	0
Ta	=
_	
	ပ
	:=
	7

ס
ĕ
\subseteq
7
ŏ
\overline{o}
<u>.</u>
0
Z
11
×
Ξ
ā
Ω

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	. DAY	DΑΥ	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
01		2.0	7.0	2.5	1.8	1.5	1.5	1.5	2.0	1.5	1.9	1.0	1.
02		1.5	0.1	1.8	1.9	1.4	2.0	4.0	1.9	0.5			
03		1.0	1.5	0.7	3.5	1.2	2.0	0.1	2.0	1.4	1.6	1.2	1.3
04	9.0	1.2	2.5	2.8	1.9	2.0	3.0	4.4	1.0				
05	1.2	2.3	2.0	2.5	2.4	1.5	1.5	2.8					
90		0.4	1.0	0.5		3.6	1.6	1.5	1.0	1.0	0.8	6.0	2.0
07	1.0	0.5	0.2	1.	1.0	2.4	3.8	1.3		1.4	0.8		
80	9.0	1.0	1.6	9.0	1.5								
60	0.1	1.3	1.2	1.2	1.0	2.0	2.5	1.0	2.4	0.5	0.3		
10		2.0	0.1	0.3	1.0	1.7	2.0	1.1	0.1	9.0	1.2		
11	2.7	4.3	2.1	6.0	3.0	4.5	6.7	5.4		1.0			
12		2.5	2.8	2.0	1.3	1.1	0.0	2.0	4.6	1.2			
13			3.3		1.4	1.8	1.5	1.8	2.0	1.1	1.3		
14			3.9	2.3	2.4	1.7	2.4	2.2	0.3				
15			2.7	2.0	3.6	1.7	1.6	2.6	1.5	2.6	2.8		
16			2,1	1.0	0.8	8.0	1.3	2.7	6.0	0.5			
17		1.0	1.0										
18		1.2	1.3	9.0	9.0	9.0	6.0	1.5	1.5	2.4	6.0		
		6.0	0.3	0.7	1.0	0.4	, 1.8	1.0	0.3				
50	i i i	6.0			1.8	2.5	3.5	3.0	1.0	2.0	1.4	3.2	
21	0.3	1.0	2.0	1.4	3.0	3.5	1.0	1.2	3.4	0.5	3.4	0.5	
Summary:	Reticulo	Reticulocyte Count	t, %										
Average	0.9	1.5	1.6	1.4	1.8	1.9	2.1	2.0	1.6	1.2	1.5	1.4	1.5
Std Dev	6.0	6.0	1.1	9.0	6.0	1.0	1.4	1.3	1.2	0.7	0.9	1.1	0.5
Max	2.7	4.3	3.9	2.8	3.6	4.5	6.7	5.4	4.6	2.6	3.4	3.2	2.0
<u>.</u>	0.1	0.4	0.1	0.3	9.0	0.4	0.0	0.1	0.1	0.5	0.3	0.5	1.1

Figure 18: SD & Range Charts for Reticulocyte Count, %



ਰ
Φ
č
-
a
<u>~</u>
•
റ
_
·
0
7
_
Ħ
¥
\Box
a
==

Table 8i WBC Differential: Eosinophils

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
10	0.0	0.0	5.1	5.1	4.6	5.4	6.2	5.8	5.6	3.3	3.9	5.6	0.0
02	0.0	0.0	3.0	4.8	4.9	5.1	5.5	6.2	0.3	1.9			-
03	1.2	1.3	1.2	2.1	1.3	2.2	2.3	2.5	1.7	1.4	3.5	0.0	0.0
04	a contract of the contract of	1.1	1.3	1.0	1.7	0.0	6.0	9.0	0.0				
05	4.7	6.0	5.7	4.0	0.0	0.0	3.8	3.4					
90	0.0	0.7	1.9	0.0	1.9	2.3	1.9	2.7	2.1	2.2	7.5	2.0	0.0
07	0.0	2.8	3.6	5.6	3.8	0.9	0.0	3.9		3.5	0.0		
80	4.0	5.4	5.9	0.9	0.0								
60	1.2	1.0	2.5	2.3	1.3	2.0	1.7	1.5	0.8	1.7	1.0		
10		2.5	2.3	1.2	2.0	1.8	1.8	2.9	1.7	2.1	1.8		
11	2.4	6.0	0.0	4.0	0.0	3.3	3.1	3.8	:	4.7			
12	6.0	8.0	1.6	2.4	2.0	2.2	1.6	1.8	0.0	1.7	1.7		
13	2.5	1.4	4.2	3.7	3.1	3.8	3.5	3.5	4.3	5.1	4.7	4.7	
14	0.0	1.4	2.0	2.0	1.2	1.7	2.0	4.1	2.0				
15	6.7	5.2	8.0	7.9	12.0	9.6	11.6	16.1	15.9	14.3	12.0		0.0
16	0.0	2.2	3.2	3.3	3.2	3.7	0.0	4,9	3.5	3.0			
17												,	
18	2.8	3.6	1.0	1.0	3.7	3.4	0.0	3.2	3.1	3.1	2.4		
19	2.7	2.8	0.0	3.0	2.6	2.0	3.3	3.4	3.3	2.7	3.0		
20	2.2	0.0	3.0	0.0	2.7	10.0	4.0	2.3	2.0	2.5	1.1	2.0	
21	2.1	2.6	2.3	2.7	3.1	2.6	2.8	3.0	0.0	3.4			-
Summary	WBC Differential:		Eos, %										
Average	1.9	2.1	2.9	3.1	2.8	3.5	2.9	4.0	2.9	3.5	3.1	2.9	0.0
Std Dev	1.8	1.8	2.1	2.1	2.6	2.7	2.7	3.2	3.8	3.1	3.1	2.3	0.0
Мах	6.7	0.9	8.0	7.9	12.0	10.0	11.6	16.1	15.9	14.3	12.0	5.6	0.0
Min	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.4	0.0	0.0	0.0

Figure 19: SD & Range Charts for WBC Differential: Eos, %




Table 8j WBC Dlfferential: Segmented

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	_	4	7	14	21	28	35	42	54	72	180
10	0.99	68.0	51.4	51.7	55.9	57.6	56.3	0.09	57.5	65.1	52.8	52.2	68.0
02	50.0	52.0	46.0	49.2	50.3	45.7	44.0	6.03	56.5	37.5			
03	54.2	53.2	51.0	43.0	63.8	48.5	47.7	44.6	52.2	47.6	57.7	76.0	50.0
90		64.9	57.7	60.3	52.5	59.0	65.1	72.1	61.0				
05	50.1	51.4	45.7	41.0	51.0	59.0	51.0	51.3	57.4				
90	58.0	64.8	54.1	58.0	58.1	8.09	66.2	55.7	59.1	6.09	58.2	9.07	64.0
07	52.0	46.5	48.7	46.4	54.3	53.2	58.0	60.3		53.6	63.0		
80	48.0	38.1	35.1	36.0	42.0								
60	61.1	67.2	61.9	64.4	67.0	53.0	65.7	8.99	69.2	68.5	65.2		
10	51.6	48.3	49.5	57.7	49.0	58.0	63.5	58.8	54.2	49.7	45.6		
11	63.3	77.6	78.0	42.4	52.0	52.2	29.7	58.8		54.7			
12	60.2	53.0	56.5	49.2	51.6	55.8	52.1	55.0	0.93	53.9	55.7		
13	54.4	53.9	42.1	48.2	54.4	46.0	43.9	43.9	46.7	43.6	40.2	57.9	
14	69.0	56.5	56.6	56.0	61.5	59.1	55.9	62.9	65.5				
15	41.4	40.0	47.0	41.8	47.0	38.5	36.3	43.9	44.9	37.0	43.0		
16	0.09	65.0	57.2	54.1	56.3	97.2	62.0	50.3	53.8	53.2			
17	58.9	72.0	54.0					,					
18	61.4	48.8	46.0	53.0	47.2	46.4	51.0	51.3	45.2	31.2	42.8		
19	53.3	55.3	50.0	51.5	48.3	65.8	45.9	49.6	49.9	58.9	56.1		
20	52.6	43.0	30.0	49.0	51.6	32.0	50.0	48.5	53.1	35.3	0.99	44.7	
21	60.4	66.1	60.1	62.0	59.9	58.9	56.3	59.3	0.09	50.9	59.4	56.5	
Summon.	WBC Diff	WBC Diff. Segmented %	% po										
Average	56.3	56.5	51.4	50.7	53.7	53.0	54.2	54.9	55.4	50.1	54.3	29.7	60.7
Std Dev	06.7	10.8	6.60	07.6	06.1	08.4	08.4	07.8	2.90	10.9	08.8	11.7	09.5
Aax	0.69	77.6	78.0	64.4	67.0	65.8	66.2	72.1	69.2	68.5	0.99	76.0	68.0
Min	41.4	38.1	30.0	36.0	42.0	32.0	36.3	43.9	44.9	31.2	40.2	44.7	50.0

SD & Range Charts for WBC Diff: Segmented, % Day of Protocol Box = Mean ±1 SD; Line = Min to Max Figure 20: Scrn WBC Diff: Segmented, %

Page 75

\mathbf{o}
a
⊆
-=
a
-
Ω
_
O
_
+
0
_
Ш
×
⊏
Ø
_
m

Table 8k WBC Differential: Monocytes

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
01	7.0	6.0	8.0	9.7	7.6	7.4	8.7	7.8	8.6	6.2	9.1	9.7	8.0
02	17.0	11.0	2.0	12.8	10.9	13.2	14.8	8.9	19.0	20.5			
03	6.5	7.8	7.0	6.5	6.2	5.7	6.5	6.2	6.5	7.8	0.9	3.0	8.0
90		3.6	6.1	7.5	7.5	6.0	7.4	8.0	0.9				
02	6.8	8.3	8.9	9.0	12.0	7.0	10.0	8.1		1	1		
90	7.0	6.7	8.6	8.0	7.4	7.0	7.1	7.5	7.7	8.2	7.1	7.9	7.0
07	9.0	9.5	9.6	10.9	10.2	10.2	10.0	10.7		10.5	7.0		
80	17.0	14.6	13.5	13.0	15.0								
60	10.5	9.5	9.6	8.9	8.0	11.0	8.1	9.4	10.1	8.0	8.6		
10	5.0	8.3	7.8	10.5	1.0	8.1	8.2	8.9	8.9	8.5	12.8		
11	7.5	8.4	6.0	9.3	0.9	8.6	9.9	6.8		8.1			
12	9.7	6.3	8.3	7.1	8.4	7.1	8.2	8.2	8.0	8.3	9.7		
13	9.2	9.4	10.0	8.1	11.8	10.5	6.6	9.9	11.1	10.3	12.6	8.1	
14	10.0	10.8	12.1	11.0	12.6	12.2	12.5	10.2	12.1				
15	7.0	8.4	0.9	8.4	10.0	. 8.8	7.5	8.4	6.7	9.7	8.0		8.0
16	6.0	2.2	7,4	7.4	6.9	8.4	6.0	7.8	7.4	7.3			
17	10.2	5.0	8.3										
18	9.6	10.6	8.0	0.9	12.0	11.8	11.0	8.8	10.5	9.6	10.0		
19	7.7	7.4	0.9	8.6	9.7	7.2	7.6	7.3	7.9	9.7	7.3		
20	8.7	0.9	7.0	9.0	7.7	18.0	8.0	10.4	10.6	11.4	8.8	10.4	
21	9.1	6.8	4.8	8.6	9.7	8.7	7.6	8.6	9.0	9.6	8.4	9.0	
										-			
Summary:	WBC Diff	WBC Diff: Monocytes,	tes, %										
Average	8.9	8.1	7.9	9.0	8.8	9.3	8.7	8.5	9.4	9.4	8.7	8.0	7.8
Std Dev	3.1	2.5	2.5	1.9	3.1	3.0	2.2	1.2	3.1	3.3	2.0	2.6	0.5
Max	17.0	14.6	13.5	13.0	15.0	18.0	14.8	10.7	19.0	20.5	12.8	10.4	8.0
Min	5.0	3.6	2.0	6.0	1.0	5.7	0.9	6.2	0.9	6.2	0.9	3.0	7.0

Figure 21: SD & Range Charts for WBC Diff: Monocytes, % Box = Mean ±1 SD; Line = Min to Max Scrn WBC Diff: Monocytes, %


Page 77

Day of Protocol

Table 8L WBC Differential: Lymphocytes

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	41	21	28	35	42	54	72	180
01	27.0	26.0	35.5	33.0	39.5	29.1	28.3	26.2	28.2	25.4	34.1	31.6	24.0
02	33.0	37.0	48.0	31.9	33.5	35.2	35.0	34.0	23.8	39.6			
03	37.7	37.7	40.7	48.2	28.3	43.3	43.3	46.7	39.4	42.9	32.9	16.0	42.0
04		30.2	34.1	30.9	38.8	35.0	26.2	18.5	33.0				
05	38.4	34.1	39.4	45.0	37.0	34.0	34.9	31.0					
90	35.0	27.6	35.1	34.0	32.5	29.4	24.5	33.7	30.6	28.1	33.0	19.1	29.0
07	39.0	40.9	38.1	36.2	31.1	30.2	32.0	24.4		32.3	28.0		
90	31.0	41.7	45.0	34.0	43.0								
60	27.2	22.2	26.0	24.2	23.5	27.0	24.3	21.2	19.5	21.7	24.9		
10	38.5	40.9	39.6	30.2	48.0	32.0	26.2	28.7	32.1	38.7	39.2		
17	26.3	12.9	16.0	44.0	42.0	35.5	30.3	2.2		31.5			
12	30.9	39.6	33.2	39.8	37.0	34.9	37.7	34.9	36.0	35.9	34.5		
13	33.6	35.2	43.6	39.1	30.6	39.6	42.6	42.6	37.8	40.9	42.5	29.2	
14	21.0	31.0	29.2	29.0	24.2	26.5	28.9	21.9	19.8				
15	43.7	46.0	37.0	41.7	31.0	42.6	44.0	31.0	32.0	39.9	37.0		21.0
16	34.0	26.7	32.0	35.2	31.5	30.0	31.0	35.7	34.4	35.7			
17	21.2	22.0	29.5										
18	26.0	36.6	44.0	40.0	36.9	48.1	38.0	36.1	40.8	55.4	44.5		
19	35.9	33.1	44.0	36.1	40.2	24.5	42.9	39.1	37.5	29.9	32.3		
20	36.4	45.0	0.09	42.0	37.9	40.0	38.0	36.1	34.0	50.5	23.6	42.1	
21	27.8	24.0	29.1	26.2	28.8	28.7	32.7	28.6	31.0	35.8	27.6	29.5	
Summary:	WBC Diff	WBC Diff: Lymphocytes. %	cvtes. %										
Average	32.2	32.9	37.1	36.0	34.8	34.0	33.7	30.1	31.9	36.5	33.4	27.9	29.0
Std Dev	6.2	8.6	9.2	6.4	6.4	6.4	9.9	9.9	6.4	8.7	6.4	9.4	9.3
Max	43.7	46.0	0.09	48.2	48.0	48.1	44.0	46.7	40.8	55.4	44.5	42.1	42.0
c	21.0	12.9	16.0	24.2	23.5	24.5	24.3	2.2	19.5	21.7	23.6	16.0	21.0


SD & Range Charts for WBC Diff: Lymphocytes, % Figure 22:



9a	Ξ
<u>Ф</u>	÷
ap	Š
\vdash	٠,

136			νΔΛ	ΛΔΛ	DAY									
01 138 136 137 140 137 140 140 140 170 140 130 136 136 136 138 136 137 138 139 140 141 141 138 139 142 142 142 142 142 142 148 141 141 141 141 141 141 141 141 141	Subject	Scrn	0	-	4	7	4	21	28	35	42	54	72	180
01 138 136 137 140 140 140 140 140 141 136 138 137 140 140 141 136 138 137 138 136 136 136 136 136 136 136 140 140 141 138 137 142 143 143 143 143 143 143 143 143 143 144 144 136 140 141 141 138 138 138 138 138 138 138 138 138														
02 136 136 138 137 138 137 138 137 138 137 138 137 136 139 134 139 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 143 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142 140	01	138	136	137	140	137	140	140	140	142	140	141	139	141
03 140 140 141 136 136 134 134 139 142 140 140 140 140 140 140 140 140 140 140 140 140 140 141 141 138 139 140 141 141 138 138 139 138 138 139 138 139 138 139 138 139 138 139 138 139 138 139 138 139 138 139 138 139 138 139 138 139 138 139 138 139	02	136	136	138	138	137	138	136	148	148	129			
04 141 141 138 134 139 139 05 142 142 136 139 142 142 142 06 142 142 136 137 141 138 149 140 07 136 148 147 142 136 139 140 09 148 141 142 138 139 140 140 10 137 134 137 132 136 140 139 11 145 136 137 141 141 136 141 141 136 13 140 139 141 142 136 141 141 138 139 139 14 141 138 141 142 139 138 138 138 16 141 142 136 141 141 142 138 138 138	03	140	140	141	136	136	134		140	140	141	140	142	139
05 142 142 136 139 142 142 142 06 142 142 137 141 138 139 141 08 147 138 132 138 139 140 09 148 141 142 138 139 140 140 10 148 141 142 138 139 140 139 140 11 145 136 136 137 140 139 140 139 12 137 138 139 141 141 141 136 136 14 141 138 139 141 141 138 139 139 15 140 139 141 142 138 139 138 16 141 142 137 141 142 138 139 149 17 140 139 141	04	141	141	138	134	139	139		141	138				
06 142 142 137 141 138 139 141 07 136 133 132 138 139 140 08 147 138 137 135 137 140 140 10 148 141 142 138 139 139 140 11 145 135 135 140 141 141 136 12 137 139 140 141 141 136 136 14 141 142 136 141 142 136 136 14 141 138 141 142 136 136 136 15 140 141 141 142 136 136 136 15 140 139 141 141 143 136 136 16 141 142 136 136 137 136 136 <	05	142		136	139	142	142	142	142					
07 136 133 132 138 139 140 08 147 138 137 135 137 140 09 148 141 142 138 139 139 140 10 137 134 137 135 137 140 139 12 137 136 139 141 141 141 138 13 140 139 139 141 142 139 138 14 141 138 141 142 138 138 15 140 139 141 141 138 138 138 16 141 142 139 138 138 138 138 15 140 139 141 141 138 138 138 19 141 142 137 138 139 138 19 144 137 <th< td=""><td>90</td><td>142</td><td>142</td><td>137</td><td>141</td><td>138</td><td>139</td><td>141</td><td>140</td><td>140</td><td>138</td><td>140</td><td>137</td><td>135</td></th<>	90	142	142	137	141	138	139	141	140	140	138	140	137	135
08 147 138 137 135 137 140 10 148 141 142 138 139 139 140 10 137 134 137 132 135 137 140 11 145 135 136 141 141 136 137 136 12 140 138 136 141 141 138 139 15 140 139 141 141 138 138 16 141 141 138 143 138 138 16 141 142 137 138 138 138 17 140 139 140 137 138 138 138 19 141 142 137 138 139 138 20 138 140 137 138 139 138 140 139 142 142 <t< td=""><td>07</td><td>136</td><td></td><td>133</td><td>132</td><td>138</td><td>139</td><td>140</td><td>143</td><td>138</td><td>141</td><td>141</td><td></td><td></td></t<>	07	136		133	132	138	139	140	143	138	141	141		
09 148 141 142 138 139 140 140 10 137 134 137 135 137 140 135 140 135 11 145 135 136 137 140 139 136 12 137 140 143 141 141 136 138 138 14 141 138 136 141 141 138 138 15 140 139 141 141 138 138 138 16 141 142 137 134 138 138 138 19 141 142 137 138 138 138 138 20 138 140 137 138 139 138 21 144 135 137 138 139 138 21 140 139 137 138 139 139	80	147	138	137	135	137								
10 137 134 137 135 135 135 136 137 140 139 12 135 135 136 137 140 141 141 136 13 140 148 139 141 142 139 138 138 14 140 139 139 141 141 138 139 138 139 16 141 148 139 141 141 138 139 16 141 141 138 141 141 138 139 17 140 139 141 139 138 139 17 140 139 141 139 138 129 20 138 140 137 138 139 138 21 144 137 138 139 138 21 144 137 138 139 138 <td>60</td> <td>148</td> <td>141</td> <td>142</td> <td>138</td> <td>139</td> <td>139</td> <td>140</td> <td>142</td> <td>140</td> <td>143</td> <td>142</td> <td></td> <td></td>	60	148	141	142	138	139	139	140	142	140	143	142		
11 145 135 135 136 137 140 139 12 137 139 140 141 141 136 13 140 143 136 137 137 137 136 15 140 139 139 141 141 138 139 16 141 143 139 141 141 138 139 16 141 141 139 141 138 138 16 141 141 141 139 138 138 17 140 139 141 138 138 138 138 19 144 142 137 138 138 139 137 20 138 137 138 139 138 138 144 137 138 139 138 139 138 148 148 142 142 <	10	137	134	137	132	135	137	135	137	138	138	135		
12 137 139 140 141 141 136 13 148 139 141 142 139 138 14 141 138 136 141 142 136 139 138 15 140 139 139 141 141 138 139 16 141 142 139 141 138 139 138 17 141 138 140 137 138 139 138 20 138 139 140 137 138 139 138 20 138 137 138 139 138 139 138 30 140 137 135 135 139 138 age 140 137 138 139 138 Bov 04 03 02 03 02 02 03 134 134 132 13	11	145	135	135	138	137	140	139	138		138			
13 140 148 139 141 142 139 138 14 148 136 137 137 137 136 15 140 139 141 141 138 139 17 140 139 141 139 138 138 18 134 137 134 137 136 20 138 140 137 138 129 20 138 140 137 138 139 137 21 144 137 136 137 138 21 144 137 136 137 139 137 21 144 137 138 139 138 138 32 140 139 138 139 138 138 32 34 34 34 34 142 34 43 134 135 135 135 <td>12</td> <td>137</td> <td>139</td> <td></td> <td>140</td> <td>141</td> <td>141</td> <td>136</td> <td>140</td> <td>138</td> <td>140</td> <td>141</td> <td></td> <td></td>	12	137	139		140	141	141	136	140	138	140	141		
14 141 138 136 137 137 136 136 15 140 139 141 141 138 139 139 139 16 141 142 139 141 139 138 138 139 17 140 139 141 137 134 137 136 139 20 138 140 137 138 139 138 138 21 144 137 135 137 139 137 mary: Sodium, mEq/L 137 138 139 138 Dev 04 03 02 03 02 03 03 134 148 148 142 141 142 142 142 134 133 132 135 134 129	13	140	148	139	141	142	139	138	134	140	139	141		
15 140 139 141 141 138 139 16 141 141 138 141 149 138 138 138 17 140 139 141 142 137 137 136 19 141 142 137 138 136 138 129 20 138 140 137 136 137 137 21 144 137 135 137 139 137 mary: Sodium, mEq/L Dev 04 03 02 03 02 03 03 134 148 142 141 142 142 142 134 134 135 135 134 129	14	141	138	136	137	137	137	136	140	140				
16 141 138 141 138 138 138 17 140 139 141 140 139 138 138 136 19 141 142 137 138 136 136 129 20 138 139 140 137 136 138 139 137 21 144 137 135 137 139 137 mary: Sodium, mEq/L Dev 04 03 02 03 02 02 03 134 134 142 141 142 142 142 134 134 133 132 135 134 129	15	140	139	139	141	141	138	139	140	139	142	139		136
17 140 139 18 134 135 137 134 137 136 19 141 142 137 138 136 139 129 20 138 139 140 137 136 137 138 139 137 21 144 137 135 137 139 137 mary: Sodium, mEq/L Dev 04 03 02 03 02 02 03 148 148 142 141 142 142 142 134 134 133 132 134 129	16	141	141	138	141	139	138	138	140	140	143	139		
18 134 135 137 134 137 136 136 136 136 136 136 136 136 139 129 129 129 129 129 129 138 138 138 138 138 138 137 137 137 137 137 137 137 137 137 137 137 137 137 137 138 137 138 138 138 138 138 138 138 138 138 138 138 138 142	17		140	139									-	
19 141 142 137 138 136 138 129 20 138 139 140 137 136 139 138 21 144 137 135 137 139 137 137 mary: Sodium, mEq/L Dev 04 03 02 03 02 03 . . 134 148 142 141 142 142 142 134 134 133 132 135 134 129	18	134	135	137	134	137	137	136	141	141	133	138		
20 138 139 140 137 138 139 138 21 144 137 135 137 139 137 imary: Sodium, mEq/L age 140 139 138 137 138 138 Dev 04 03 02 03 02 03 148 148 142 141 142 142 142 134 134 133 135 136 139 129	19	141	142	137	138	136	138	129	141	137		138		
21 144 137 135 137 139 137 mary: Sodium, mEq/L . <th< td=""><td>20</td><td>138</td><td>139</td><td>140</td><td>137</td><td>138</td><td>139</td><td>138</td><td>142</td><td>140</td><td>135</td><td>138</td><td>141</td><td></td></th<>	20	138	139	140	137	138	139	138	142	140	135	138	141	
mary: Sodium, mEq/L . rage 140 139 138 137 138 139 138 Dev 04 03 02 03 02 02 03 148 148 142 141 142 142 142 134 134 133 132 135 134 129	21	144		137	135	137	139	137	135	142	139	144	143	
mary: Sodium, mEq/L age 140 139 138 137 138 139 138 Dev 04 03 02 03 02 03 03 148 148 142 141 142 142 142 134 134 133 132 135 134 129														
age 140 139 138 137 138 139 138 Dev 04 03 02 03 02 03 03 148 148 142 141 142 142 142 134 134 133 132 135 134 129	ummary:	Sodium,	mEq/L											
Dev 04 03 02 03 02 02 03 148 148 142 141 142 142 142 134 134 133 132 135 134 129	verage	140	139	138	137	138	139	138	140	140	139	140	140	138
148 148 142 141 142 142 142 134 134 132 135 134 129	td Dev	04	03	02	03	02	02	03	03	02	04	05	05	03
134 134 133 132 135 134 129	ax	148	148	142	141	142	142	142	148	148	143	144	143	141
	lin	134	134	133	132	135	134	129	134	137	129	135	137	135

Figure 23: SD & Range Charts for Sodium, mEq/L




بے
5
ш
Ξ
::
ţ2
Ξ
_

0	Ε
×	⋾
ø	ï
Ī	U
a 2	<u>.</u>
~	O
	^

Subject	Scrn	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
		0	-	4	7	14	21	28	35	42	24	72	180
10	3.9	3.5	3.9	3.7	3.6	3.8	3.7	3.3	3.7	3.8	3.6	3.7	4.0
02	4.1	4.1	4.4	4.2	3.9	4.0	4.1	3.9	3.6	4.5			
03	3.8	4.3	4.3	4.5	4.1	4.2	4.2	4.2	4.1	4.7	4.1	4.4	4.2
04	3.7	3.5	4.5	3.9	4.2	3.9		4.6	4.4				
05	3.7		4.1	3.6	3.8	3.8	3.7	4.0			4.3		
90	4.5	4.9	3.9	4.0	3.8	3.9	4.2	4.2	44.0	4.0	4.3	4.4	3.9
07	4.6		3.8	3.8	4.3	4.2	4.7	4.4	4.9	4.1	4.4		
80	4.5	4.0	3.6	3.9	4.1								
60	4.1	4.0	3.9	3.8	4.1	4.0	4.0	4.3	4.0	4.2	4.3		
10	3.5	3.7	3.9	4.0	4.0	4.2	4.0	3.9	4.0	4.3	4.0		
11	3.8	3.9	3.7	4.0	4.1	4.0	3.9	3.7	3.7	3.9			
12	4.0	4.6		4.1	4.4	4.3	4.3	4.1	4.3	4.1	3.9		
13	4.4	4.1	4.0	3.8	3.9	3.9	4.1	3.6	3.7	4.4	3.8		
14	4.2	3.6	4.0	4.2	4.8	4.3	4.6	4.1	4.3				4.1
15	3.9	3.5	3.6	3.9	4.1	4.0	4.1	4.3	4.6	3.8	4.1	4.7	
16	5.1	4.3	4,3	4.5	4.2	4.9	4.3	4.4	4.6	4.4			
17		3.8	3.6										
18	4.6	ļ	4.6	4.5	4.1	4.2	4.2	4.2	4.5	4.2	4.5		
19	4.0	4.2	3.8	4.2	4.1	4.4	4.0	4.2	4.2		4.0	3.5	4.2
20	3.6	3.7	3.8	4.1	3.6	4.3	4.2	3.2	3.7	3.5	4.0	4.7	4.1
21	4.5	3.8		4.5	4.1	4.3	4.2	4.3	4.4	4.2	4.6		4.5
Summary:	Potassium, mEq/L	m, mEq/L											
Average	4.1	4.0	4.0	4.1	4.1	4.1	4.1	4.0	4.2	4.1	4.1	4.2	4.1
Std Dev	9.0	0.4	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.3	0.3	0.5	0.2
Max	5.1	4.6	4.6	4.5	4.8	4.9	4.7	4.6	4.9	4.7	4.6	4.7	4.5
Min	2.5	2.5	3.6	3.6	3.6	ď	3.7	3.2	36	3.5	3.6	2	0

SD & Range Charts for Potassium, mEq/L Figure 24:



Page 83

ത	τ
	•=
a	_
w	
_	•
Ω	_
	_
æ	
⊢	ι.
	-

to	0	1	4	٢								
			•	,	14	21	28	35	42	54	72	180
	95	101	101	103	105	66	102	105	101	105	108	106
	66 (105	103	103	100	98	101	103				
	7 106	103	105	107	102		104	110	106	106	112	109
	3 103	104	101	105	105		104	104				
		104	108	109	108	108	106		-			
	3 108	107	106	104	106	105	102	105	100	103	104	86
	č	106	109	104	108	102	108	105	105	106		
08 113	3 105	104	108	104								
09 113	3 106	107	108	105	109	105	104	105	104	106		
10 102	2 102	106	107	105	109	104	105	106	108	103		
11 109	901 6	106	108	104	110	104	104		108			
12 103	3 104		104	105	103	106	105	105	107	105		
13 102	2 103	103	109	104	104	102	66	105	100	106		
14 104	104	103	108	103	105	106	107	107				
15 103	3 102	103	107	103	105	106	103	103	110	108		96
16 102	2 106	107	108	107	104	106	109	109	110	108		
17	101	106					,				,	
18 102	2 102	105	100	104	104	101	102	103	106	100		
19 104	4 104	104	102	66	104	105	102	106		111		
20 106	3 104	103	100	102	103	105	103	103	104	107	104	
21 105	2	102	102	104	100	107	100	105	105	105	109	
Summary: Chlori	Chloride, mEq/L											
Average 104	103	104	105	104	105	104	104	105	105	106	107	102
Std Dev 04	. 03	02	03	02	60	03	03	02	03	03	03	90
Max 113	3 108	107	109	109	110	108	109	110	110	111	112	109
Min 98	95	101	100	66	100	98	66	103	100	100	104	96

SD & Range Charts for Chloride, mEq/L Day of Protocol Box = Mean ±1 SD; Line = Min to Max Figure 25: Scrn Chloride, mEq/L

Page 85

		DAY	DAY	DAY	DAY	DAY	DAY						
Subject	Scrn	0	-	4	7	4	21	28	35	42	54	72	180
10	34.2	26.4	28.8	29.8	29.5	26.9	29.0	31.2	25.4	26.3	29.9	28.0	30.9
02	27.1	27.7	26.0	28.5	29.4	30.0	28.2	29.3	26.7				
03	28.0	29.4	29.6	25.3	25.5	24.6		28.7	25.7	19.9	22.4	25.4	28.0
04	24.6	36.2	27.1	27.2	27.1	28.5		25.3	29.0				
05	29.6		25.9	28.3	28.4	29.2	27.1	30.6					
90	33.2	27.1	27.9	31.4	26.7	28.0	28.2	27.9	31.2	23.1	31.2	27.3	30.1
20	31.0		27.8	23.7	26.9	28.0	25.1	29.7	26.0	29.3	25.6		
80	25.4	25.5	26.2	29.7	25.3								
60	25.2	29.5	28.3	27.2	26.0	27.8	26.7	29.6	30.4	30.9	27.5		
10	22.4	20.8	24.1	23.0	21.2	24.3	24.2	24.9	23.2	24.1	22.4		
11	24.2	26.1	27.6	26.9	29.6	28.3	26.1	25.8		26.4			
12	29.2	26.0		24.0	29.0	28.4	24.9	28.5	28.6	25.2	28.8		
13	27.4	28.9	27.7	28.3	27.8	30.7	28.1	26.1	25.0	25.5	29.0		
14	29.1	22.3	24.5	24.3	26.1	24.0	22.3	23.5	21.4				
15	31.1	27.7	29.2	29.6	27.9	25.0	25.5	29.8	27.6	25.5	31.5		
16	33.7	22.0	24.8	26.8	24.2	30.0	26.9	26.4	24.6	23.6	28.9		
17		26.9	26.5										
18	27.7	27.1	25.4	28.2	28.0	24.2	24.1	26.8	29.9	27.0	29.3		
19	29.1	25.9	26.3	27.5	28.5	27.3	28.3	28.5	29.3				
20	28.7	25.5	24.3	26.8	24.9	27.2	26.9	20.1	28.8	23.5	25.7	25.4	
21	29.5		24.8	29.8	26.3	27.9	30.3	26.1	27.6	22.2	30.5	29.4	
Summary.	CO2 mEa/l							Control of the state of the sta					
Average	28.5	26.7	26.6	27.3	26.9	27.4	26.6	27.3	27.1	25.2	27.9	27.1	29.7
Std Dev	03.2	03.4	01.7	02.3	02.1	02.1	02.1	02.7	02.7	02.8	03.0	01.7	01.5
Max	34.2	36.2	29.6	31.4	29.6	30.7	30.3	31.2	31.2	30.9	31.5	29.4	30.9
Min	22.4	20.8	24.1	23.0	21.2	24.0	22.3	20.1	21.4	19.9	22.4	25.4	28.0


SD & Range Charts for CO2, mEq/L Day of Protocol Box = Mean ±1 SD; Line = Min to Max Figure 26: Scrn CO2, mEq/L

Page 87

O	
õ	
Ε	
::	
ţ	
Ξ	
$\overline{}$	

Ø	മ
Ď	ŭ
a	0
_	Ü
Ω	3
Œ	盂
_	G

SD & Range Charts for Glucose, mg/dL Figure 27:




Page 89

Units: IU/L

Table 10a Alkaline Phosphatase

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
						ALT SATE OF THE SA							
10	91	100	83	83	79	90	94	77	88	06	87	88	113
02	81	98	77	80	22	98	8	92	20				
03	46	47	59	45	49	20	54	55	46	51	64	59	65
94	65	62	54		56	55		58	99				•
05	63		55	55	59	57	09	20	•				
90	77	75	72	29	70	7.1	77	93	96	93	96	100	103
07	88		70	83	74	72	69	84	73	77	80		
90	65	09	56	53	53								
60	29	65	64	69	89	65	73	.99	28	61	29		
10	84	78	72	69	74	82	77	81	87	98	82		
11	104	109	110	101	84	110	102		83				
12	29	55		53	26	29	-	65	65	65	64		
13	89	65	57	55	09	64	65	63	28	64	54		
14	71	7.7	75	92	9/	65	28	29					
15	72	57	53	26	55	52	55		65	53	29		89
16	86	83	80	85	82	88	100	68	80	70	78		
17		81						,					
18	61	61	.09	. 64	64	59	22	63	99	63	78		
19	78	79	20	75	72	75	69	75	. 9/		81		
20	73	78	7.1	72	69	62	65	20	99	62	69	9/	
21	61		22	28	09	58	29	26	26	53	09	22	
Summary:	Alkaline	Alkaline Phosphate,	e, IU/L										
Average	73	73	89	89	29	20	71	72	71	89	74	76	87
Std Dev	13	16	14	14	10	16	15	13	13	14	12	19	24
Max	104	109	110	101	84	110	102	92	96	93	96	100	113
'n	46	47	53	45	49	20	54	22	46	51	54	22	65


Figure 28: SD & Range Charts for Alkaline Phosphate, IU/L



.⊆
Ε
Ξ
2
4

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	1	4	7	14	21	28	35	42	54	72	180
			,					000	7		00	00.1	00.4
01	4.50	4.60	4.10	4.00	3.70	4.10	4.40	3.90	4.40	4.20	4.20	4.50	4.00
02	4.10	3.60	3.70	3.80	4.20	4.20	4.00	4.00	3.70				
03	4.00	3.70	4.10	3.40	3.40	3.60	4.00	4.30	3.80	4.10	3.70	3.90	4.00
04	4.50	4.10	4.30	4.00	3.90	3.70		4.20	4.30				
02	4.10	3.60	3.70	3.60	3.60	3.70	3.90	4.60					
90	4.30	4.50	4.30	3.90	4.10	3.70	4.20	4.30	4.50	4.20	4.10	3.90	4.60
07	4.30	3.90	3.90	3.90	4.30		4.10	4.20	4.10	4.10	4.10		
90	4.40	4.10	3.80	3.80	3.90								
60	3.80	3.40	3.60	3.60	3.60	3.40	3.80	3.70	3.20	3.60	3.70		
10	3.80	3.70	3.60	3.60	3.50	3.50	3.20	3.70	3.70	3.30	3.80		
11	3.80	3.70	3.90	3.50	3.80	3.70	3.60	3.90	3.50				
12	4.80	4.60	4.60	3.80	3.90	3.90	4.00	4.20	4.20	4.00	3.90		
13	4.20	4.40	3.90	3.60	3.80	3.60	4.00	4.00	4.30	4.80	4.20		
14	3.60	3.30	3.10	3.50	3.70		3.60	3.60	3.60				
15	4.90	4.10	3.80	4.00	4.00	3.80	4.00	4.30	4.30	3.20	3.70		4.70
16	3.80	3.70	3.50	3.60	3.40			/	3.70				
17			4.20										
18	3.80	3.70	3.60	3.70	3.50	3.50	3.60		3.90	3.40	4.20		
19	4.30	4.30	4.00	4.10	3.90	4.00	3.90	4.20	4.30		4.00		
20	4.50	4.10	4.00	4.20	3.90	3.90	3.90	4.40	4.20	3.70	4.10	4.40	
21	4.30		4.00	4.00	4.10	4.10	4.20	4.20	4.20	3.80	3.90	4.20	
Summary:	Albumin,	, g/dL											
Äverage	4.19	3.95	3.89	3.78	3.81	3.78	3.91	4.10	3.99	3.87	3.97	4.14	4.33
Std Dev	0.36	0.40	0.33	0.23	0.26	0.24	0.28	0.27	0.37	0.46	0.20	0.23	0.38
Max	4.90	4.60	4.60	4.20	4.30	4.20	4.40	4.60	4.50	4.80	4.20	4.40	4.70
Min	3.60	3.30	3.10	3.40	3.40	3.40	3.20	3.60	3.20	3.20	3.70	3.90	4.00

SD & Range Charts for Albumin, g/dL Figure 29:




Subject	Scrn	DAY	DAY	AVQ	DAY	DAY	DAY						
		0	-	4	7	14	21	28	35	42	54	72	180
10	0.4	0.6	0.8	0.5	9.0	0.5	0.7	9.0	9.0	0.7	0.5	0.4	0.70
02	9.0	0.7	0.5	0.5	9.0	0.5	0.5	0.7	0.4				
03	0.5	9.0	6.0	0.5	9.0	0.4		0.7	0.4	0.7	0.3	0.5	0.50
04	0.5	9.0	9.0	0.4	0.4	0.4		0.3	0.4	9.0			
05	9.0		0.5	9.0	0.5	9.0	9.0	9.0					
90	1.0	0.8	1.1	0.4	0.7	0.7	9.0	0.8	8.0	1.3	0.8	0.6	1.10
07	9.0		0.7	0.3	0.4	0.2	0.4	0.5	0.4	0.5	0.4		
80	0.5	9.0	9.0	0.5	0.5								
60	9.0	9.0	9.0	6.0	0.7	9.0	8.0	0.3	0.5	0.5	9.0		
10	0.2	0.3	0.4	0.4	0.3	0.2	0.4	0.3	0.3	0.2	0.3		
7	0.7	0.3	9.0	0.4	9.0	9.0	6.0	0.5		0.5			
12	1.3	1.1		1.0	0.7	0.9	9.0	6.0	8.0	6.0	9.0		
13	1.5	1.9	2.6	1.5	1.3	1.1	8.0	1.7	1.4	2.4	1.1		
14	0.8	0.7	1.0	0.8	7.0	9.0	9.0	1.0	1.0				
15	1.0	0.5	0.8	9.0	7.0	6.0	9.0	8.0	0.7	0.5	9.0		
16	0.3	0.5	0.8	8.0	0.7	6.0	9.0	0.8	0.7	0.5	9.0		
17		0.8	1.0										
18	0.4	0.5	9.0	0.4	0.2	0.2	0.3	0.3	0.5	0.4	0.5		
19	1.0	0.7	1.0	6.0	0.7	9.0	9.0	9.0	0.8		0.7		
70	1.5	1.6	1.6	1.4	1.3	1.2	1.1	1.7	1.2	0.9	1.3	1.7	
21	0.4		0.8	0.8	0.8	0.5	0.7	0.4	0.5	9.0	9.0	9.0	
Summary:	Bilirubin, mg/dl	mg/dL											
Average	0.7	0.7	6.0	0.7	0.7	9.0	9.0	0.7	0.7	0.7	0.7	8.0	77.0
Std Dev	0.4	0.4	0.5	0.3	0.3	0.3	0.2	0.4	0.3	0.5	.0.3	0.5	0.31
Max	1.5	1.9	2.6	1.5	1.3	1.2	1.1	1.7	1.4	2.4	1.3	1.7	1.10
Min	0.2	0.3	0.4	0.3	0.2	0.2	0.3	0.3	0.3	0.2	0.3	0.4	0.50

180 72 54 Figure 30: SD & Range Charts for Bilirubin, mg/dL 42 35 28 21 4 Box = Mean ±1 SD; Line = Min to Max 4 0 Scrn 0.5 2.5 1.5 0 Ö က Bilirubin, mg/dL

Day of Protocol


		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
									The state of the s				
5	16	14	17	10	17	14	18	13	16	15	15	12	12
02	19	10	10	12	11	12	18	6	8		,		
03	14	17	16	12	7	12		12	12	15	14	12	15
9	14.8	11.2	16	14	15	11		13	12				
02	6		14	12	12	13	12	8					
90	11	14	16	18	16	14	15	13	12	17	15	12	4
07	20		10	15	16	20	21	16	10	16	13		
80	13	14	18	18	20					-			
60	14	12	7	14	13	15	14	13	15	18	12		
9	. 15	11	1	6	10	18	12	7	12	13	8		
1	13	12	10	13	10	13	8	10		6			
12	10	15		12	12	14	14	11	12	10	11		
13	13	14	17	14	13	13	13	11	13	6	19		
14	12	14	12	12	-	13	15	15	15				
15	12	13	11	13	13	12	11	11	17	9	11		16
16	10	14	<u>(1</u>)	17	14	13	15	15	12	10	15)
17		10.5	6										
18	8	14	6	11	8	10	14	12	10	11	7		
19	16	18	15	17	17	14	18	11	13		12		
20	12	7	10	10	10	12	11	8.3	8	10	6	14.1	
24	25		18	23	21	17	20	22	23	22	24	22	
											-		
Summary:	BUN, mg/dL	Jp,											
Average	14	13	13	14	14	14	15	12	13	13	13	14	14
Std Dev	04	05	03	03	03	02	03	03	03	40	90	94	02
Мах	25	18	18	23	21	20	21	22	23	22	24	22	16
Viin	08	10	60	60	80	9	80	07	90	60	07	12	12

Figure 31: SD & Range Charts for BUN, mg/dL



		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	41	21	28	35	42	54	72	180
	9	0	00	c c	7	000	0 7 0	000	010	0 20	08.8	00 8	00.0
נס	9.40	9.30	8.90	8.50	8.70	8.80	9.10	0.00	9.10	06.0	0.00	0.30	9.20
02	9.20	9.20	9.20	8.80	9.10	9.50	9.30	9.40	8.40	i.			
03	9.30	9.30	9.60	8.30	8.90	6.80		9.10	8.40	9.00	8.70	9.20	9.20
40	9.10	8.70	9.10	8.70	8.70	8.60		9.20	8.80	9.00			
05	8.80		8.30	8.40	8.30	8.20	8.50	9.10					
90	9.10	9.40	8.60	8.30	8.50	7.80	9.20	9.30	9.10	8.80	8.70	8.80	9.10
70	9.00		8.60	8.30	8.90	8.70	9.10	9.10	8.70	8.80	8.50		
90	9.00	8.90	8.50	7.80	8.40							The state of the s	
60	8.60	8.70	8.20	7.90	8.60	8.70	9.00	8.70	7.60	8.50	8.80		
10	8.50	8.90	8.60	7.70	8.60	8.50	8.70	8.60	8.30	8.50	9.00		
-	8.50	8.30	8.20	8.10	8.80	8.20	8.60	8.20		8.00			
12	9.50	9.50		8.80	9.10	9.00	9.30	9.40	9.50	9.10	9.20		
13	9.00	8.90	9.10	8.10	8.30	8.70	9.60	8.70	00'6	9.40	9.00		
14	8.70	8.20	8.30	8.90	8.90	8.70	9.00	9.00	8.60				
15	9.10	8.60	8.60	8.20	8.90	8.70	8.80	8.90	9.00	7.70	8.10		
16	8.60	8.00	8.40	8.30	8.40	8.60	8.90	8.40	8.50	8.30	8.10		
17		9.60	8.70										
18	9.30	8.70	9.10	9:30	9.10	8.70	9.20	8.80	9.00	8.70	9.20		
19	9.10	8.80	8.70	9.20	8.80	9.30	8.90	9.30	9.00		8.80		
20	8.50	8.00	8.30	8.70	8.30	8.50	8.30	9.00	6.80	8.30	8.30	8.80	
21	8.90		8.40	8.80	8.80	8.70	8.80	8.80	9.20	8.10	8.80	9.00	
Summary:	Calcium, mg/dL	mg/dL											
Average	8.96	8.83	8.67	8.46	8.71	8.56	8.96	8.94	8.65	8.57	8.70	9.00	9.17
Std Dev	0.31	0.49	0.38	0.44	0.27	0.57	0.33	0.33	0.65	0.46	0.36	0.17	90.0
Max	9.50	9.60	9.60	9.30	9.10	9.50	9.60	9.40	9.50	9.40	9.20	9.20	9.20
Min	0 50	0	000	07.7	0000	00 0	000	00 0	8 80	7.70	α 10	200	0 10

SD & Range Charts for Calcium, mg/dL Figure 32:



		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
5	200	229	210	198	192	201	210	192	207	188	185	225	184
02		186	167	165	169	177	170	150	118				
03	207	187	225	171	168	175	207	203	167	175	137	146	126
04	191	154	164	179	173	173		171	160				
05	101		92	97	97	101	105	06					
90	191	182	175	172	188	172	201	196	182	177	163	155	176
10	364	308	297	288	326	424	484	440	381	349	171		
80	192	191	186	195	194								
60	202	188	189	200	204	187	214	189	154	182	209		
10	179	164	166	153	158	171	172	171	163	163	171		
11	217	188	186	170	191	158	207	178	192				
12	242	231		224	222	225	232	225	234	206	201		
13	177	183	177	167	162	159	179	160	165	182	166		
14	214	193	185	212	220	206	214	218	220				
15	206	173	184	197	202	213	193	200	201	192	225		
16	173	172	175	175	156	161	166	172	180	157	164		
17								/					
18	206	173	184	197	202	213	193	200	201	192	225		
19	217	199	196	219	207	201	199	195	222	217	206		
20	118	117	118	114	132	121	141	138	127	109	105	125	
21	184		197	199	198	189	217	199	209	183	185	186	
Summary:	Choleste	Cholesterol, mg/dl											
Average	199	190	183	185	188	191	206	194	194	191	180	167	162
Std Dev	52	39	40	40	44	64	9/	29	22	52	33	39	31
Max	364	308	297	288	326	424	484	440	381	349	225	225	184
Min	101	117	92	97	97	101	105	66	118	109	105	125	126

Figure 33: SD & Range Charts for Cholesterol, mg/dL Day of Protocol Box = Mean ±1 SD; Line = Min to Max Scrn Cholesterol, mg/dL

Dec. 17, 1998

	T			ШС				 T	Ι	<u> </u>	· 	<u> </u>		<u> </u>	Γ			1	Ι			T	ĺ	Τ-	Τ	1		Γ
DAY	180	38		20			29																		39	7	20	5
DAY	72			61			35																		48	18	61	נים
DAY	54	39		53			36	50		52	57	40-THE LANGE OF THE PARTY OF TH	54			89	90		89	89	46	59			59	18	89	00
DAY	42	47		47			32	48		45	43		56			82	71		83	82	45	55			57	17	83	Ç
DAY	35	54	36	71	44			43		41	49		64	50	98	61	99		61	61	55	62			57	13	86	20
DAY	28	50	42	72	41	49	36			48	29	55	56	48	92	74	99		,	74	46	20			56	15	92	36
DAY	21	42	40	52		47	33	55		41	53	49	38	51	83	62	61		62	62	49	41			51	12	83	22
DAY	14					43	32		54		51	48	52	41	72	99	57		99	99	38	47			52	12	72	33
DAY	7	32	36		09	44	85	54		40	46	37	52	51	73	64	09		64	64	36	41			52	15	85	22
DAY	4	41	38	54	22	44	37	46		42	45		55	44	28	63	28		63	63	38	40			49	60	63	37
DAY	-	47	40	79		39	38	47	46	48	56	59		54	63	61	61		61	61	47	29			54	11	79	38
DAY	0	 57	40	99			38		44	42	47	57	65		09	64	58	39	64	64	44				53	11	99	38
Scrn					50			48				55										63		HDL	54	07	63	αν
Subject		5	02	03	04	05	90	07	80	60	10	11	12	13	14	15	16	17	18	19	20	21		Summary:	Average	Std Dev	Max	Win


Figure 34: SD & Range Charts for HDL Box = Mean ± 1 SD; Line = Min to Max Scrn HDF

Dec. 17, 1998

Day of Protocol

	Ha	alo	tan	tri	ne	IN	D:9	984	7																			
DAY	180		111		65			128	-																101	33	128	65
DAY	72				75			110						,								09			82	26	110	90
DAY	54		119		73			118	98		138	102		122			117	92	-	117	140	54	97		106	25	140	54
DAY	42		128		116			29	290		122	94		136			28	78		87	145		118		119	62	290	29
DAY	35	`	132	99	88	107			314		94	98		155	102	125	102	101		102	151	20	134		121	22	314	99
DAY	28		130	8	116	122	33	146			127	66	109	160	93	113	91	92		91	132	79	133		108	29	160	33
DAY	21		147	111	148		49	147	391		157	104	127	181	103	122	123	85		123	112	105	162		139	70	391	49
DAY	14							126				66	57	153	101	125	134	92		134	139	51	140		113	33	153	51
DAY	7		121	114		102	46	83	229	129	143	101	117	150	86	134	118	83		118	141		143		118	39	229	46
DAY	4		126	105	106	95	44	122	205		140	97		139	103	145	120	102		120	153	48	133		117	37	205	44
DAY	-		142	114	135		41	117		122	123	86	118		106	114	102	103		102	127	49	119		108	26	142	41
DAY	0		150	124	111			123	252	131	130	102	118	154		122	83	95	150	83	125	53			124	42	252	53
Scrn						119			307				133										109	LDL	167	94	307	109
Subject	•		01	05	03	04	05	90	70	08	60	10	11	12	13	14	15	16	17	18	19	20	21	Summary:	Average	Std Dev	Max	Min

Figure 35: SD & Range Charts for LDL



Units: mg/dL

Table 10i Triglycerides

	II.a	1014	4111	1 111	e II	1.D.	704	, ,										,		 1		,		. 1		-			
DAY	180		177		99			66					and the same of th													111	61	177	99
DAY	72		77		53			20														48	09			28	12	7.7	48
DAY	54		136		22			46	179		66	09			183		97	63		97	104	34	149			100	49	183	34
DAY	42		68		64			83	55		9/	134		127	61		118	42		118	136	30	54			83	36	136	30
DAY	35		108	82	41	46		22	124		48	84		74	69	46	190	. 99		190	81	36	99	The state of the s		83	47	190	36
DAY	28		64	143	75	42	42	70	35		73	69		7.7	92	29	176	22		176	89	41	84			82	42	176	35
DAY	21		107	95	38		46	100	190		84	78		49	128	46	44	104		44	139	47	47			81	43	190	38
DAY	14		167	113	79	165	44	70	199		84	108		. 99	98	45	65	62		65	122	48	55			91	46	199	44
DAY	7		197	96	56	56	38	101	218	22	105	57	187	103	69	65	102	69		102	152	47	73			98	52	218	38
DAY	4		155	113	55	146	47	29	187	59	91	59	123	101	104	48	73	78		73	140	47	132			92	41	187	47
DAY	-		107	69	57	20	09	100	41	06	94	64	96		87	41	108	58		108	114	78	92			80	24	114	41
DAY	0		110	109	50	125		106	47	83	80	78	118	09	88	56	134	95		134	152	46			Triglycerides, mg/dl	93	33	152	46
	Scrn		91		65	114	99	59	45	62	55	94	145	95	193	126	102	73		102	147	32	62		Triglyceri	91	41	193	32
	Subject		10	02	03	04	05	90	20	90	60	10	11	12	13	14	15	16	17	18	19	20	21		Summary:	Average	Std Dev	Max	Min

SD & Range Charts for Triglycerides, mg/dL Box = Mean ±1 SD; Line = Min to Max Figure 36: Scrn Triglycerides, mg/dL


Page 107

Day of Protocol

Table 10j Creatinine

Subject Scrn 0 01 1.00 0.90 02 1.60 1.40 03 0.80 0.80 04 1.10 1.00 05 1.00 0.90 07 0.80 0.90 07 0.80 0.90 08 1.00 0.90 09 1.00 0.90 10 0.90 0.90 11 0.70 0.70		-	7	7	14	7	28	35	•	24	72	180
1.00 1.60 0.80 0.90 0.90 0.80 0.90 0.90 0.90			 r		-	21	,	33	42	5		
1.00 1.60 0.80 1.10 0.90 0.80 0.80 1.00 1.00 0.90 0.90												i
1.60 0.80 1.00 0.90 0.80 1.00 1.00 1.00 0.90		0.70	0.80	06.0	1.10	06.0	08.0	06.0	06.0	0.80	0.80	1.00
0.80 1.00 0.90 0.80 1.00 1.00 0.90 0.90		1.20	1.40	1.30	1.50	1.40	1.30	1.30				
1.10 1.00 0.90 0.80 0.80 1.00 1.00 0.90		1.00	0.80	0.70	08.0		08.0	0.70	0.80	0.80	0.80	0.80
1.00 0.90 0.80 1.00 1.00 0.90		0.80	0.70	0.70	0.70		08.0	08.0				
0.90 0.80 0.90 0.90 0.90 0.90 0.90	-	1.00	06.0	1.10	1.30	1.10	1.20					
0.80 1.00 1.00 0.90		0.80	0.80	08.0	0.70	06.0	08.0	06.0	0.80	0.80	0.80	06.0
1.00		09.0	09.0	0.50	08.0	08.0	09.0	0.80	1.00	0.70	,	
1.00		08.0	06.0	0.70								
0.90	<u> </u>	08.0	06.0	06.0	06.0	06.0	1.00	06.0	0.00	0.00		
0.70		0.70	06.0	0.70	1.00	08.0	08.0	06.0	0.00	1.00		
) ;;)		08.0	0.70	08.0	0.80	0.70	09.0		0.70			
12 1.00 1.20	20		1.10	1.00	1.00	1.10	1.10	1.00	1.00	1.00		
13 0.90 1.00	<u> </u>	06.0	08.0	06.0	1.00	1.00	06.0	06.0	1.00	1.00		
14 1.00 1.00		08.0	06.0	1.10	1.10	1.00	1.00	06.0				
15 1.00 0.90		1.00	1.00	1.10	1.00	06.0	1.10	1.00	0.30	1.00		0.90
16 1.00 1.00		0.90	06.0	0.90	1.10	06.0	1.00	06.0	0.90	1.00		
17 1.50		1.10										
1.00 1.00		1.00	1.10	0.90	06.0	1.00	1.00	1.10	1.00			
19 0.90 0.80	_	06.0	06.0	08.0	1.00	1.00	0.90	1.00		0.50		
20 1.00 0.90		06.0	06.0	08.0	0.90	08.0	06.0	1.00	0.80	06.0	0.90	
21 1.10		08.0	1.00	1.00	0.00	1.00	1.20	1.00	0.80	1.00	1.00	
Summary: Creatinine, mg/dL	Jp/6											
Average 0.99 0.98		0.88	06.0	0.88	0.97	0.95	0.94	0.94	0.89	0.88	0.86	0.90
Std Dev 0.18 0.20		0.14	0.17	0.19	0.20	0.16	0.19	0.13	0.09	0.15	0.09	0.08
1.60		1.20	1.40	1.30	1.50	1.40	1.30	1.30	1.00	1.00	1.00	1.00
0.70		09.0	09.0	0.50	0.70	0.70	09.0	0.70	0.70	0.50	0.80	0.80

Figure 37: SD & Range Charts for Creatinine, mg/dL



숨	
₹	\vdash
Ф	Ö
五	ō
Ø	

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	ΛVU
Subject	Scrn	0		4	7	4	21	28	35	42	54	72	180
									!				
01		:	:										16
02									7. 15.7.1				2
03				- Property									17
04													=
02													
90							7.77		14	6	17	10	12
07						21	21	19	9		14		!
08													
60						10	13	12	9		10		
10						24	20	24		21			
11					59	27	44	37		22	35		
12				28	26	28	28	28	25	23	37		
13	13	13	6	10	÷	12	13	12	10		11		
14	43	84	79	9/	69	59	53	47	43				
15	21	19	17	17	15	11	15		20	16	18		
16		31	30	29	26	35	48	51	42	36	35		
17			09										
18			76			43	45		30	26	37		
19		7	11	11	12	10	6	11	13	10	12	A STATE OF THE STA	
20		2	æ	9	6	10	10	12	6	8	6		
21			16	15	16	22	15	14	17	13	16	16	
	H												
Summary:	gG1, 10/L												
Average	26	27	28	24	24	24	26	24	20	18	20	13	15
Std Dev	16	30	25	23	19	15	16	15	13	60	12	40	03
Max	43	84	79	9/	69	59	53	51	43	36	37	16	17
Min	13	05	80	90	60	10	60	11	90	90	60	10	12

SD & Range Charts for gGT, IU/L Figure 38: Box = Mean Scrn gGT, IU/L

Day of Protocol

_
_
$\overline{}$
_
• •
S
ű
=
_
_

5	
_	I
Φ	
Ξ	
ಡ	
-	

Subject	נייני	,		ָ :	- {	ב	DAY	DAY	DAY	באַ	באַר	DAT	DAY
3	5	0	_	4	7	14	21	28	35	42	54	72	180
3													
5	158	158	152	138	130	153	161	163	161	160	140	113	152
02	165	180	208	155	140	175	198	196	195				
03	185	176	222	219	170	231		194	165	292	161	220	191
90	183	176	200	177	157	146		268	194	218			
05	153		189	126	126	120	130	155					
90	134	163	155	152	128	126	133	195	147	170	151	177	161
20	243		252	186	260	181	237	262	392	226	220		
80	179	158	196	181	171								
60	138	135	192	185	191	156	196	261	211	160	149		
10	171	169	154	196	177	156	196	261	211	160	149		
1	191	178	168		152	132	170	204		147			
12	208	259		213	218	208	164	184	185	181	157		
13	156	168	186	117	170	106	120	137	169	176	148		
14	160	189	258	131	126	129	155	202	257				
15	188	166	145	127	166	245	128		175	147	145		192
16	153	157	152	130	119	127	146	194	197	165	149		
17		231	164										
18	230	173	159	147	101	123	107	233	170	134	178		
19	161	247	161	144	118	148	154	162	170		164		
20	252	273	281	262	184	207	171	326	222	195	188	248	
21	163		154	168	134	209	136	209	201	175	196	171	
Summary: L	LDH, IU/L												
Average	179	186	187	166	157	162	159	211	201	180	164	186	174
Std Dev	33	39	40	38	38	41	34	48	26	40	. 23	52	21
Max	252	273	281	262	260	245	237	326	392	292	220	248	192
Min	134	135	145	117	101	106	107	137	147	134	140	113	152

Figure 39: SD & Range Charts for LDH, IU/L




Table 10m Magnesium

Blank = Not Obtained

1 4 7 14 21 28 35 42 21 2.2 1.9 2.1 2.0 2.0 2.2 20 1.7 1.8 2.0 1.8 2.1 2.1 20 1.7 1.9 1.9 2.0 1.8 2.1 2.1 1.9 1.9 1.9 2.0 2.2 2.2 2.0 2.0 2.1 2.2 2.3 2.2 2.0 2.0 2.0 2.0 2.1 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.2 2.2 2.2 2.3 2.3 2.2 2.2 2.0			DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	
2.1 2.2 1.9 2.1 2.0 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.2 2.2 2.3 2.2 2.2 2.3 2.2 2.3 2.2 2.2 2.3 2.2 2.2 2.3 2.2 2.2 2.3 2.2 2.2 2.3 2.2 2.2 2.3 2.2 <th></th> <th>Scrn</th> <th>0</th> <th>-</th> <th>4</th> <th>7</th> <th>14</th> <th>21</th> <th>28</th> <th>35</th> <th>42</th> <th>54</th> <th>72</th> <th>180</th> <th>Hal</th>		Scrn	0	-	4	7	14	21	28	35	42	54	72	180	Hal
2.1 2.2 1.9 2.1 2.0 2.0 2.2 1.6 1.8 2.0 1.8 2.1 2.1 2.1 2.0 1.7 1.9 1.9 1.9 2.2 1.9 2.1 2.1 1.9 1.9 1.9 1.9 1.9 2.1 2.2 2.0 2.0 2.1 2.1 2.2 2.0 2.0 2.2 2.0 2.0 2.1 2.2 2.3 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2															lofa
2.0 1.8 2.0 1.8 2.1 2.0 1.7 1.9 2.2 1.9 2.1 2.1 1.9 1.9 1.9 2.0 2.2 2.1 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.1 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.1 1.9 1.9 2.0 2.0 2.1 2.1 2.2 2.3 2.2 2.2 2.3 2.2 2.2 2.3 2.2		2.0	2.0	2.1	2.2		1.9	2.1	2.0	2.0	2.2	2.1	2.1	2.1	int
2.0 1.7 1.9 2.2 1.9 2.1 2.1 1.9 1.9 1.9 2.0 2.0 2.2 1.9 1.9 1.9 1.9 2.0 2.0 2.2 2.0 2.0 2.1 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.1 1.9 2.0 2.0 2.0 2.1 2.2 2.2 2.3 2.3 2.2 2.2 2.2 2.2 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.0 2.3 2.2 2.1 1.8 1.8 2.0 2.0 2.0 2.0 2.3 2.2 2.1 2.1 2.1 2.0 2.	t -	2.3	1.9		1.6		1.8	2.0	1.8	2.1					rine
2.1 1.9 1.9 1.9 1.9 2.0 2.0 2.2 1.9 1.9 1.9 1.9 1.9 1.9 2.0 2.0 2.1 2.0 2.0 2.1 1.9 1.9 2.0 2.0 2.1 2.1 2.2 2.1 2.0		2.0	1.9	2.0	1.7		1.9		2.2	1.9	2.1	2.0	2.0	2.4	e IN
1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.2 2.3 2.3 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.0 <th></th> <td>2.3</td> <td></td> <td>2.1</td> <td>1.9</td> <td>1.9</td> <td>1.9</td> <td></td> <td></td> <td>2.0</td> <td>2.2</td> <td></td> <td></td> <td></td> <td>VD:</td>		2.3		2.1	1.9	1.9	1.9			2.0	2.2				VD:
2.0 2.0 2.1 1.9 2.0 1.9 2.1 2.3 2.2 2.3 2.3 2.2 2.2 2.1 2.2 2.3 2.3 2.2 2.2 2.1 2.2 2.1 2.2 2.3 2.2 2.3 2.1 2.1 2.1 2.2 2.2 2.3 2.0 2.0 2.0 2.3 2.2 2.2 2.1 2.0 2.0 2.0 2.1 2.0 2.1 2.1 2.1 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.1 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 1.9 2.1 1.8 2.1 1.8 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2	i	1.9		1.9		1.9	6.1	1.9							984
2.3 2.1 2.2 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.1 2.1 2.1 2.2 2.2 2.3 2.1 2.1 2.2 1.7 1.8 2.0 2.0 2.0 2.3 2.2 2.1 2.0 2.0 2.0 2.0 2.3 2.2 2.1 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.2 2.1 2.2 2.1 2.1 2.1 2.2 2.2 2.3 2.3 2.3 2.1 2.1 2.1 1.8 2.1 2.1 1.8 1.8 2.1 2.0 1.9 2.0 2.0 2.2 2.2 1.9 1.9 2.0 2.0 1.9 1.9 1.7 2.1 2.1 1.8 2.2 2.2 2.2 2.2 2.3 2.3 2.1 2.0 2	\vdash	1.9	1.9	2.0	2.0	2.1	1.9	2.0	2.0	1.9	2.1	2.1	2.1	2.0	7
2.2 2.2 2.3 2.1 2.1 2.2 2.3 1.8 1.8 2.2 1.7 1.8 2.0 2.0 2.0 2.3 2.2 2.2 2.1 2.0 2.0 2.0 2.0 2.3 2.2 2.2 2.1 2.0 2.1 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.2 2.1 2.0 2		2.2	2.1	2.3		2.1	2.2	2.3	2.3	2.2		2.0			
2.1 2.1 2.2 2.2 2.3 1.8 1.8 2.2 1.7 1.8 2.0 2.0 2.0 2.3 2.2 2.2 2.1 2.0 2.0 2.0 2.3 2.2 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.1 2.0 2.1 2.0 2.1 2.1 2.1 2.0 2.1 2.0 2.1 2.0 2.2 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 1.9 1.8 2.1 2.1 1.8 2.1 2.2 2.2 2.2 1.9 1.9 2.0 <t< td=""><th>1</th><td>2.1</td><td>2.0</td><td>2.2</td><td></td><td>2.2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	1	2.1	2.0	2.2		2.2									
1.8 1.8 2.2 1.7 1.8 2.0 2.0 2.0 2.3 2.2 2.1 2.0 2.0 2.0 2.0 2.3 2.2 2.1 2.0 2.1 2.0 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.3 2.2 2.2 2.3 2.3 2.3 2.1 2.1 2.1 2.1 2.1 2.1 1.8 2.1 2.1 1.9 2.0 2.0 2.2 2.1 1.9 2.2 2.0 1.9 2.0 2.0 2.2 2.1 1.9 2.0 2.0 1.9 1.9 2.1 2.1 2.1 1.9 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.0 2.0 2.0 2.0	—	2.1	2.0	2.1		2.1	2.1	2.2		2.2	2.3	1.9			
2.0 2.3 2.2 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.0 2.1 2.2 2.2 2.2 2.1 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.2 2.2 2.2 1.9 1.9 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 <th>1</th> <td>1.9</td> <td>1.8</td> <td>1.8</td> <td>1.8</td> <td>1.8</td> <td>2.2</td> <td>1.7</td> <td>1.8</td> <td>2.0</td> <td>2.0</td> <td></td> <td>1.8</td> <td></td> <td></td>	1	1.9	1.8	1.8	1.8	1.8	2.2	1.7	1.8	2.0	2.0		1.8		
2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.1 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.3 2.2 2.2 2.3 2.3 2.3 2.3 2.1 2.1 1.9 2.0 2.0 2.2 2.2 1.9 2.2 2.0 1.9 2.0 2.0 2.2 2.2 1.9 2.0 2.0 1.9 1.9 2.1 2.1 2.1 1.9 2.2 2.2 2.2 2.2 2.2 1.9 2.0 2.0 1.9 1.9 2.1 2.1 1.9 2.2 2.2 2.2 2.2 2.3 2.3 2.1 2.0 2.0 2.0 2.0 2.0 1.8 1.8 2.2 2.2 2.2 2.3 2.3 2.1 2.0 2.0 2.0 2.0 2.0 2.0 1.9 2.0 2.1 2.0 2	1	2.4	2.0	2.0	2.3	2.2	2.2	2.1		2.0					
2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.3 2.3 2.3 2.2 2.3 2.2 2.2 2.2 2.3 2.3 2.3 2.1 2.1 2.1 1.9 2.1 1.8 2.1 2.1 1.8 2.2 2.0 1.9 2.0 2.0 2.0 2.2 2.2 1.9 2.0 2.0 1.9 1.9 2.1 2.1 2.1 1.9 2.0 2.0 2.0 2.0 2.0 2.1 2.1 1.9 2.2 2.1 1.9 1.9 1.7 2.1 1.8 2.0 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.0 2		2.2	2.2	-	2.0	2.1	2.1	2.1	2.0	2.1	2.0	1.9			
2.2 2.3 2.2 2.2 2.3 2.3 2.3 2.1 2.1 1.9 2.1 1.8 2.1 2.1 1.8 2.1 2.0 1.9 2.0 2.0 2.2 2.2 1.9 2.2 2.0 1.9 2.0 2.0 2.0 2.1 2.1 1.9 2.0 2.0 1.9 1.9 2.1 2.1 2.1 1.9 2.2 2.1 2.2 2.2 2.2 2.3 2.1 1.9 2.0 2.0 2.0 2.0 2.0 1.9 1.7 2.1 1.8 2.0 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.0 2.3 2.3 2.3 2.3 2.3 2.3 <th>+</th> <td>2.1</td> <td>2.2</td> <td>2.1</td> <td>2.1</td> <td>2.1</td> <td>2.1</td> <td>2.1</td> <td>2.2</td> <td>2.1</td> <td>2.2</td> <td>2.0</td> <td></td> <td></td> <td></td>	+	2.1	2.2	2.1	2.1	2.1	2.1	2.1	2.2	2.1	2.2	2.0			
2.1 2.1 1.9 2.1 1.8 2.1 2.1 1.8 2.1 2.0 1.9 2.0 2.0 2.2 2.2 1.9 2.2 2.2 2.0 2.0 2.0 2.0 1.9 1.9 2.0 2.0 1.9 1.9 2.1 2.1 2.1 1.9 2.2 2.2 2.1 2.2 2.3 2.3 2.1 1.9 2.0 2.0 2.0 2.0 2.0 1.9 1.7 1.8 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 2.0 2.1 2.1 2.0 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.1 2		2.4	2.2	2.2	2.3	2.2	2.2	2.2	2.3	2.3					
2.1 2.0 1.9 2.0 2.2 2.2 1.9 2.2 2.2 2.0 2.0 1.9 2.1 2.1 2.1 1.9 2.0 2.0 2.1 2.2 2.2 2.3 2.1 1.9 2.2 2.1 2.2 2.2 2.3 2.3 2.1 2.0 2.0 2.0 2.0 1.9 1.7 2.1 1.8 2.0 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 2.1 2.1 2.0 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2			2.0	2.1	2.1	1.9	2.1	1.8	2.1	2.1	1.8	1.9			(***
2.2 2.0 1.9 1.9 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 1.9 1.9 1.9 2.1 2.1 2.1 1.9 2.1 1.9 2.1 1.9 2.1 2.1 1.8 1.8 1.8 1.9 1.9 2.1 1.8 1.8 1.8 1.9 2.1 2.0 2.3 2		2.2	2.1	2.1	2.0	1.9	2.0	2.0	2.2	2.2	1.9	2.0			
2.0 2.0 1.9 1.9 2.1 2.1 2.1 2.1 1.9 2.2 2.2 2.2 2.2 2.3 2.3 2.1 1.9 2.0 2.0 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 2.3 2.3 2.2 2.2 2.3 2.3 2.3 2.3 1.8 1.6 1.8 1.7 1.8 1.9 1.8	\vdash		2.3	2.2											
2.2 2.2 2.1 2.2 2.3 2.3 2.1 2.2 2.1 1.9 1.7 2.1 1.8 2.0 2.0 2.0 2.0 1.9 2.1 1.8 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 2.0 2.0 2.0 0.1 0.2 0.1 0.1 0.2 0.1 0.2 2.3 2.3 2.2 2.2 2.3 2.3 2.3 1.8 1.6 1.8 1.7 1.8 1.9 1.8	 		1.9	2.0	2.0	1.9	1.9	2.1	2.1	2.1	1.9	2.1			
2.2 2.1 1.9 1.9 1.7 2.1 1.8 2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 2.1 2.1 2.0 2.1 2.0 2.0 2.0 2.0 2.0 2.0 0.1 0.2 0.1 0.1 0.2 0.1 0.2 2.3 2.3 2.2 2.2 2.3 2.3 2.3 1.8 1.6 1.8 1.7 1.8 1.9 1.8	1		2.3	2.2	2.2	2.1	2.2	2.2	2.3	2.3	2.1	2.2			
2.0 2.0 2.0 2.0 1.9 2.1 2.0 2.1 2.0 2.0 2.0 2.1 2.1 2.0 0.1 0.2 0.1 0.2 0.2 0.1 0.2 2.3 2.3 2.2 2.3 2.3 2.3 2.3 1.8 1.6 1.8 1.7 1.8 1.9 1.8		1.8	2.1	2.2	2.1	1.9	1.9	1.7	2.1		1.8	1.8	2.1		,
2.1 2.0 2.0 2.0 2.1 2.1 2.0 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1		2.0		2.0	2.0	2.0	2.0	2.0	1.9	2.1	2.0	2.0	2.2		
2.1 2.0 2.0 2.0 2.0 2.1 2.1 2.0 0.1 0.2 0.1 0.1 0.2 0.1 0.2 2.3 2.3 2.3 2.3 2.3 2.3 1.8 1.6 1.8 1.7 1.8 1.9 1.8	İ														
2.1 2.0 2.0 2.0 2.1 2.1 2.0 2.0 0.1 0.2 0.1 0.2 0.1 0.2		Magnesi	um, mg/dL												
0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 2.3 2.3 2.3 2.2 2.2 2.3 2.3 2.3 2.3 1.8 1.8 1.7 1.8 1.9 1.8		2.1	2.1	2.1	2.0	2.0	2.0	2.0	2.1	2.1	2.0	2.0	2.1	2.2	
2.3 2.3 2.3 2.2 2.2 2.3 2.3 2.3 2.3 1.8 1.8 1.8 1.7 1.8 1.9 1.8		0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.2	
1.8 1.8 1.8 1.8 1.7 1.8 1.9 1.8	1	2.4	2.3	2.3	2.3	2.2	2.2	2.3	2.3	2.3	2.3	2.2	2.2	2.4	
		1.8	1.8	1.8	1.6	1.8	1.8	1.7	1.8	1.9	1.8	1.8	1.8	2.0	

Figure 40: SD & Range Charts for Magnesium, mg/dL 1.8 2.6 2.4 2

∆agnesium, mg/dL

0

Scrn

180

72

54

42

35

28


4

Box = Mean ±1 SD; Line = Min to Max

Table 10n Phosphorus

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
10	4.0	3.3	2.9	4.2	4.7	3.7	3.6	3.4	4.0	4.3	3.8	4.0	3.3
02	4.7	3.9	4.0	3.9	4.1	5.8	4.6	4.7	4.0				
03	2.6	3.3	2.9	3.0	3.1	3.2	3.5	3.6	3.4	3.4	2.7	2.8	2.9
94	5.1	4.7	3.2	3.5	3.4	4.1		3.0	3.8				
05	3.1		2.8	2.5	3.8	3.4	4.1	2.9					
90	3.9	3.9	3.2	3.5	3.6	3.7	3.9	3.5	3.6	3.3	3.1	3.6	3.3
07	3.0		3.1	3.1	3.3	3.7	4.4	3.5	3.1		-		
80	3.5	3.4	4.3	4.3	5.1	4.4							
60	4.1	3.5	4.3	3.6	4.3	3.4	3.7	3.1	3.4	3.2	3.8		
10	3.3	3.3	3.5	3.3	3.3	3.0	3.1	3.2	3.3	3.2	3.6		
11	2.9	3.0	3.1	2.9	2.7	2.8	3.5	2.6		2.7			
12	3.0	3.2		3.0	3.7	3.4	3.6	3.9	3.7	3.3	3.5		
13	3.7	3.4	3.9	3.7	3.4	3.9	4.4	3.7	3.3	4.0	4.3		
14	4.5	4.0	3.5	3.6	3.5	4.1	-	3.4	3.6				
15	3.6	3.4	4:5	4.7	4.7	4.7	3.7	3.4	3.8	3.8	3.1		4.4
16	0.3	3.3	3.1	3.2	3.0	3.0	3.2	2.9	3.2	3.2	3.5		
17		3.4	4.1										
18	3.6	3.7	3.0	3.4	2.8	3.8	4.1	3.0	4.1	3.2	3.8		
19	3.8	3.4	3.5	3.8	3.2	4.0	4.2	3.6	3.7		3.1		
20	3.6	3.2	3.4	3.3	3.5	4.1	4.0	3.0	3.2	3.2	3.6	3.4	
21	3.9		3.6	4.1	4.2	4.4	4.3	3.4	4.4	3.9	3.7	4.1	
Summary:	Phospho	Phosphorus, mg/dl											
Average	3.5	3.5	3.5	3.5	3.7	3.8	3.9	3.4	3.6	3.4	3.5	3.6	3.5
Std Dev	1.0	0.4	0.5	0.5	0.7	0.7	9.0	0.5	0.4	0.4	0.4	0.5	9.0
Max	5.1	4.7	4.5	4.7	5.1	5.8	4.6	4.7	4.4	4.3	4.3	4.1	4.4
Min	0.3	3.0	2.8	2.5	2.7	2.8	3.1	2.6	3.1	2.7	2.7	2.8	2.9

Figure 41: SD & Range Charts for Phosphorus, mg/dL



0	
\mathbf{c}	⊏
_	ē.
Ø	ب
ā	Ö
ਲ	ቯ

Subject	Scrn	DAY	DAY	DAY	DAY								
	-	0	-	4	7	14	21	28	35	42	54	72	180
5	8.50	8.80	7.90	7.60	7.40	7.90	8.50	7.30	7.10	8.00	7.70	7.90	8.10
02	7.30	7.40	7.00	08.9	6.90	7.60	7.20	7.30	6.90				
03	7.20	09.9	7.60	6.10	6.00	6.40		7.40	6.10	6.50	09.9	6.70	7.10
04	7.30	09.9	7.20	06.9	6.90	09.9		7.60	7.20	7.60			
02	6.70		6.40	6.10	6.10	6.20	6.50	7.60					
90	7.70	7.40	7.20	6.90	7.00	9.60	7.60	7.70	8.00	7.40	7.40	7.30	7.80
20	7.80		6.90	6.70	7.70	7.30	7.50	7.60	7.60	7.00	7.10		
08	8.20	7.50	7.40	7.10	7.50								
60	7.10	6.50	6.40	6.50	6.80	6.60	7.00	6.70	5.90	6.70	6.80		
10	7.50	7.20	7.30	7.00	7.00	7.40	09.9	7.40	7.20	6.80	7.60		
7	7.90	7.80	7.50		8.20	6.70	7.40	7.20		6.90			
12	8.50	7.50		7.40	7.20	7.60	7.50	7.50	7.70	7.20	7.20		
13	7.50	7.50	6.70	6.30	6.70	6.60	7.10	6.90	7.00	7.90	7.00		
14	7.20			7.20	7.50	7.10	7.10	7.10	6.90	THE PARTY NAMED IN COLUMN TO THE PARTY NAMED			
15	8.20	7.20	6.50	06:9	6.70	6.50	6.80		7.40	5.80	6.30		
16	7.10	7.00	09.9	06.9	6.50	6.50	6.70	7.00	6.90	6.20	7.00		
17		8.10	7.10										
18	7.20	7.00	08.9	7.00	6.70	09.9	6.70	7.20	7.00	09'9	7.90		
19	6.80	6.70	6.20	6.80	6.30	6.50	6.30	09.9	6.80		6.40		
20	7.10	7.00	06.9	7.50	6.80	6.70	6.70	8.00	7.00	6.30	6.50	7.50	
21	7.20		08.9	7.00	7.00	06.9	06.9	7.40	7.10	6.70	6.90	7.10	
summary:	Summary: Protein, g/dl	g/dL				:							
Average	7.50	7.28	6.97	6.88	6.95	98.9	7.06	7.31	7.05	6.91	7.03	7.30	79.7
Std Dev	0.53	0.59	0.45	0.42	0.54	0.48	0.53	0.36	0.51	0.62	0.49	0.45	0.51
Мах	8.50	8.80	7.90	7.60	8.20	7.90	8.50	8.00	8.00	8.00	7.90	7.90	8.10
Min	6.70	6.50	6.20	6.10	00.9	6.20	6.30	09'9	5.90	5.80	6.30	6.70	7.10

Blank = Not Obtained

180 72 54 Figure 42: SD & Range Charts for Protein, g/dL 42 35 28 Day of Protocol 21 4 Box = Mean ±1 SD; Line = Min to Max Scrn O 8.5 7.5 6.5 5.5 Ŋ ∞ 9 Protein, g/dL


Dec. 17, 1998

10p	AST
Table	SGOT (

Subject		L A	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
	Scrn	0	_	4	7	14	74	28	35	42	54	72	180
10	18	19	19	15	17	17	19	15	13	14	14	17	22
02	21	29	26	21	18	22	20	17	18				
03	15	18	24	19	14	22		22	16	37	16	25	21
04	18	17	17	15	18	17		17	18	19			
05	1		14	13	13	6	10	14					
90	16	16	15	14	19	16	22	23	19	16	18	15	19
07	20		25	14	61	24	26	28	30	23	21		
90	14	13	11	12	13								
60	20	16	16	17	15	16	13	62	20	12	16		
10	16	17	14	17	15	18	14	18	16	15	18		
11	17	18	15		14	10	16	16		1			
12	25	27		18	20	21	20	18	17	19	15		
13	16	16	17	14	14	11	13	18	17	20	16		
14	18	17	14	13	13	13	12	12	14				
15	18	15	14	13	13	16	11		16	13	11		25
16	26	22	20	23	26	28	27	30	22	23	29		
17		26	23										
18	28	28	22	13	16	24	19	19	13	18	17		
19	15	13	12	6	æ	10	. 10	6	11		15		
20	14	18	16	19	16	14	17	56	16	12	17	17	
21	17		18	16	15	19	14	20	18	13	21	22	
									-				
Summary:	SGOT (AST), IU/L	ST), IU/L											
Average	18	19	18	16	18	17	17	21	19	18	17	19	22
Std Dev	40	05	90	03	11	05	02	11	60	07	04	04	03
Max	28	29	26	23	61	28	27	62	20	37	29	25	25
Min	11	13	11	60	80	60	10	60	7	=======================================	7	15	19

Blank = Not Obtained

Figure 43: SD & Range Charts for SGOT (AST), IU/L



	_
ᄑ	\vdash
ŏ	_
Ξ.	4
-	\sim
O	
豆	Ť
₹	Δ
Ë	O
_	7

70	
t Obtained	
Blank = No	

	Hal	lofa	nt)	rine	e IN	ND:	984	7																					
DAY	180		18		17			21									21									19	02	21	17
DAY	72		11		16			8														10	13			12	03	16	90
DAY	54		6		15			15	14		19	15		13	10		13	43		14	12	6	18	į		16	08	43	60
DAY	42		10		24	14		10	20		18	14	8	13	10		16	28		19		10	13			15	90	28	08
DAY	35		တ	14	15	13		18	29		28	12	15	6	9	12	23	28		16	12	13	11			16	07	29	90
DAY	28		15	21	13	22	8	29	40		45	17	တ	17	9	16		36		29	14	10	17			20	11	45	90
DAY	21		20	26			9	25	55		တ	15	11	19	9	14	13	89		31	=	15	17			21	17	89	90
DAY	14		19	32	21	34	8	20	45		11	17	6	20	6	13	. 12	70		39	16	12	16			22	16	20	80
DAY	7		17	27	11	30	6	18	65	9	11	11	9	14	4	15	11	46		16	7	11	12			18	15	65	40
DAY	4		Ξ	27	13	20	6	11	12	9	14	7		13	5	13	8	30		11	10	10	14			13	90	30	05
DAY	-		16	29	16	21	10	14	16	9	15	19	11		7	17	11	25	27	14	11	10	13			15	90	29	90
DAY	0		17	32	13	20		15		8	17	11	7	13	8	20	13	27	30	16	13	10			T), IU/L	16	07	32	80
	Scrn		15	24	7	16	9	16	13	တ	27	6	15	16	9	32	16	36		22	13	11	16		SGPT (ALT), IU/L	16	80	36	90
	Subject		9	02	03	40	05	90	07	80	60	10	11	12	13	14	15	16	17	18	19	20	24		Summary:	Average	Std Dev	Max	Min

Figure 44: SD & Range Charts for SGPT (ALT), IU/L




Table 10r Uric Acid

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
0.1	5.6	6.6	6.9	5.8	6.1	7.1	7.4	6.0	6.9	6.3	6.1	5.8	6.9
02	6.3	5.7	5.7	5.5	0.9	5.8	6.3	5.0	4.2				
03	3.2	3.8	5.5	4.4	3.7	3.9		4.8	3.8	4.5	3.7	4.3	4.7
04	5.2	5.1	5.1	5.5	5.2	5.0		5.8	5.8	5.2			
0.5	5.8		6.4	5.6	5.7	5.6	5.7	5.4					
90	4.8	4.5	4.7	4.0	4.8	4.4	4.6	4.5	4.3	5.2	5.3	4.4	2.0
07	6.3		4.9	4.8	4.8	5.7	5.6	7.3	5.1	0.9	5.8	-	
90	5.5	5.4	5.4	5.7	5.4								
60	6.1	4.5	4.3	4.8	5.0	5.6	5.4	4.3	5.7	4.8	4.6		
19	3.9	3.8	3.7	4.7	3.9	5.1	4.5	4.3	4.5	4.6	4.1		
11	4.1	6.5	4.5	3.9	3.4	3.8	4.0	4.6		3.9	-		
12	4.4	6.0		5.2	5.0	5.2	5.2	9.6	5.4	4.8	5.2		
13	4.6	4.8	4.8	4.8	4.1	4.7	5.0	4.9	4.2	4.7	4.8		
14	5.3	6.1	6.0	6.9	9.9	7.1	9.9	2.9	5.7				
15	9.9	6.0	6.4	7.0	9.9	9.9	5.9	5.5	6.1	6.3	5.8		6.4
16	4.8	5.1	4.9	5.5	5.3	5.2	5.6	5.1	4.9	5.1	4.9		
17		8.1	7.3										
18	5.4	6.1	5.6	5.1	5.5	5.8	6.1	6.7	5.8	4.7	4.8		
19	9.9	6.5	6.4	6.9	6.4	6.8	6.5	5.9	6.7	-	9.9		
20	5.6	5.7	5.6	5.7	5.4	6.1	9.9	6.2	5.7	5.4	5.7	5.6	
21	5.7		5.1	5.9	5.3	5.8	5.9	5.2	5.8	5.5	5.4	5.3	
	Ci V Visi	17/2m											
Average	5.3	5.6	5.5	5.4	5.2	5.5	5.7	5.5	5.3	5.1	5.2	5.1	5.8
Std Dev	6.0		6.0	0.9	6.0	1.0	6.0	6.0	6.0	0.7	0.8	0.7	7.
Max	9.9	8.1	7.3	7.0	9.9	7.1	7.4	7.3	6.9	6.3	9.9	5.8	6.9
Min	3.2	3.8	3.7	3.9	3.4	3.8	4.0	4.3	3.8	3.9	3.7	4.3	4.7

Figure 45: SD & Range Charts for Uric Acid, mg/dL




Table 11a Urinalysis: Casts

DAY 180																				_
DAY 72																				-
DAY 54																				
DAY 42																				
DAY 35																				
DAY 28																		,	,	
DAY 21																				
DAY 14																				
DAY 7																				
DAY 4															- -					
DAY 1																	,-*		*****	
DAY 0																				
Scrn																				
Subject	2	02	03	04	05	90	07	80	60	10	11	12	13	44	15	16	17	18	19	

Table 11b Urinalysis: Occult Blood

O
Φ
ŧ,
Ω
0
-
Ö
- <u>-</u>
~
11
¥
$\overline{}$
=
10
$\overline{\mathbf{m}}$
ш

Subject		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
	Scrn	0	-	4	7	14	21	28	35	42	54	72	180
5	•			1	,	3	1	ı	ŧ	1	•	,	•
02	,	,	•	1	ı	•	•	1					
03	4+	1	+	•	1	-	4+	+	+	•	•	4+	4+
04	1		•	1	1	1	1	1					
05	1	1		1		-	•	î	•				
90		•	1	-	1	1	i	-	1	1	-	•	•
70	1	1	•	•	1	ı		ı	•	1	-		
90	'	•	•	-	1								
60		•	-	-	ı	1	•	1	1	•			
10	1	•	+	1	1	1		J	4+	1			
17	ı	1	1	1	'	1		ı	0.00	•			
12	'		1	1	-	,	1	•	+	,	•		
13	•	1	•		1	1	•	ı	•	1	,		
14	•		1	ı	-		+	+	+				
15	•	1	1.	'	ı	1	•	•	t	1	•		1
16	ı	1	í	t	1	•	ı	,	1	1			
17	1		1	ı	•	•							
18	1	F	•	1	•	ι	1	1	-		t		
19		1	•	1	1	1	1	-	•	1	•		
20	,	ı	•	•	1	1	1			ŧ	,	1	
21	1	1		,	Ī	•	ı	1	ı	1	1	-	

Table 11c Urinalysis: RBC

70
ĕ
듣
ŧ
증
ž
2
ī
يز
an
≕

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	~	4	7	14	21	28	35	42	54	72	180
-	0	0	0	0	0	0	0	0	18	_	-	0	3
2	0	0	0	0	0	0	0	0	18				
3	50	0	2	0	0	0	13	6	_	3	9	1	٦
4	0	0	0	2	-	0	0	2	0				
5	0	16	0	0	0	0	_	0	2				
9	-	15	0	0	0	0	0	-	0	0	0	0	-
7	~	0	0	0	0	0		-	0	0	0		
8	0	0	0	0	0								
6	0	0	0	0	0	0	0	0	-	0			
10	0	0	0	0	0	0	0	0	_	0	0		
11	2	7	0	0	0	0	0	1	0		0		
12	0	0	0	0	0	0	0	1	1	0	0		
13	0	0	0	0	0	0	0	0	0	_	0		-
14	2	0	0	0	0	0	0	0				the state of the s	
15	0	0	0	0	0	2	2	0	0	0			0
16	0	0	Ó	0	0	0	1	Ò	0	0	0		
17	0	0	0										
18	0	3	0	0	0	0	0	0	0	0	0		
19	0	0	0	0	0	0	0	0	0	0	0		
20	0	0	0	0	0	0	0		2	0	0	0	
21	0	0	0	0		0	0	0	0	0	0	က	
					į								191.111
Summary:	Urine RBC	O											
Average	2.7	2.0	0.1	0.1	0.1	0.1	6.0	1.0	2.4	0.4	0.5	0.8	1.3
Std Dev	10.9	4.8	0.4	0.4	0.2	0.5	3.1	2.3	5.7	0.8	1.6	1.3	1.3
Max	20	16	2	2	_	2	13	6	18	က	9	3	3
Min	0	0	0	0	0	0	0	0	0	0	0	0	0

Figure 46: SD & Range Charts for Urine RBC





Table 11d Urinalysis: WBC

Subject	Scrn	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
	;	0	_	4	7	14	21	28	35	42	54	72	180
							The state of the s	\					
01	0	0	0	0	0	0	0	0	2	0	0	0	2
02	-	0	0	0	0	0	0	2	0				
03	0	0	40	0	_	0	0	11	15	3	7	0	0
04	_	0	0	0	-	0	0	3	0	0			
05	0	0	0	0	0	0	_	0	1				
90	-	2	_	0	0	0	0	1	0	0	0	0	0
07	-	0	0	0	0	0	0	0		0	0	0	
08	0	0	0	က	0								
60	0	0	0	-	0	0	0	0	0	0	0		
10	0	0	4	5	0	0	0	0	2	0	0		
11	4	19	0	-	2	0	0	-	0	0	0		
12	0	က	0	0	0	0	0	1	-	0			
13	0	0	0	0	0	0	0	0	0	_	0		
14	0	0	0	0	0	0	0	0					
15	0	0	0	0	0	0	2	0	0	0	0		
16	0	0	0	0	0	0	2	0	0	0			
17	0	-	0	0	0	0	0	0	0	0			
18	0	0	ó	0	0	0	0	0	0	0	0		
19	0	0	0	0	0	_	0	2	0	0	0		
20	0	8	0	0	0	0	0	0	_	0	2		
21	0	0	0	0	0	0	0	0	~	0	0	2	
											100		
Summary:	Urine WBC	3C											
Average	0.4	1.6	2.1	0.5	0.2	0.1	0.3	1.1	1.3	0.2	0.3	0.4	0.7
Std Dev	6.0	4.4	8.7	1.2	0.5	0.2	9.0	2.5	3.5	0.8	0.8	6.0	1.2
ax	4	19	40	5	2	-	2	11	15	3	2	2	2
Min	0	0	0	0	0	0	0	0	0	0	0	0	0

Figure 47: SD & Range Charts for Urine WBC



Blank = Not Obtained

Table 11e Urinalysis: Specific Gravity

		DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY	DAY
Subject	Scrn	0	~	4	7	14	21	28	35	42	54	72	180
10	1.026	1.023	1.031	1.030	1.026	1.027		1.029	1.029	1.022	1.032	1.031	1.018
02	1.026	1.015	1.018	1.022	1.025	1.021	1.019	1.025	1.015				
03	1.009	1.019	1.016	1.007	1.019	1.005	1.005	1.019	1.022	1.022	1.019	1.019	1.021
04	1.027	1.016	1.018	1.026	1.026	1.014	1.027	1.030	1.028				
05	1.015	1.008	1.016	1.025	1.019	1.026	1.023	1.009	1.013				
90	1.028	1.012	1.026	1.026	1.022	1.023	1.025	1.027	1.027	1.021	1.025	1.026	1.020
07	1.034	1.022	1.023	1.008	1.009	1.011		1.027	1.029	1.028	1.030		-
80	1.033	1.021	1.015	1.029	1.029								
60	1.029	1.007	1.026	1.029	1.020	1.019	1.020	1.016	1.028	1.022			
10	1.026	1.015	1.008	1.018	1.010	1.020	1.015	1.018	1.030	1.007	1.007		
-	1.030	1.026	1.019	1.026	1.019	1.025	1.019	1.027		1.027			į
12	1.005	1.030	1.031	1.016	1.031	1.021	1.012	1.030	1.030	1.013	1.022		
13	1.025	1.025	1.016	1.019	1.022	1.016	1.018	1.028	1.026	1.026	1.026		
14	1.029	1.014	1.020	1.004	1.004	1.019	1.022	1.025					
15	1.016	1.005	1.016	1.016	1.022	1.018	1.019	1.007	1.017	1.016	1.020		1.033
16	1.009	1.015	1.026	1.029	1.025	1.025	1.027	1.029	1.028	1.027			
17	1.030	1.034											
18	1.018	1.017	1.021	1.016	1.010	1.021	1.020	1.010	1.025	1.022	1.021		
19	1.026	1.031	1.028	1.019	1.015	1.013	1.016	1.019	1.021	1.014	1.018		
20	1.027	1.028	1.025	1.022	1.020	1.017	1.016		1.032	1.017	1.028	1.013	
21	1.021	1.025	1.016	1.025		1.019	1.021	1.009	1.026	1.026	∙1.028	1.029	
Summary:	Urine: Sp	Urine: Specific Gravity	/ity										
Average	1.023	1.023	1.031	1.030	1.026	1.027	1.019	1.029	1.029	1.022	1.032	1.031	1.018
Std Dev	0.008	0.008	900.0	0.008	0.007	900'0	0.005	0.008	900.0	0.006	0.007	0.007	0.007
Max	1.027	1.034	1.031	1.030	1.031	1.027	1.027	1.030	1.032	1.028	1.032	1.031	1.033
Min	1.005	1.005	1.008	1.004	1.004	1.005	1.005	1.007	1.013	1.007	1.007	1.013	1.018

180 72 SD & Range Charts for Urine: Specific Gravity 54 42 35 28 21 4 Box = Mean ±1 SD; Line = Min to Max Figure 48: 0 Scrn 1.015 1.045 1.035 1.04 1.03 1.02 1.01 Urine: Specific Gravity


Page 133


Day of Protocol

Figure 49a: Pharmacokinetics of Halofantrine Accumulation

	Accumulation Rat	e Constant (/day)	Accumulation F	lalf-time (days)
Subject	Halo (+)	Halo (-)	Halo (+)	Halo (-)
1	0.101	0.086	6.89	8.10
2	0.058	0.048	11.88	14.30
4	0.392	0.730	1.77	0.95
5	0.160	0.159	4.33	4.35
7	0.139	0.211	4.97	3.28
8	0.058	0.060	12.00	11.63
9	0.126	0.116	5.49	5.99
10	0.038	0.056	18.26	12.43
. 11	0.262		2.65	
15	0.096	0.050	7.23	13.80
16、	0.062	0.064	11.10	10.79
. 18	0.284	0.318	2.44	2.18
19	0.379	0.340	1.83	2.04
20	0.095	0.158	7.29	4.38
		·		
Mean:	0.161	0.184	7.01	7.25
SD:	0.120	0.191	4.80	4.82
p-value:	0.:	27	9.0	90

Based on exponential curve fit during administration of Halofantrine p-values from paired Student t-test





Dec. 17, 1998 Page 134

+ + Figure 49b: Halofantrine Kinetics for Subject 01 + Days Ŋ Conc. Halofantrine (ng/mL)

Figure 49c: Halofantrine Kinetics for Subject 02 +Days S Conc. Halofantrine (ng/mL)

Figure 49d: Halofantrine Kinetics for Subject 04 + Days + + + Conc. Halofantrine (ng/mL)


Dec. 17, 1998

Figure 49e: Halofantrine Kinetics for Subject 05 Days ++ Conc. Halofantrine (ng/mL)


Dec. 17, 1998


Figure 49f: Halofantrine Kinetics for Subject 07 + Days + Conc. Halofantrine (ng/mL)

Figure 49g: Halofantrine Kinetics for Subject 08




Dec. 17, 1998





Dec. 17, 1998



Dec. 17, 1998

Figure 49k: Halofantrine Kinetics for Subject 14 + Conc. Halofantrine (ng/mL)

Days




Figure 49m: Halofantrine Kinetics for Subject 16 Days Conc. Halofantrine (ng/mL)

Figure 49n: Halofantrine Kinetics for Subject 18 + Days + + Conc. Halofantrine (ng/mL)

+ Figure 490: Halofantrine Kinetics for Subject 19 Days + + + Conc. Halofantrine (ng/mL)

Dec. 17, 1998






Figure 50: Pharmacokinetics of Halofantrine Clearance

	Steady-State	Conc (ng/mL)	Clearand	ce (L/hr)
Subject	Halo (+)	Halo (-)	Halo (+)	Halo (-)
1	, ,			
1	82.9	40.3	117.1	241.0
2	108.1	61.5	89.8	157.9
4	88.3	33.8	109.9	287.0
5	31.3	14.8	310.2	656.0
7	151.6	71.9	64.0	135.1
9	62.3	40.8	155.8	238.0
10	107.4	66.1	90.4	146.9
11	54.6	30.9	177.7	314.2
14	204.3	67.4	47.5	144.0
15	73.6	37.0	131.9	262.2
16	97.9	44.6	99.2	217.8
18`	94.6	48.3	102.6	201.1
19	46.3	29.7	209.8	327.4
20	40.5	25.3	240.0	384.5
				,
Mean:	88.8	43.7	139.0	265.2
SD:	46.2	17.3	73.0	135.4
p-value:	0.0	000	0.0	000

Based on an average infusion rate of 233 mg/day of each isomer p-values from paired Student t-test





Page 150

		Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 2	Day 3	Day 4	Day 4	Day 4
Subj	Scrn	Pre	.5hr	1hr	2hr	3hr	4hr	6hr	8hr	10hr	12hr	Pre	Pre	Pre	2hr	4hr
01	87	58	29	72	59	61	29	69	89	74	70	29	62	9	09	71
02	71	55	51	55	55	99	59	57	65	63	58	28	64	22	89	64
03	09	09	58	55	59	58	63	58	09	56	53	09	28	54	55	62
04	6/	69	71	69	99	64	29	71	69	29	73	70	64	20	75	2.2
05	09	56	51	52	58	51	52	61	58	09	09	56	20	22	54	61
90	72	64	59	57	55	69	99	54	55	64	54	53	54	29	54	70
07	28	46	41	41	51	52	47	44	46	45	46	41	49	29	20	99
80	61	55	51	57	57	25	59	29	54	51	61	54	53	20	55	62
60	51	49	20	51	52		55	63	57	58	22	20	48	58	53	63
19	89	59	59	62	64	72	70	29	64	75	62	65	64	99	71	77
1	92	84	86	83	88	89	98	98	96	93	85	9/	64	29	99	71
12	59	09	09	58	58	70	77	63	65	29	09	22	52	54	51	63
13	51	46	44	46	45	56	54	52	22	53	51	48	44	46	52	52
14	49	45	45	46	44	48	47	44	43	47	44	45	44	45	47	49
15	89	65	29	09	74	62	83	73	99	99	64	73	29	25	72	99
16	74	78	72	70	99	9/	72	69	09	99	71	70	65	78	7.1	77
17	55	59	53	57	59	29	89	29								
18	89	58	26	55	58	65	63	64	29	9/	99	58	61	63	62	72
19	69	58	61	62	61	09	69	68	09	72	64	89	63	73	74	82
20		20	46	52	52	52	64	62	55	54	22	49	58	20	53	29
21	29	62	58	59	59	63	20	69	65	65	99	64	22	63	63	64
	(Mad of														
Summary:	ال ال ال ال ال ال ال ال ال ال ال ال ال ا	rate, Driv	n 57	58	50	63	65	63	69	64	61	59	57	09	09	99
Avelage Std Dav	3 +	5	7	10	10	9	12	9	1	11	10	10	07	60	60	88
Max	92	84	86	83	88	89	98	86	96	93	85	9/	29	78	75	82
Min	49	45	41	41	44	48	47	44	43	45	44	41	44	45	47	49

	Day 4	Day 4	Day 4		Day 6	Day 7	Day 7	Day 7	Day 7	Day 7	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12
Subj	6hr	8hr	12hr	PRE		Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre	Pre	Pre
2	98	64	74	62	29	56	64	62	65	25	69	29	29	58	53	61
02	79	69	71	64	62	61	55	62	89	106	80	61	53	54	25	61
03	09	68	62	52	54	57	62	65	62	09	61	61	54	54	26	68
04	7.1	93	79	89	69	74	99	71	78	72	7.1	69	75.	68	73	75
05	89	59	52	46	55	54	49	54	67	52	55	55	20	20	49	56
90	99	89	65	57	53	65	54	75	70	58	64	59	58	54	64	61
07	51	52	55	47	29	59	54	72	64	22	69	58	65	65	62	22
08	61	58	58	54	51	52	54	62	58	57	09	56	56	22		
60	59	56	58	51	49	53	51	29	61	56	09	50	25	54	48	53
10	69	29	92	65	75	89	73	77	74	94	7.1	72	09	06	75	29
1	29	74	73	65	64	49	61	74	29	65	65	62	61	09	64	09
12	63	56	. 99	64	64	55	56	65	99	65	64	99	72	61	62	61
13	09	51	54	47	53	20	20	29	52	22	61	53	20	47	46	45
14	47	48	41	45	48	47	45	51	20	46	46	48	45	45	42	47
15	63	57	55	59	99	69	63	29	28	62	61	58	29	22	62	55
16	79	65	73	79	64	65	68	78	76	73	69	74	29	99	78	65
17																
18	70	99	64	. 63	61	70	65	2.2	78	72	68	63	29	62	65	61
19	79	9/	64	68	99	63		73	69	99	62	56	99	64	22	62
20	58	55	29	51	53	51	22	64	29	58	55	55	56	52	26	55
21	75	99	29	64	09	22	55	65	64	89	71	58	59	56	58	99
Summary:															-	
Average	29	63	63	59	09	09	58	29	65	65	64	09	59	29	59	29
Std Dev	10	10	10	60	80	80	20	80	90	14	07	07	08	10	10	07
ax	86	93	79	79	75	74	73	78	78	106	80	74	75	06	78	75
Min	47	48	41	45	48	47	45	51	20	46	46	48	45	45	42	45

	Day 13	Day 14	Day 14	Day 14	Day 14	Day 14	Day 14	Day 15	Day 16	Day 17	Day 18	Day 19	Day 20	Day 21
Subj	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre						
									\					
01	99	29	29	59	64	99	64	22	63	22	65	80	64	89
02	52	54	29	09	9/	29	7.1	63	53	63	54	54	56	58
03	64	. 89	62	99	20	63	65	61	09	61	59	59	52	57
04	89	73	74	9/	83	83	84	79	9/	77	98	81	9/	75
05	58	53	54	65	28	52	51	51	53	54	58	56	54	52
90	22	56	54	71	89	65	63	99	61	68	99	909	59	09
07	59	89	61	68	72	84	65	70	63	29	64	65	29	85
80														
60	26	45	59	09	55	54	22	53	20	56	20	49	56	51
10	59	75	64	75	73	80	65	62	69	61	88	79	29	71
11	54	99	63	74	20	71	79	61	64	62	62	64	29	65
12	63	59	59	56	57	63	76	29	. 61	63	29	65	59	62
13	46	42	49	09	44	91	58	50	50	49	22	48	43	44
14	42	45	44	51	51	48	49	46	44	46	46	45	20	49
15	28	55	56	71	65	58	56	54	51	52	61	69	57	54
16	81	64	65	. 78	80	65	72	70	71	78	20	70	71	75
17														
18	70	65	68	89	95	82	85	68	29	62	29	65	89	74
19	28	62						63	56	22	25	61	09	57
20	55	54	56	59	58	62	63	54	53	55	54	55	54	28
21	28	52	57	64	69	61	.68	55	54	55	29	09	55	54
Summary:														
Average	59	59	09	99	29	89	99	61	59	09	63	.62	09	62
Std Dev	60	60	07	10	12	12	10	90	80	90	12	10	90	11
Мах	81	75	74	83	95	91	85	79	9/	78	86	81	9/	85
Min	42	42	44	51	44	48	49	46	44	46	46	45	43	44

4hr 6hr 8hr 75 71 76 53 64 72 53 64 72 51 56 53 88 82 85 63 65 57 76 78 76 66 67 68 66 67 68 66 67 68 67 63 58 67 63 58 64 64 66 64 64 66 64 64 66 61 58 57 69 67 67 11 11 11 12 11 11	Da	Day 21	Day 21	Day 21	Day 21	Day 21	Day 22	Day 25	Day 29	Day 32	Day 36	Day 39	Day 42	Day 45	Day 45
01 56 75 71 76 02 51 53 64 72 03 49 51 56 53 04 75 88 82 85 04 75 88 82 85 05 54 63 65 57 06 64 63 66 66 07 68 68 69 66 08 61 64 63 61 10 65 80 73 74 11 70 80 73 74 14 57 52 46 49 14 57 52 46 49 15 56 67 63 65 16 64 89 77 73 17 72 83 85 85 20 56 64 66 65 21 54 61 66 67 22 54 64 <th< th=""><th>7</th><th></th><th>4hr</th><th>6hr</th><th>8hr</th><th>12hr</th><th>Pre</th><th>Pre</th><th>Pre</th><th>Pre</th><th>Pre</th><th>Pre</th><th>Pre</th><th>.5hr</th><th>1hr</th></th<>	7		4hr	6hr	8hr	12hr	Pre	.5hr	1hr						
01 56 75 71 76 02 51 53 64 72 03 49 51 56 53 04 75 88 82 85 05 54 63 55 57 05 64 76 78 76 05 64 63 65 85 10 65 80 73 74 11 70 80 73 74 11 70 80 73 74 13 43 52 46 49 14 57 52 46 49 15 56 67 63 58 16 64 89 77 73 17 56 67 68 65 20 56 64 64 66 21 54 61 66 21															
02 51 53 64 72 03 49 51 56 53 04 75 88 82 85 05 54 63 55 57 06 64 76 78 76 07 68 68 69 66 07 68 68 69 66 10 65 80 73 74 11 70 80 73 74 13 43 52 46 49 14 57 52 46 49 14 57 52 46 49 15 66 67 63 65 16 64 89 77 73 17 70 83 85 85 18 72 83 85 85 20 66 64 64 66		99	75	71	9/	75	82	73	73	75	63	72	22	63	29
03 49 51 56 53 04 75 88 82 85 06 64 76 78 76 06 64 76 78 76 07 68 68 69 66 07 68 68 69 66 08 61 64 63 61 10 65 80 73 74 12 59 66 67 68 14 57 52 46 49 14 57 52 46 49 15 56 67 63 65 16 64 89 77 73 16 64 89 77 73 17 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 21 54 61 58 67 3ee 60 67 67 3e 69 67 67 60 69 67 67	4,	5.1	53	64	72	73	72	77	89	109	80	89			
04 75 88 82 85 05 54 63 65 57 06 64 76 78 76 07 68 68 69 66 07 68 68 69 66 08 61 64 63 61 10 65 80 82 76 11 70 80 73 74 12 59 66 67 68 13 43 52 46 49 14 57 52 51 50 14 57 63 58 58 16 64 63 65 66 17 64 63 65 66 18 72 83 85 85 20 56 64 64 66 21 54 61 63 67	7	61	51	56	53	63	54	52	59	62	58	99	26	61	62
05 54 63 55 57 06 64 76 78 76 07 68 68 69 66 08 61 64 63 61 10 65 80 82 76 10 65 80 73 74 12 59 66 67 68 74 13 43 52 46 49 77 14 57 52 51 50 77 15 56 67 63 58 77 15 56 67 63 58 77 73 16 64 89 77 73 73 17 54 61 58 57 20 56 64 66 65 21 54 61 58 57 22 54 61 58 67		75	88	82	85	78	85	81	72	75	75				
06 64 76 78 76 07 68 68 69 66 08 61 64 63 61 60 10 65 80 73 74 76 11 70 80 73 74 77 12 59 66 67 68 77 13 43 52 46 49 14 57 52 54 69 65 15 56 67 63 58 77 73 16 64 89 77 73 85 17 17 56 67 68 65 66 65 20 56 64 64 66 65 66 21 54 61 58 57 80 mary: 60 69 67 67 90 65 67 67		54	63	55	57	56	55	53							
07 68 68 69 66 08 61 64 63 66 10 65 80 82 76 11 70 80 73 74 12 59 66 67 68 13 43 52 46 49 14 57 52 54 49 16 64 89 77 73 16 64 89 77 73 17 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 21 54 61 58 57 3ee 60 69 67 67 3e 69 67 67 3e 75 83 85		34	92	78	9/	69	70	77	29	73	62	64	58	57	26
08 61 64 63 61 10 65 80 82 76 11 70 80 73 74 12 59 66 67 68 13 43 52 46 49 14 57 52 51 50 15 56 67 63 58 16 64 89 77 73 17 73 73 18 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 Dev 08 12 11 11 3ev 75 89 85 85		38	89	69	99	69	65	79	59	75	53	89	59	55	56
09 61 64 63 61 10 65 80 82 76 11 70 80 73 74 12 59 66 67 68 13 43 52 46 49 14 57 52 51 50 15 56 67 63 58 16 64 89 77 73 17 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 69 67 67 Dev 08 12 11 11 36 69 67 67 67 89 85 85 85															
10 65 80 82 76 11 70 80 73 74 12 59 66 67 68 13 43 52 46 49 13 43 52 46 49 14 57 52 51 50 15 56 67 63 58 16 64 89 77 73 17 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 3ey 08 12 11 11 3ey 85 85 85		51	64	63	61	09	09	72	29	52	54	20	47	58	46
11 70 80 73 74 12 59 66 67 68 13 43 52 46 49 14 57 52 51 50 15 56 67 63 58 16 64 89 77 73 17 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 Dev 08 12 11 11 75 89 85 85		35	80	82	9/	67	72	75	84	72	22	09	69	29	63
12 59 66 67 68 13 43 52 46 49 14 57 52 51 50 15 56 67 63 58 16 64 89 77 73 17 73 77 73 18 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 69 67 67 Dev 08 12 11 11 75 89 85 85		0,2	80	73	74	72	99	71	77	70		73	64	63	9
13 43 52 46 49 14 57 52 51 50 15 56 67 63 58 16 64 89 77 73 17 73 77 73 17 73 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 Dev 08 12 11 11 75 89 85 85		29	99	29	89	29	65	74	70	70	61	20	29	62	59
14 57 52 51 50 15 56 67 63 58 16 64 89 77 73 17 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 Dev 08 12 11 11 75 89 85 85		43	52	46	49	47	54	62	20	09	54	26	47	48	49
15 56 67 63 58 16 64 89 77 73 17 72 83 85 85 18 72 83 85 85 19 59 76 69 65 20 56 64 66 57 21 54 61 58 57 mary: 60 69 67 67 Dev 08 12 11 11 75 89 85 85		57	52	51	50	49	20	29	58	54	22	56			
16 64 89 77 73 17 83 85 85 18 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: age 60 69 67 67 Dev 08 12 11 11 75 89 85 85		56	29	63	58	67	55	9/	75	7.1	72	89	09	22	62
17 83 85 85 18 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 Jev 08 12 11 11 75 89 85 85		94	89	77	73	75	72	9/	29	20	72	75	29	63	61
18 72 83 85 85 19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: mary: 69 67 67 Dev 08 12 11 11 75 89 85 85															
19 59 76 69 65 20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 Jev 08 12 11 11 75 89 85 85		72	83	85	85	77	72	80	88	81			22	29	28
20 56 64 64 66 21 54 61 58 57 mary: 60 69 67 67 Jev 08 12 11 11 75 89 85 85		59	76	69	.65	63	29	09	61	89	69	29	64	61	90
21 54 61 58 57 mary: 60 69 67 67 Jev 08 12 11 11 75 89 85 85		56	64	64	99	09	29	54	99	54	51	54	58	53	54
mary: 60 69 67 67 Jev 08 12 11 11 75 89 85 85		54	61	28	57	72	56	54	26	61	09	52	52	57	24
mary: 60 69 67 67 Dev 08 12 11 11 75 89 85 85															
age 60 69 67 67 Dev 08 12 11 11 75 89 85 85	 														
Dev 08 12 11 11 75 89 85 85		09	69	29	29	99	9	69	29	20	62	64	58	58	22
75 89 85 85		90	12	11	11	60	10	10	10	13	60	80	90	8	05
		75	89	85	85	78	85	81	88	109	80	75	69	63	63
43 51 46 49		43	51	46	49	47	20	52	20	54	21	20	47	48	46

Subj 2hr 01 63 02 63 03 57 04 05 05 58 06 58 07 56 09 51 10 70 11 64 12 55 13 52 14 64 15 64 16 57 18 57	3hr 86 86 62 62 65 65 65	4hr	6hr				•	,			1	, ;	. :
	62 62			8hr	10hr	12hr	AM	AM	AM	ΜΑ	ΜΥ	AM	AM
	86 62 86						,			C	ļ	00	3
	62	70	29	69	9/	71	26	28	09	29	54	89	64
	62												
	58	62	65	53	56	58	73	20	74	69	64	65	61
	58												
	58												
		78	09	29	59	53	29	22	55	64	61	64	63
	48	29	47	54	59	55	36		74	89	65	83	78
												-	
	55	54	49	53	53	52	20	22		54	09	26	69
	87	76	63	59	70	72	71	79		70	81	81	
		77	71	89	89	20	89	89	79				
	-	61	55	55	58	09	58	61	52	. 29	74	09	78
		51	45	46	49	49	20	62	64	49	29	62	62
	73	71	89	89	71	75	75	69	63	61	78	89	63
		89	9/	73	73	75	78	96					
	65	64	29	56	62	09	22	73	75		80	98	81
	29	89	63	62	63	62	62	69	65	74	80	74	63
		99	62	63	28	55	28	54	53	28	65	28	51
		63	57	65	64	22	22	71	70	74	93	71	72
Summary:													
Average 59	99	99	09	09	63	62	09	29	99	64	20	69	29
		80	60	80	08	60	7	7	60	08	7	10	60
	ļ	78	9/	73	9/	75	78	96	79	74	93	98	81
	48	51	45	46	49	49	36	54	23	49	54	56	51

Table 12a-6 ECG: Rate

Blank = Not Obtained

	Day 72	Day 180
34:0	7 7 8	
fans	AM	AM
10	74	84
02		
03	62	09
04		
05		
90	99	83
07	29	29
80		
60	51	62
10		
11		
12	64	69
13	59	62
14		
15	111	87
16	74	83
17		
18	06	
19	58	
20	55	
21		
Summary:		
Average	69	73
Std Dev	17	11
Мах	111	87
Min	21	09

Dec. 17, 1998

Page 156

472,h0 04,43b 04,84b 04'tbp 442,512 84,S4b 442,64 442,62 442,h0.5 04'6EP 432,50 Figure 51: SD & Range Charts for ECG: Rate, BPM 925,50 211,1Sb 421,h6 421,52 920,60 418,h0 04,816 214,41b 94**'**†lp 74,41b 913,50 04'11P 04'6P 214,7b 94,7b Z4,7b 04,8b 214,4b 94'tp 74,5b 04,66 £14,1b 84,1b **†**4'lp 24,1b 3.04,1b Scm 120 100 8 9 4 20 0 ECG: Rate, BPM

Dec. 17, 1998

Day and Hour of Protocol

2b-1	Interva
ble 1	R
Ta	ECG -

12b-1	Inter
Table	ECG - PR

Blank = Not Obtained

		Dav 1	Day 1	Day 1	737.4	7	1											
idi.	0.50				_ g	Lay -	Day 1	Day 1	Day 1	Day 1	Day 1	Day 2	Day 3	Day 4	Day 4	Day 4	Day A	7
	5	ב	JUC:	Jul	Zhr	3hr	4hr	6hr	8hr	10hr	12hr	2				֓֞֝֜֜֜֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֓֡֓֓֓֓֓֡֓֓֡֓֡֓֡֓	ray t	7 ay 4
										5	1117	D L	a L	7 6	Zhr	4hr	6hr	8hr
5	146	138	148	136	156	15/	151	100	7,70									
02	162	162	164	170	168	170	104	130	148	148	142	150	160	170	162	158	146	156
03	174	162	166	174	2 2	161	477	100	156	156	168	158	160	152	152	150	152	142
04	162	156	160	164	163	1 04	7/1	7/1	1/0	184	184	170	180	196	198		186	176
05	150	160	160	156	150	727	100	200	150	152	156	156	158	158	162	162	168	154
90	136	142	154	144	146	40,	200	148	144	154	160	156	170	166	162	144	150	154
07	160	148	154	150	137	100	130	124	148	140	136	142	150	136	144	142	140	142
80	146	150	136	134	104	150	140	158	152	164	158	164	156	154	160	150	156	150
60	168	170	168	168	160	001	144	30	128	134	120	158	158	162	144	130	138	138
10	140	144	140	142	142	132	126	130	40.5	120	154	162	168	166	160	142	148	152
11	136	130	128	132	133	130	128	130	471	200	138	144	148	114	140	130	143	140
12	164	164	172	164	163	450	150	130	97	128	128	130	136	136	146	140	138	140
13	150	152	154	156	150	200	00,	00	164	164	170	166	138	176	168	166	166	170
14	170	170	170	178	200	200	140	142	144	142	144	160	164	164	154	148	140	148
15	150	146	153	2 2 2	200	2/5	80	1/4	180	168	174	166	176	182	180	174	164	178
16	174	183	172	40	148	126	138	146	148	116	150	146	152	150	148	146	ξ α	150
17	177	701	7/1	200	1/8	180	178	178	164	180	174	178	182	178	787	7 70	2 2	2
	1/4	2/1	1/6	194	176	172	160	160				,	7	2	5	0/	180	1/4
218	140	142	142	142	144	140	138	130	140	136	140	151	7					
19	126	136	136	134	134	130	132	12	100	3 5	2 5	40	701	154	146	142	142	144
20		142	146	142	154	146	136	130	071	132	871	138	130	136	132	128	124	130
21	154	180	152	156	170	170	160	200	28	142	138	140	148	144	150	148	140	152
				3		2	3	000	20	1/2	162	158	148	164	160	158	152	162
Summary:	ECG - P	ECG - PR Interva	ā															
Average	154	155	155	155	154	151	150	07.7	1									
Std Dev	14	1.5	14	17	2 4	2 7	3	43	148	150	151	155	157	158	158	149	151	153
Max	174	182	176	194	180	100	170	15	15	18	18	12	14	19	16	14	15	13
Min	126	130	128	130	400	126	0 0	8/2	180	184	184	178	182	196	198	176	186	176
				70	071	071	97	124	124	116	120	130	130	114	132	128	124	100
																?	14.1	2


	Day 4	Day 5	Day 6	Day 7	Day 7	Day 7	Day 7	Day 7	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13	Day 14	Day 14
Subj	12hr	PRE	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre	Pre	Pre	Pre	Pre	2hr
5	158	160	154	164	160	142	15.4	158	152	138	150	166	152	167	186	162	116
5	2 2	200	5 5		3 5	1 0	5 2	3 5	1 2	2 .	3 5	227	102	t 0	3 5	301	2 5
70	128	701	140	140	162	166	152	140	156	154	160	150	162	168	162	146	168
03	198	178	148	186	182	182	166	166	186	164	176	184	180	166	160	172	156
04	154	154	156	150	150	152	150	144	150	148	140	144	164	155	152	150	148
05	152	158	164	154	158	156	142	148	156	160	152	160	164	154	158	168	154
90	140	142	136	144	134	134	136	116	142	156	144	144	136	138	134	134	128
07	156	158	156	156	164	148	146	148	132	160	132	152	154	132	134	146	140
80	146	140	166	156	152	130	146	152	144	150	138	150					
60	158	168	174	168	150	152	156	154	154	162	162	174	174	174	168	166	158
10	134	118	140	140	142	134	138	142	136	128	146	140	134	136	148	136	140
11	144	150	146	142	140	134	132	134	136	142	146	142	146	138	152	140	148
12	176	168	178	184	178	174	164	168	170	170	178	178	176	174	176	178	184
13	144	160	156	156	150	146	140	146	148	162	160	156	136	164	162	156	148
14	182	176	180	176	178	160	166	174	172	164	158	166	162	176	182	182	184
15	152	146	150	152	148	138	140	144	152	152	154	152	158	154	154	156	154
16	188	182	184	174	190	180	174	192	172	192	184	192	196	184	186	198	192
17																	
18	152	150	160	154	154	138	136	140	146	154	154	156	152	158	156	162	154
19	128	136	134	136		126	126	130	130	138	134	136	134	130	136	136	
20	132	152	142	138	136	140	130	136	140	146	146	148	86	148	142	142	146
21	150	154	176	168	170	156	156	146	153	158	166	170	174	166	172	158	174
	i ;		i i	:				:									
Summary:																	:
Average	155	156	157	157	158	149	148	149	151	155	154	158	155	157	158	157	157
Std Dev	18	15	15	15	16	16	13	17	15	14	14	15	22	16	15	17	17
Max	198	182	184	186	190	182	174	192	186	192	184	192	196	184	186	198	192
Min	128	118	134	136	134	126	126	116	130	128	132	136	86	130	134	134	128

	Day 14	Day 14 Day 14	Day 14	Day 14	Day 15	Day 16	Day 17	Day 18	Day 19	Day 20	Day 21	Day 21	Day 21	Day 21	Day 21
Subj	4hr	6hr	8hr	12hr	Pre	2hr	4hr	6hr	8hr						
01	150	136	150	140	142	148	148	156	146	158	164	160	148	144	150
02	152	158	152	156	168	166	176	180	168	172	170	176	166	188	170
03	142	158	178	180	176	162	156	176	190	170	156	154	176	176	176
04	142	144	146	154	150	142	156	150	144	146	144	150	148	140	148
05	144	146	154	170	166	156	150	140	150	162	154	146	150	144	150
90	142	136	142	148	152	136	150	144	136	132	136	146	140	138	138
07	154	158	150	136	140	156	126	152	136	144	150	152	154	152	160
80															
60	148	162	164	162	172	174	174	172	172	174	168	168	164	160	152
10	142	146	142	148	148	146	150	150	150	140	150	146	138	138	140
11	130	132		130	148	146	144	148	148	144	138	138	126	136	138
12	170	170	178	140	170	178	166	186	186	174	178	174	170	166	176
13	140	144	142	144	164	162	140	154	160	140	162	134	150	154	144
14	162	162	162	174	176	174	166	174	168	170	166	158	158	164	174
15	152	144	150	144	152	144	148	156	154	150	158	156	148	140	150
16	184	182	100	186	184	184	186	186	188	184	184	186	178	180	182
17															
18	136	132	136	144	154	152	156	156	156	160	156	146	142	140	140
19					132	136	132	140	136	136	138	126	130.	128	136
20	144	136	134	130	148	146	150	144	146	144	146	146	140	134	134
21	172	154	170	168	164	180	176	166	184	186	176	176	166	156	172
				-											
Summary:															
Average	150	150	150	153	158	157	155	159	159	157	158	155	152	151	154
Std Dev	14	14	19	17	14	15	16	15	18	11	14	16	15	17	16
Max	184	182	178	186	184	184	186	186	190	186	184	186	178	188	182
Min	130	132	100	130	132	136	126	140	136	132	136	126	126	128	134

	Day 21	Day 22	Day 25	Day 29	Day 32	Day 36	Day 39	Day 45	Day 45	Day 45	Day 45	Day 45	Day 45	Day 45	Day 45
Subj	12hr	Pre	Pre	Pre	Pre	Pre	Pre	Pre	.5hr	1hr	2hr	3hr	4hr	6hr	8hr
	!														
5	148	160	172	148	146	148	144	148	158	138	136	144	144	146	142
05	166	172	202	180	176	152	158								
03	164	166	160	170	176	178	144	156	162	166	160	138	164	162	164
94	148	142	152	134	150	146									
05	154	154	152												
90	142	146	150	140	140	144	124	140	128	140	136	140	136	128	120
07	156	150	156	162	164	166	164	166	162	172	170	166	172	166	156
88															
60	162	168	152	158	164	146	154	168	160	150	146	144	150	144	148
10	128	150	142	134	128	140	138	138	140	148	144	142	144	150	136
11	138	136	132	134	134		130	136	144	144	136	132	134	138	142
12	172	168	162	160	162	170	158	182	178	178	182	182.	178	176	174
13	148	164	152	134	154	158	154	164	160	158	160	166	168	160	162
14	164	172	166	180	164	158	162								
15	142	150	144	138	146	140	146	148	146	152	158	148	142	146	164
16	182	186	176	180	178	174	176	184	180	162	154	188	156	168	170
17															
2	148	152	134	140	142			140	138	142	138	136	136	130	134
19	134	134	126	134	144	128	126	126	126	130	126	120	128	116	122
20	138	142	140	140	148	140	136	152	144	148	150	148	144	142	140
21	160	188	156	146	154	148	148	178	172	174	162	170	146	160	156
Summary:															
Average	152	158	154	151	154	152	148	155	153	153	151	151	149	149	149
Std Dev	14	16	17	17	15	14	15	18	17	14	15	19	15	17	17
Max	182	188	202	180	178	178	176	184	180	178	182	188	178	176	174
Min	128	134	126	134	128	128	124	126	126	130	126	120	128	116	120

	Day 42	Day 45	Day 43	Day 44	Day 45	Day 48	Day 51	Day 54	Day 57	Day 72	Day 180
Subj	10hr	12hr	AM	AM	AM	AM	ΑM	ΑM	ΑM	AM	AM
01	152	154	148	148	154	146	150	158	160	160	160
02								3	3	2	3
03	164	162	150	158	176	162	154	136	174		178
04											
05											
90	128	124	130	134	122	124	111	138	146	128	
07	162	164	170		168	182	182	154	130	170	182
08										,	200
60	148	156	166	162		158	142	154	152	172	158
10	126	148	146	148	130	136	140	152			
11	144	128	146	138	128						
12	176	174	170	166	174	176	168	180	166	166	172
13	164	162	160	152	152	126	148	142	154	140	
14											
15	152	148	146	144	146	148	142	138	148	140	140
16	170	170	170	178						180	174
17											
18	132	136	140	126	132		138	132	146	132	
19	128	130	130	118	136	130	124	132	118	124	
20	140	148	148	142	138	146	138	146	138	134	
21	146	140	160	146	142	154	162	136	134		
Summary:	1										
Average	149	150	152	147	146	149	146	146	147	150	166
Std Dev	16	16	14	16	18	19	18	14	16	20	15
Max	176	174	170	178	176	182	182	180	174	180	182
Min	126	124	130	118	122	124	111	132	118	124	140

Figure 52: SD & Range Charts for ECG - PR Interval



Subj Subj Subj Subj Subj Subj Subj Subj	E	Pre 86 84 84 84	.5hr	thr .	2hr	3hr	4hr	6hr	Shr -	10hr	12hr	Day 2 Pre	Pre	Pre Pre	2hr
	88 88 88 88 88 106	86 84					-		;	5	:::!	· ·	-		
	88 88 88 88 88 106	86													
	88 88 88 88 1106	84	28	82	82	80	80	82	80	78	78	82	86	80	82
	88 88 88 106	84	82	92	98	72	98	82	82	98	80	84	89	74	76
	88 88 106	5	98	98	84	98	98	84	86	84	98	82	98	88	92
	88 106 108	84	06	90	06	82	06	88	06	92	84	06	94	96	98
	106	80	98	06	82	84	98	78	98	84	86	88	98	84	80
-	108	106	102	104	104	108	108	110	106	108	106	104	108	104	106
-		106	110	108	100	104	98	104	110	108	110	102	108	102	102
	/4	98	86	88	94	74	78	72	70	98	80	82	06	98	74
- -	100	100	100	96	86		94	98	94	96	94	86	98	98	94
	74	72	20	0/	72	20	72	72	68	70	72	72	70	74	74
11	86	80	78	80	78	86	84	84	84	9/	78	78	84	82	80
	88	92	100	94	100	88	06	06	84	98	92	86	94	104	86
13	92	84	98	94	94	90	92	88	88	06	88	100	100	92	92
	108	100	100	102	86	100	90	100	110	102	102	100	100	84	100
	102	104	104	104	100	100	104	94	102	96	102	110	86	104	102
16	84	82	80	82	98	84	84	06	88	98	88	82	94	98	84
17 8	84	88	88	94	94	96	96	96							
18	98	90	88	98	06	06	98	06	98	88	88	06	94	06	90
19	92	82	88	98	84	84	84	84	9/	78	88	80	82	9/	68
20		100	108	92	94	94	86	88	90	06	88	100	98	94	106
21	96	102	104	104	104	102	104	100	102	100	100	100	108	100	98
								-							
Summary ECG -		QRS Interval, msec	il, msec												
<i>a</i> \	90	06	92	92	91	89	06	89	89	89	06	91	92	06	06
Std Dev	10	10	11	60	60	11	60	10	12	10	10	-	1	10	12
Max	108	106	110	108	104	108	108	110	110	108	110	110	108	104	106
Min 7	74	72	70	20	7.2	20	72	72	68	70	72	72	89	74	89

Subj				Day 4	Day o	Day 6	Day 7	Day 7	Day 7	Day 7	Day 7	Day /	Day &	Day 9	ב כ
	4hr	6hr	8hr	12hr	PŘE	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre
01	82	80	80	82	82	82	78	82	80	80	96	84	84	80	84
02	78	70	74	72	89	84	74	9/	82	98	98	98	94	80	72
03	06	06	06	84	84	78	98	84	88	98	84	98	84	82	80
04	96	92	92	92	92	96	90	06	92	94	06	78	92	84	92
05	74	82	80	82	78	98	78	98	98	84	74	88	82	82	78
90	106	106	106	108	110	110	110	108	104	108	106	110	106	106	110
07	102	100	104	98	86	96	110	110	110	114	110	108	98	110	106
08	06	86	84	9/	84	98	86	98	06	84	80	84	70	84	82
60	96	94	94	96	98	100	100	96	94	96	94	98	100	106	100
10	74	72	92	72	9/	74	74	74	74	72	74	74	74	74	74
11	80	82	84	84	84	84	78	78	9/	82	80	84	9/	9/	84
12	100	96	98	06	92	06	100	88	98	96	88	100	98	88	90
13	88	96	88	88	92	88	94	88	88	98	88	98	94	98	96
14	100	94	100	100	102	100	88	104	06	100	06	100	92	88	92
15	104	102	100	100	96	102	86	102	98	100	98	104	104	104	104
16	86	84	86	80	98	94	06	88	88	98	99	80	88	88	88
17															
18	88	98	8	92	92	92	06	06	98	98	86	06	94	94	102
19	78	9/	74	78	98	70	80		84	82	98	80	82	84	92
20	94	94	104	94	102	104	100	94	92	94	96	82	108	102	102
21	100	98	96	86	100	100	104	102	86	102	100	104	108	108	102
Summary															
Average	06	88	89	88	06	91	06	91	88	92	89	90	91	91	92
Std Dev	9	10	10	10	10	10	11	11	60	10	11	1	7	12	7
Max	106	106	106	108	110	110	110	110	110	114	110	110	108	110	110
Min	74	70	74	72	89	70	74	74	74	72	99	74	70	74	72

Subj Pre 01 84 02 82 03 76 04 92 05 88 06 106 07 106	Pre 84 84 84 84 82 82	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre	Pre
	84 84 82									-		
	84 84 82											
	72 84 82	88	84	98	98	98	96	98	84	82	98	84
	84	98	82	98	98	98	98	88	78	86	70	82
	82	84	98	84	78	84	98	98	80	78	78	84
		06	80	80	92	92	80	80	9/	92	98	06
	78	78	20	82	9/	80	9/	92	80	74	78	92
	106	106	100	104	104	106	102	108	104	106	106	108
08	98	94	106	108	108	108	112	110	106	106	106	96
001 100	102	102	102	96	06	92	96	96	98	86	86	104
10 74	74	74	9/	9/	9/	74	74	74	74	74	74	74
11 78	74	84	82	84	82	82	78	9/	82	84	84	82
12 94	88	96	92	96	96	94	92	9/	92	94	102	92
13 98	96	92	102	98	92	94	98	94	96	86	94	96
14 100	92	100	06	100	06	102	86	102	84	102	92	102
15 104	104	106	102	100	106	104	102	108	102	106	104	102
16 88	06	84	06	90	06	98	88	84	88	84	88	98
17												
18 92	06	95	94	92	92	98	98	06	94	94	94	06
19 86	84	74	72						9/	80	74	86
20 108	78	80	102	82	98	98	102	88	06	78	100	94
21 98	102	86	100	102	100	98	98	96	100	104	106	102
Summan,												
Average 92	88	06	06	6	16	92	94	U6	80	9	91	92
	11	10	11	60	10	10	10	12	10	7	12	60
	106	106	106	108	108	108	112	110	106	106	106	108
Min 74	72	74	70	92	92	74	74	74	74	74	70	74

	Day 19	Day 20	Day 21	Day 21	Day 21	Day 21	Day 21	Day 21	Day 22	Day 25	Day 29	Day 32	Day 36
Subj	Pre	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre	Pre	Pre
				i				,			C	3	70
5	92	84	82	82	98	84	84	82	84	ng R	88	84	40
02	70	84	88	72	82	92	98	84	88	20	80		06
03	8	84	82	06	82	06	82	82	82	82	88	98	98
04	06	88	06	06	92	82	96	86	80	06	90	06	88
05	86	78	78	92	74	74	9/	9/	80	80			
90	106	108	106	106	110	106	104	108	106	104	106	108	106
20	86	100	96	86	102	96	102	100	106	104	106	110	106
90													
60	102	102	96	86	96	98	96	90	98	100	94	96	102
10	74	72	74	72	72	74	72	72	72	72	74	74	74
=	84	84	86	82	80	80	8	74	80	98	9/	98	
12	88	96	82	96	88	84	06	06	06	82	98	94	88
133	94	100	102	84	86	98	88	98	94	88	104	92	96
14	06	100	88	100	92	100	92	84	92	98	06	106	100
15	104	106	102	104	102	100	102	100	106	104	102	100	104
16	88	06	.98	84	88	84	82	88	98	84	98	92	84
17													
18	92	92	92	94	6	98	88	94	94	06	84	94	
19	84	06	9/	74	80	8	72	80	74	88	9/	80	88
20	102	96	9/	102	96	96	92	92	80	94	94	90	86
21	108	106	100	104	100	100	100	100	102	102	102	106	06
i i i i i i i i i i i i i i i i i i i													
Summary			. 6	6	000	00	Co	88	08	ő	Ob	93	92
Average	06	93	88	98	80	60	80	90	3	3 7	2 2	5 5	5 8
Std Dev	~	10	10	-	10	60	9	10	11	11	10	2	<u> </u>
Лах	108	108	106	106	110	106	104	108	106	104	106	110	106
Min	70	72	74	72	72	74	72	72	72	20	74	74	74

	Day 39	Day 42	Day 42	Day 42	Day 45	Day 42	Day 45	Day 45	Day 42	Day 45	Day 45	Day 43	Day 44
Subj	Pre	Pre	.5hr	1hr	2hr	3hr	4hr	6hr	8hr	10hr	12hr	Ψ	PΑ
3	Co	2	20	00	7.8	82	SO.	82	84	80	84	100	86
5	82	94	94	00	0	70	3	3	5	3	5		
05	06									(5
03	84	86	84	82	98	82	84	94	82	86	84	84	35
04													
05													
90	108	106	104	106	106	106	104	112	112	. 112	114	108	108
70	110	112	112	112	114	114	116	114	110	116	112	112	
80													
60	86	100	06	98	06	92	96	98	94	96	86	102	94
10	74	72	74	72	82	72	74	72	02	74	72	74	74
17	84	84	84	84	78	84	9/	98	98	82	78	9/	9/
12	96	88	06	86	88	92	92	98	98	92	88	95	96
13	86	96	108	100	06	94	94	100	100	88	06	92	94
14	84												
15	104	100	96	100	106	104	108	100	104	96	104	108	102
16	84	06	88	78	86	74	82	84	78	86	80	. 48	84
17													
18		94	92	6	94	94	94	84	06	88	84	92	86
19	78	80	72	80	72	82	78	74	78	74	74	78	80
20	96	84	98	80	98	98	98	98	84	82	98	84	98
21	96	108	106	106	106	102	108	104	106	106	104	104	106
Summary	CC	03	93	94	9,	4	9.1	91	91	91	06	93	91
Average Ctd Dov	11	5 5	10 1	12	12	12	13	13	13	13	13	12	-
Max	110	112	112	112	114	114	116	114	112	116	114	112	108
Min	74	72	72	72	72	72	74	72	70	74	72	74	74

Table 12c-6 ECG- QRS Interval

Blank = Not Obtained

AM AM AM AM AM 80 84 84 86 98 80 82 80 86 98 80 82 80 86 110 114 110 112 106 110 108 112 108 106 110 108 112 108 106 108 86 88 88 88 88 90 90 88 88 96 104 102 98 100 102 104 102 98 100 102 104 102 98 100 104 105 90 96 108 104 106 110 96 104 82 106 110 96 104 96 108 110 96 94 96 104 112 112 110		Day 45	Day 48	Day 51	Day 54	Day 57	Day 72	Day 180
01 92 80 84 84 86 98 02 03 94 80 82 80 86 98 04 04 80 82 80 86 98 98 05 110 114 110 112 106 110 06 110 114 110 112 106 110 07 108 108 112 106 110 108 09 94 102 94 96 94 108 11 84 74 72 88 88 88 88 13 92 90 90 88 88 96 102 14 104 102 98 88 98 106 102 15 76 78 80 74 74 82 20 96 96 108 104 96 104	Subj	AM	AM	AM	AM	ΑM	ΑM	ΑM
01 92 80 84 84 86 98 02 02 80 82 80 86 98 03 94 80 82 80 86 98 04 104 110 112 106 110 05 110 112 106 110 08 112 108 106 110 09 94 112 106 110 10 76 74 72 94 96 94 11 84 102 94 96 94 106 110 14 104 102 98 86 88 88 96 14 104 102 98 86 88 96 102 15 104 102 98 88 96 94 96 11 76 74 74 74 82 20					- Day			
02 94 80 82 80 86 7 03 94 80 82 80 86 7 05 110 114 110 112 106 110 06 110 114 110 112 106 110 07 108 108 112 106 110 08 112 108 106 108 110 10 76 74 72 96 94 11 84 72 88 88 88 88 13 92 80 88 88 88 88 100 102 14 104 102 98 88 98 98 98 100 102 15 10 10 10 10 10 10 10 10 18 96 96 96 10 10 10 10	10	92	80	84	84	98	98	84
03 94 80 82 80 86 86 86 96 97 98 98 98 98 98 110 111 110 110 1	02							
04 04 05 10 114 110 114 110	03	94	80	82	80	86		86
05 110 114 110 112 106 110 06 110 114 110 112 106 110 08 108 112 108 106 110 09 94 102 94 96 94 10 76 74 72 96 94 11 84 76 74 72 96 94 12 92 86 88 88 88 88 96 13 92 80 80 88 88 88 88 14 104 102 98 88 88 88 88 15 104 102 98 88 88 88 100 16 104 102 98 100 102 94 86 17 76 78 80 74 82 74 82 110 112 <th>04</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	04							
06 110 114 110 112 106 110 07 108 108 112 108 106 108 09 09 94 102 94 96 94 10 76 74 72 96 94 11 84 76 74 72 96 94 12 92 86 88 86 88 88 96 13 92 90 90 88 88 96 102 16 104 102 98 88 96 102 96 17 10 10 74 82 96 10 84 17 76 78 80 74 74 82 20 96 102 96 104 104 104 10 10 10 96 104 104 21 10 10 10	05							
07 108 108 112 108 106 108 08 09 94 102 94 96 94 10 76 74 72 96 94 11 84 102 94 96 94 96 12 92 86 88 86 88 88 88 96 13 92 90 90 88 88 96 96 14 104 104 102 98 100 102 96 15 104 104 102 98 100 102 84 17 76 78 90 96 104 82 20 96 102 96 104 96 104 96 21 108 106 110 96 104 96 94 96 94 96 94 96 94 96 96	90	110	114	110	112	106	110	104
08 94 102 94 96 94 10 76 74 72 96 94 11 84 76 74 72 96 94 12 92 86 88 86 88 88 96 13 92 90 90 88 88 96 96 14 104 104 102 98 100 102 15 104 104 102 98 88 96 96 17 17 96 14 74 82 19 76 78 80 74 74 82 20 96 106 110 96 104 96 21 108 106 110 96 104 96 21 11 11 10 32 94 91 95 94 32 94	07	108	108	112	108	106	108	108
09 94 102 94 96 94 10 76 74 72 96 94 11 84 76 74 72 98 98 88 88 13 92 90 90 88 88 88 96 14 92 90 88 88 96 96 15 104 104 102 98 100 102 15 104 102 98 100 102 98 84 17 76 78 80 74 74 82 20 96 102 96 104 74 82 20 96 102 96 104 74 82 110 110 96 104 96 94 91 95 94 110 112 112 112 111 110 110 114	80							
10 76 74 72 88 88 88 88 11 84 88 88 88 88 88 88 10 88 10 88 88 88 88 88 88 88 88 88 88 96 14 14 14 10 88 96 100 1	60		94	102	94	96	94	06
11 84 88 86 88 88 88 88 88 88 88 100 102 113 114 110	10		92	74	72			
12 92 86 88 86 88 88 88 88 103 113 113 113 113 114 110 100 188 188 188 96 96 96 100 102 103 104 103 104 103 104 103 104 103 104 103 104 104 104 104 104 104 104 104 104 104 104 104 <t< th=""><th>11</th><th>84</th><th></th><th></th><th></th><th></th><th></th><th></th></t<>	11	84						
13 92 90 88 88 96 14 14 104 102 98 100 102 16 104 102 98 100 102 16 104 104 102 98 100 84 17 78 80 74 74 82 20 96 102 96 108 82 21 108 106 110 96 104 82 21 108 106 110 96 104 10 1mary 10 13 12 12 11 10 Dev 10 13 12 12 11 10 110 110 112 112 110 110 110 110 112 112 14 10 110 110 112 112 14 10 110 120 120	12	92	86	88	98	88	88	06
14 104 102 98 100 102 15 104 104 102 98 100 102 16 17 8 100 102 84 102 17 7 8 9 94 92 94 86 86 19 76 78 80 74 74 82 82 82 20 96 102 90 96 108 104 82 21 108 106 110 96 104 82 nmary 96 93 94 91 95 94 Dev 10 13 12 12 11 10 76 76 76 74 82	13	92	06	06	88	88	96	94
15 104 104 102 98 100 102 16 16 104 105 98 100 102 17 18 92 94 92 94 86 19 76 78 80 74 74 82 20 96 102 96 108 82 21 108 106 110 96 104 82 mary 10 13 12 12 11 10 crage 96 93 94 91 95 94 Dev 10 13 12 12 11 10 76 76 74 82	14			-				
16 96 94 92 94 86 86 18 92 94 92 94 86 19 76 78 80 74 74 82 20 96 102 90 96 108 82 21 108 106 110 96 104 82 1mary 10 13 12 12 11 10 Dev 10 13 12 12 11 10 76 76 76 74 82	15	104	104	102	98	100	102	104
17 92 94 92 94 86 19 76 78 80 74 74 82 20 96 102 90 96 108 82 21 108 106 110 96 104 82 nmary 10 13 12 12 11 10 crage 96 93 94 91 95 94 Dev 10 13 12 12 11 10 76 76 76 74 72 74 82	16						84	84
18 92 94 92 94 86 86 86 86 74 86 86 74 86 87 82<	17							
19 76 78 80 74 74 82 20 96 102 90 96 108 82 21 108 106 110 96 104 82 nmary 10 34 91 95 94 rage 96 93 94 91 95 94 Dev 10 112 112 111 10 76 76 76 74 72 74 82	18	92		94	92	94	98	
20 96 102 90 96 108 82 21 108 106 110 96 104 82 nmary rage 96 93 94 91 95 94 Dev 10 13 12 12 11 10 76 76 76 74 72 74 82	19	9/	78	80	74	74	82	
21 108 106 110 96 104 Property nmary rage 96 93 94 91 95 94 Dev 10 13 12 12 11 10 76 76 76 74 72 74 82	20	96	102	06	96	108	82	
Imary 96 93 94 91 95 94 Dev 10 13 12 12 11 10 76 76 76 74 72 74 82	21	108	106	110	96	104		
Dev 96 93 94 91 95 94 Dev 10 13 12 12 11 10 76 76 76 74 72 74 82	Summary							
Dev 10 13 12 12 11 10 76 76 74 72 74 82	Average	96	93	94	91	95	94	94
110 114 112 112 108 110 76 76 74 72 74 82	Std Dev	10	13	12	12	=	10	60
76 74 72 74 82	Мах	110	114	112	112	108	110	108
	Min	76	9/	74	72	74	82	84

Dec. 17, 1998

Page 169

472,h0 04,45b 04,84b 04,44b 214,54b 84,S4b 442,64 242,h2 3.04,24b 04'6EP Figure 53: SD & Range Charts for ECG - QRS Interval, msec 04,SEb 975,h0 214,12b 94,156 421,62 970,h0 04,816 04,816 214,41b 94,41b 414,62 04,81b 04,116 04'6P 214,7b 94,7b Zd, Tb 04,8b 214,4b 94,4b 24,4b 04,6b £14,1b 84,1b 44,1b 24,1b 3.04,1b Scrn 110 100 120 90 80 20 9 ECG - QRS Interval, msec

Day and Hour of Protocol

		Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 1	Day 2	Day 3	Day 4	Day
gns	Scrn	Pre	.5hr	1hr	2hr	3hr	4hr	6hr	8hr	/ 10hr	12hr	Pre	Pre	Pre	2hr
01	397	399	397	403	384	371	407	396	393	402	391	384	392	389	386
02	413	404	409	405	387	419	410	382	442	411	414	399	408	393	413
03	380	402	379	375	410	412	401	403	406	392	384	388	393	392	407
04	406	383	389	373	376	398	395	395	396	389	397	388	401	411	423
05	372	390	376	394	407	372	373	387	383	404	404	388	383	403	397
90	385	382	368	356	347	369	363	345	353	386	358	341	348	352	348
07	412	398	378	403	420	409	408	364	368	396	406	388	391	410	388
88	383	372	371	380	380	366	371	401	383	379	383	383	384	377	372
60	379	395	374	375	359		386	401	391	381	391	368	393	416	384
10	400	398	392	400	402	409	399	395	396	406	400	377	404	404	413
7	418	412	421	414	409	455	474	414	414	415	416	423	444	435	425
12	394	384	376	399	387	399	396	367	389	378	364	379	390	360	363
13	394	383	397	395	390	394	390	392	393	389	389	391	373	377	395
4	408	403	406	399	421	416	389	385	426	419	426	420	403	408	412
15	389	401	388	349	395	374	362	397	392	388	388	399	405	381	416
16	399	380	396	393	390	400	400	394	374	400	400	392	382	399	395
17	409	360	409	341	349	346	359	346							
18	417	403	394	400	409	403	403	402	403	409	402	409	411	416	412
19	418	395	377	366	389	404	418	402	402	405	404	402	422	410	404
20		422	392	415	404	402	402	398	398	392	402	438	383	397	422
21	401	406	403	412	408	409	423	405	406	408	409	408	409	418	422
Summary	ECG - QTc Interval, msec	c Interval	, msec												
Average	399	394	390	388	392	396	398	389	395	397	396	393	396	397	400
Std Dev	14	14	14	21	21	24	24	19	19	12	16	21	20	20	21
Мах	418	422	421	415	421	455	474	414	442	419	426	438	444	435	425
Min	372	360	368	341	347	346	359	345	353	378	358	341	348	352	348

	Day 4	Dav 4	Day 4	Day 4	Dav 5	Day 6	Day 7	Day 7	Day 7	Day 7	Day 7	Day 7	Day 8	Day 9	Day 10
Subj	4hr	6hr	8hr	12hr	PRE	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre
01	398	409	382	399	375	393	369	411	402	399	389	403	405	398	403
05	408	417	413	413	406	412	409	401	408	419	507	420	425	419	406
03	406	400	404	402	380	390	401	414	403	404	404	407	401	383	404
04	398	398	417	404	399	411	406	398	402	396	400	402	398	400	398
05	381	410	402	391	382	415	411	374	395	399	369	413	400	389	396
90	379	371	385	385	349	357	391	355	374	388	387	382	390	356	364
20	423	414	413	417	403	410	414	398	435	419	411	453	418	418	414
80	388	404	382	407	385	385	387	398	409	394	398	384	402	417	390
60	403	391	385	409	384	397	372	358	389	407	396	406	399	428	411
10	412	405	412	414	412	409	410	419	405	399	418	406	414	414	438
=	437	416	448	439	439	444	421	434	424	429	437	410	424	423	430
12	391	393	382	361	396	356	382	399	391	394	378	392	394	400	403
13	394	402	380	394	384	409	407	403	396	374	401	399	411	394	396
14	410	403	407	398	404	419	412	413	416	412	420	420	413	413	424
15	396	383	401	381	388	404	398	383	395	365	394	371	397	396	401
16	396	399	401	401	403	404	405	404	401	400	399	407	406	405	400
17															
18	413	441	411	415	422	415	421	410	438	435	422	421	418	451	422
19	409	410	418	404	404	404	403	i : !	403	413	421	408	403	409	406
20	404	403	413	416	378	411	407	411	413	408	400	405	411	407	413
21	404	420	402	406	411	404	417	411	420	408	421	426	409	416	407
Summary	403	404	403	403	395	402	402	400	406	403	409	407	407	407	406
Std Dev	14	15	17	16	20	20	15	20	15	17	28	18	10	19	16
Max	437	441	448	439	439	444	421	434	438	435	202	453	425	451	438
Min	379	371	380	361	349	356	369	355	374	365	369	371	390	356	364

	Day 11	Day 12	Day 13	Day 14	Day 14	Day 14	Day 14	Day 14	Day 14	Day 15	Day 16	Day 17	Day 18
Subj	Pre Pre	Pre	Pre	-	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre	Pre
10	389	389	404	396	404	404	402	406	404	372	393	385	401
02	428	433	418	413	464	416	450	422	452	434	422	411	428
03	405	402	388	405	402	382	403	403	408	386	410	399	410
20	401	400	400	401	402	398	404	399	402	399	402	396	403
0.5	405	403	416	417	395	396	409	370	401	391	387	394	416
90	360	359	359	346	350	382	374	389	381	377	387	369	388
07	401	423	412	408	407	446	440	485	424	408	418	403	411
80													
60	391	413	423	398	412	406	393	411	417	383	407	403	416
10	420	418	406	402	406	442	439	450	420	414	426	411	431
= =====================================	427	412	407	438	409	447	436	439	452	448	446	424	437
12	404	401	401	394	392	375	401	391	396	395	399	369	397
. E	379	403	391	389	398	408	371	438	410	403	407	395	417
14	428	421	418	413	419	413	413	405	417	407	Å 12	422	401
15	404	388	401	396	398	430	410	409	398	400	385	375	403
16	408	397	411	402	416	403	404	403	400	399	402	412	396
17													
18	416	419	440	430	425	428	425	420	428	426	437	424	431
19	407	408	393	416						403	399	415	405
20	409	425	415	411	405	410	410	426	424	409	417	411	411
21	416	419	409	400	411	406	416	403	410	415	419	405	412
Summary											,		777
Average	405	407	406	404	406	411	411	415	414	404	409	401	4
Std Dev	17	17	17	19	21	21	21	26	48	19	17	17	13
Max	428	433	440	438	464	447	450	485	452	448	446	424	437
Min	360	359	359	346	350	375	371	370	381	372	385	369	388

	Day 19	Day 20	Day 21	Day 21	Day 21	Day 21	Day 21	Day 21	Day 22	Day 25	Day 29	Day 32	Day 36
Subj	Pre	Pre	Pre	2hr	4hr	6hr	8hr	12hr	Pre	Pre	Pre	Pre	Pre
10	427	404	400	396	409	400	421	402	423	416	450	449	407
02	434	432	428	393	419	466	505	450	455	462	432	479	441
03	408	389	409	387	390	409	406	418	404	405	408	412	389
9	399	402	402	402	409	406	411	408	427	420	414	404	402
05	407	400	390	385	403	380	415	389	395	395			
90	380	368	360	394	393	389	391	388	382	396	390	394	370
07	420	412	440	432	423	420	432	431	424	481	440	456	405
80													
60	374	421	368	427	427	440	433	416	438	438	410	409	432
10	440	420	415	403	433	451	429	446	416	405	432	414	377
1	431	458	451	454	441	450	483	438	440	474	441	438	
12	393	390	382	390	400	395	393	399	393	402	401	406	405
13	389	374	377	393	405	395	399	398	394	420	420	412	409
14	422	421	421	415	413	420	414	421	416	444	450	430	448
15	409	397	392	401	435	416	409	403	394	423	418	402	407
16	403	411	404	391	421	414	410	411	400	420	426	434	424
17													
18	452	432	426	414	437	446	428	428	431	450	426	453	
19	411	408	396	404	407	405	405	405	410	408	411	442	420
20	402	409	410	411	417	417	432	416	424	415	448	426	427
21	426	413	411	406	407	397	407	429	409	409	413	415	417
Summary						3		1					
Average	412	408	404	405	415	417	422	416	414	425	424	426	411
Std Dev	21	21	24	17	15	24	29	18	19	26	17	23	21
Max	452	458	451	454	441	466	202	450	455	481	450	479	448
Min	374	368	360	385	390	380	391	388	382	395	390	394	370

	Day 33	Day 47	Day 47	Day 42	Day 42	Day 42	Day 42	Day 42	Day 42	Day 42	Day 43	2	
Subj	Pre	Pre	.5hr	1hr	2hr	3hr	4hr	6hr	8hr	10hr	2ay 42 12hr	Day 43 AM	Day 44 AM
5	700	407											
5	403	407	405	406	405	456	397	369	425	398	406	407	440
02	427										2	101	714
03	385	401	387	385	403	377	353	376	205	040			
04						5	3	2	200	3/0	395	401	401
05			-	!									
90	385	371	376	364	361	345	394	25.4	267	2.42	C		
07	453	424	427	428	423	420	416	400	202	343	352	382	352
80						27	2	2	174	430	41/	364	442
60	419	415	470	387	391	417	413	113	440	707	00,		
10	414	413	373	392	379	445	436	217	110	474	420	418	413
7	452	473	434	418	451	491	176	470	1 1	2 1	,418	430	415
12	408	404	408	378	300	- 00	2 1	0/1	1/4	425	450	434	427
13	409	383	807	310	030	402	405	353	369	399	404	391	411
4	438	3	100	61.4	114	3/4	390	375	375	383	395	396	422
12	707	904	000										
25	404	400	393	410	392	414	389	408	404	402	420	415	401
0	174	438	420	407	403	433	408	416	414	410	415	410	422
17			er.								2	2	477
18		475	462	456	434	464	454	420	115	476	007	00,	
19	401	440	409	398	405	416	406	403	2 0	420	470	423	445
20	421	438	437	425	428	442	CVV	426	2 6	403	410	406	398
21	416	415	407	411	413	130	717	5 1	470	416	425	414	411
					2	120	40 /	405	403	408	411	401	411
Summary													
Average	416	420	414	405	406	421	412	402	407	707		100	
Std Dev	20	53	28	23	22	37	300	30.5	10	5 6	114	407	412
Max	453	475	470	456	451	707	37.6	35	17	23	21	19	21
Min	385	371	373	26.4	26.4	- 10	0 1	4/0	4/1	430	450	434	445
		-	200	+00	100	345	353	353	362	343	352	364	352

	Day 45	Day 48	Day 51	Day 54	Day 57	Day 72	Day 180
Subj	AM	AM	AM	AM	AM	АМ	AM
10	396	385	383	396	398	410	397
02							
03	404	403	404	385	268	401	406
97							
05							
90	337	384	389	388	385	375	402
07	432	428	444	428	424		424
80							
60		404	454	384	433	367	388
9		406	411	404			
7	463						
12	394	403	406	398	415	360	411
13	421	408	404	404	406	412	394
41							
15	395	389	399	347	383	432	397
16						399	416
17						-	
18	440		424	419	415	416	
19	393	406	415	367	401	403	
20	411	412	414	407	382	409	
21	422	434	410	468	411	446	
Summary							
Average	409	405	412	400	404	403	404
Std Dev	31	15	20	29	16	25	7
Max	463	434	454	468	433	446	424
Min	337	384	383	347	382	360	388




Table 13a-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 01

<u>Day</u>	Time	QTc	Halo +	<u> Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	399				
1	.5HR	397				
1	1HR	403				
1	2HR	384				
1	3HR	371				16.4
1	4HR	407	10.9			20.9
1	6HR	396	15.1			18.5
1	8HR	393	15			27
1	10HR	402	17.2	10.4		27.7
1	12HR	391	12.9			22.3
2	PRE	381				23.2
3 、	PRE	392	10.9			29.5
4 `	PRE	389	32			36.4
4	2HR	386	30.6	22.8		38.4
4	4HR	398	73.2	41.7		44.3
4	6HR	409	47.9	37.7		84.7
4	8HR	382	38.9	17.1		52.4
4	12HR	399	54.6	30.7		64.7
5	PRE	375	25.9	22.5	17.2	76.2
6	PRE	393	37.9	16.5	20.8	108
7	PRE	369	43.4	18.2	26.1	128
7	2HR	411	55.8	33.7	16.8	74.1
7	4HR	402	93.4	59.3	32.6	153
7	6HR	399	131	73.1	37.2	202
7	8HR	389	144	79.6	74	203
7	12HR	403	101	50.6	56.4	149
8	PRE	405	57.6	27.4	62.7	183
9	PRE	398	77.2	33.1	72.6	221
10	PRE	403	68.9	28	87.8	282
11	PRE	389	50.6	20.4	54.2	227
12	PRE	389	51.3	20.8	45.3	325
13	PRE	404	55.9	25.4	44.1	334
14	PRE	396	58.6	25.5	29.7	311
14	2HR	404	65.6	30.3	22.8	211
14	4HR	404				
14	6HR	402	73.3	37.4	36.4	324
14	8HR	406	68.2	36.2	32.2	318
14	12HR	404	80.8	35	35	260

Dec. 17, 1998 Page 178

Table 13a-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 01

Day	<u>Time</u>	QTc	Halo +	Halo -	Metab +	<u> Metab -</u>
15	PRE	427	68.3	32.8	41.1	409
16	PRE	404	80.6	36.6	32.6	361
17	PRE	400	84.5	37.4	38.8	497
18	PRE	396	92.8	41	59.1	532
19	PRE	.409	94.6	51.7	51	435
20	PRE	400	127	70	59.1	496
21	PRE	421	81	40.6	32.2	290
21	2HR	402	96.8	51.7	30.5	251
21	4HR	423	52.5	24.4	38.2	295
21	6HR	416	70.5	31.1	54.4	386
21	8HR	450	169	93.7	51.2	335
21、	12HR	449	82.4	35.8	33.6	385
22	PRE		59.2	25.9	49	329
25	PRE	407	54.6	26.7	29.3	289
29	PRE	403	54.4	23.7	30.9	355
32	PRE	407	109	50.2	52.8	484
33	PRE	405	121	55.8	63.5	506
36	PRE	406	112	56	53	468
39	PRE	405	134	68	67	535
42	PRE	456	160	88.2	66.8	687
42	.5HR	397	157	91.4	53.8	565
42	1HR	369	181	106	59.1	576
42	2HR	425	193	110	61.1	538
42	3HR	398	153	93.7	32.6	339
42	4HR	406	168	90.5	77.7	633
42	6HR	407	64	35.2	29.7	224
42	8HR	412	67.9	27.6	39	424
42	10HR	396	46.3	18.8	37.8	508
42	12HR	385	46.7	18.4	15.8	340
43	AM	383	34.9	12.7		255
44	AM	396	29.9	10.4		.175
45	AM	398	32.1	12.3		128
48	AM	410	33.8	15.2	27.7	243
51	AM	397				16.4
54	AM					
57	AM					
72	AM					
180	AM					

Table 13b-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 02

<u>Day</u>	Time	QTc	<u>Halo +</u>	<u>Halo -</u>	<u>Metab +</u>	<u>Metab -</u>
1	PRE	404				
1	.5HR	409				
1	1HR	405				
1	2HR	387				
1	3HR	419				
1	4HR	410			•	•
1	6HR	382	31.5	22.7		
1	8HR	442	25	35.1		
1	10HR	411	29.5	20.1		
1	12HR	414	20.1	12.3		
2	PRE	399	13			
3 (PRE	408				
4 `	PRE	393	30.4	16.5		31.5
4	2HR	413	37.7	37.1		60.6
4	4HR	408	79.1	55.5	19	61.2
4	6HR	417	63.5	38.7		63.6
4	8HR	413	46.4	26.3		34.7
4	12HR	413	33.1	18.1		53
5	PRE	406	26.9	16.6		55.8
6	PRE	412	29.7	16.6		77.7
7	PRE	409	30.3	14.8	18	84.4
7	2HR	401	31.2	19.2	16.8	71.8
7	4HR	408	78.4	53.7	29.7	121
7	6HR	419	72.8	43	17.6	78.1
7	8HR	507	67.9	41.4	23.3	91.8
7	12HR	420	48.6	25.9	29.3	100
8	PRE	425	30.3	15.7	20.2	93.8
9	PRE	419	50.7	27	23.9	101
10	PRE	406	61	27.8	31.1	140
11	PRE	428	64.4	32.7	34.3	174
12	PRE	433	69.7	33.2	36.6	174
13	PRE	418	79.8	43.4	36	194
14	PRE	413	52.8	25	32.9	161
14	2HR	464	75.5	46.7	29.7	160
14	4HR	416	83.9	51.8	36	188
14	6HR	450	107	62.5	39.8	229
14	8HR	422	123	71.9	42.8	232
14	12HR	452	84.2	46	36	201

180

AM

Table 13b-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 02

						, , , , , , , , , , , , , , , , , , , ,
<u>Day</u>	Time	QTc	<u>Halo +</u>	<u> Halo -</u>	Metab +	<u>Metab -</u>
15	PRE	434	104	59.8	39.4	218
16	PRE	432	125	66.4	39.6	219
17	PRE	428	83.1	40.8	33.9	193
18	PRE	393	139	99.5	36.6	209
19	PRE	419	273	240	43.4	263
20	PRE	466	369	298	52.3	274
21	PRE	505	319	239	59.7	336
21	2HR	450	263	179	62	372
21	4HR	455	127	75.4	35.6	243
21	6HR	462	108	60.4	53.3	289
21	8HR	432	195	122	48.9	292
21 \	12HR	479	111	60.6	74.9	432
22	PRE		65.9	31.2	57.9	431
25	PRE	441	60.8	33.2	60.8	459
29	PRE	427				
32	PRE					
33	PRE					
36	PRE					
39	PRE					
42	PRE					
42	.5HR					
42	1HR					
42	2HR					
42	3HR					
42	4HR					
42	6HR					
42	8HR					
42	10HR					
42	12HR					
43	AM	•		المستعدد . مستعدد .		
44	AM					
45	AM					
48	AM		•			
51	AM					
54	AM					
57	AM					
72	AM					

Table 13c-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 04

<u>Day</u>	<u>Time</u>	QTc	Halo +	Halo -	<u>Metab +</u>	<u> Metab -</u>
1	PRE	383				
1	.5HR	389				
1	1HR	373				
1	2HR	376	16.4	12.6		
1	3HR	398	52.6	37.9		18.6
1	4HR	395	35.1	20.5		20.1
1	6HR	395	71.1	32.8	20.9	46
1	8HR	396	44.5	19	18.5	47.1
1	10HR	389	18.9			33.9
1	12HR	397	29.6	10.2		40.7
2	PRE	388	14.6		18	38
3 \	PRE	401	25.6	10.7	20.1	69.5
4	PRE	411	79.9	41.8	30.3	96.8
4	2HR	423	308	356	62	199
4	4HR	398	348	329	40.5	125
4	6HR	398	446	310	54.8	165
4	8HR	417	292	191	55.3	192
4	12HR	404	246	146	51.5	181
5	PRE	399	107	57.9	65.8	211
6	PRE	411	132	74.4	53.7	234
7	PRE	406	85.6	38.6	52.1	260
7	2HR	398	109	60.3	45.9	242
7	4HR	402	183	107	64.7	314
7	6HR	396	141	72.5	44.6	207
7	8HR	400	111	55.7	32.2	149
7	12HR	402	109	49.7	28.2	134
8	PRE	398	97.9	35	20.1	92.4
9	PRE	400	69.2	30	24.4	138
10	PRE	398	70.6	29.8	26.3	138
11	PRE	401	68.9	30.3	30.3	175
12	PRE	400	73.1	32.2	21.5	135
13	PRE	400	74.5	28.1	23.9	121
14	PRE	401	124	52.7	31.4	200
14	2HR	402	110	50.2	32.5	160
14	4HR	398	205	104	33	174
14	6HR	404	234	119	39.5	193
14	8HR	399	166	79.4	27.9	124
14	12HR	402	117	51.6	22.5	114

Table 13c-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 04

Day	<u>Time</u>	QTc	Halo +	<u>Halo -</u>	Metab +	<u> Metab -</u>
15	PRE	399	66.4	28.1	40.8	264
16	PRE	402	81.4	31.5	46.7	313
17	PRE	402	97.7	38.6	45.4	283
18	PRE	402	137	62.7	67.4	449
19	PRE	409	195	113	41.1	303
20	PRE	406	224	122	45.1	285
21	PRE .	411	190	95.4	67.1	368
21	2HR	408	146	63.9	57.2	330
21	4HR	427	92.8	36.9	43.8	296
21	6HR	420	84	32.8	59.3	349
21	8HR	414	75.9	28.5	60.4	318
21\	12HR	404	105	40.2	54	411
22	PRE		1			
25	PRE	402	59.1	23.5	45.4	259
29	PRE		52.2	19.2	31.4	219
32	PRE					
33	PRE					
36	PRE					
39	PRE					
42	PRE					
42	.5HR					
42	1HR					
42	2HR					
42	3HR					
42	4HR					
42	6HR					
42	8HR					
42	10HR					
42	12HR					
43	AM					
44	AM					
45	AM		.* 1			
48	AM					
51	AM					
54	AM					
57 3 0	AM					
72	AM					
180	AM				•	

Table 13d-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 05

<u>Day</u>	<u>Time</u>	QTc	Halo +	<u> Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	390				
1	.5HR	376				
1	1HR	394	11.4	10.7		
			19.9	17.2		
1	2HR	407				. 45
1	3HR	372	19.5	15.1		15
1	4HR	373	15.1	40.0		15
1	6HR	387	34.7	18.6		29.3
1	8HR	383	20.3	10.3		18.7
1	10HR	404	37.4	16.3		47.3
1	12HR	404	14.5			18.4
2	PRE	388				29.3
3、	PRE	383	14.3			54.2
4	PRE	403	20.1	13.1		46.4
4	2HR	397	22.2	15.1		40.5
4	4HR	381	78.6	44.2		88
4	6HR	410	50.2	27		70
. 4	8HR	402	67.3	32.6	22.4	98.6
4	12HR	391	52.6	25.5	20.7	97
5	PRE	382	26.7	11.7	28.8	118
6	PRE	415	26.1		16.2	100
7	PRE	411	27.2	11.2	17.9	136
7	2HR	374	19.4	11.4	15.6	79.3
7	4HR	395	43.3	23.9	26	175
7	6HR	399	58.7	31.8	26	199
7	8HR	369	37.8	18.6	18.7	139
7	12HR	413	31.9	14.8		83
8	PRE	400	28.4	12.3	17.9	131
9	PRE	389	33	15.4	27.4	179
10	PRE	396	35.8	14	23.2	155
11	PRE	405	27.8	11.4	22.1	161
12	PRE	403	34.8	14.9	19.8	186
13	PRE	416	35.3	16	26.6	283
14	PRE	417	51.6	26.9	32.2	304
14	2HR	395	56.4	35.1	19.8	192
14	4HR	396	116	66.5	55.4	453
14	6HR	409	74	41.3	36.1	274
14	8HR	370	67.4	35.2	29.4	235
14	12HR	401	46.4	23	29.1	.198

Table 13d-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 05

<u>Day</u>	Time	QTç	Halo +	<u> Halo -</u>	Metab +	<u>Metab -</u>
15	PRE	407	50	23.1	29.1	297
16	PRE	400	39.4	18.2	30.5	· 331
17	PRE	390	40.5	19	39.7	340
18	PRE	385	75.1	46.2	31.9	333
19	PRE	403	79.3	41.9	32.2	312
20	PRE	380	95.3	55.1	48.4	438
21	PRE	415	62.2	32.9	31.9	260
21	2HR	389	54.3	28.7	47.3	401
21	4HR	395	35.9	16.8	24.9	246
21	6HR	395	31.3	14.8	29.4	32.1
21	8HR					
21\	12HR					
22	PRE		/			
25	PRE					
29	PRE					
32	PRE					
33	PRE					
36	PRE					
39	PRE					
42	PRE					
42	.5HR					
42	1HR					
42	2HR					
42	3HR					
42	4HR					
42	6HR					
42	8HR					
42	10HR					
42	12HR					
43	AM		14.2	a marine Se		20.9
44	AM		14.2			20.0
45	AM					
48 51	AM		.*			
51 54	AM					
54	AM					
57 70	AM AM					
72 190	AM					
180	AIVI					

Table 13e-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 07

Day	<u>Time</u>	QTc	Halo +	<u> Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	398				
1	.5HR	378				
1	1HR	403		*		
1	2HR	420	10.8			
1	3HR	409	14.9	10.6		
1	4HR	408	28.4	18.7		15.8
1	6HR	364	23.3	15.6		15.8
1	8HR	368	23.5	15.6		17.6
1	10HR	396	20.9	14.1		18.3
1	12HR	406	17.5	12.5		
2	PRE	388	10.3	10.6		
3 \	PRE	391	50.8	36.6		38.9
4	PRE	410	75.4	48.3	22.6	71.8
4	2HR	388	342	326	34.6	92.8
4	4HR	423	572	570		110
4	6HR	414	456	343	50.3	135
4	8HR	413	290	223	40.2	131
4	12HR	417	235	158	39.3	101
5	PRE	403	88.4	56.5	22.9	93.8
6	PRE	410	73.3	45	31.7	132
7	PRE	414	149	85.6	80.9	211
7	2HR	398	186	128	40.9	202
7	4HR	435	184	127	28.6	106
7	6HR	419	227	152	40.6	150
7	8HR	411	229	152	42.8	135
7	12HR	453	180	117	42.4	138
8	PRE	418	108	67.3	24.8	113
9	PRE	418	89.1	56	21.3	102
10	PRE	414	105	58.8	27	132
11	PRE	401	121	71.5	33.9	138
12	PRE	423	112	63.8	25.7	123
13	PRE	412	145	74.5	27.9	128
14	PRE	408	142	75.9	27.9	174
14	2HR	407	142	84.8	27	163
14	4HR	446	265	161	32	138
14	6HR	440	264	154	41.5	180
14	8HR	485	213	115	33	143
14	12HR	424	232	124	43.7	187

Halofantrine IND:9847

Table 13e-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 07

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	<u>Halo -</u>	Metab +	<u>Metab</u> -
15	PRE	420	150	72.4	32.7	166
16	PRE	412	160	79	36.1	174
17	PRE	440	226	110	54.8	257
18	PRE	432	272	156	52.5	246
19	PRE	423	292	152	61.7	279
20	PRE	420	312	171	62	260
21	PRE	432	258	130	48.4	211
21	2HR	431	250	121	50.3	212
21	4HR	424	170	80.8	41.8	205
21	6HR	481	162	73.2	42.4	184
21	8HR	440	123	57	38.7	177
21\	12HR	456	155	78	51.6	297
22	PRE		93.9	55.7	34.9	189
25	PRE	405	116	60.2	47.5	267
29	PRE	453	206	97.6	61.1	312
32	PRE	424	182	80.6	79.7	402
33	PRE	427	123	56.2	61.1	246
36	PRE	428	150	71.5	63.3	289
39	PRE	423	151	79.1	55.4	244
42	PRE	420	165	81.7	47.8	277
42	.5HR	416	204	106	59.8	382
42	1HR	419	172	83.2	47.2	350
42	2HR	421	202	95.6	63.3	408
42	3HR	430	224	92.9	56.3	335
42	4HR	417	201	88.5	53.8	353
42	6HR	364	175	72.7	60.1	382
42	8HR	442				
42	10HR	432	68.6	45.2	20.7	217
42	12HR	428		g with		
43	AM	444	42	18.7		97.3
44	AM	428	46.6	21.1		48
45	AM	424	49.9	21.6		51.5
48	AM		29.2	23.4		17.2
51	AM	424				
54	AM					
57	AM					
72	ΑM					
180	AM		-			

Table 13f-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 08

Day	Time	QTc	Halo +	<u>Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	372				
1	.5HR	371				
1	1HR	380	15.9	13.9		
1	2HR	380	37.6	32.9		
1	3HR	366	65.3	50.3		33.1
1	4HR	371	78.9	57.7	16.4	35.7
1	6HR	401	162	113	18.8	50.5
1	8HR	383	102	69.7	21.5	51.5
1	10HR	379	61.9	41.7		37.1
1	12HR	383	62.1	40.3		41.4
2	PRE	383	24.1	13.6		33.4
3 \	PRE	384	45.5	21.7		44.1
4	PRE	377	33.2	19.9	17.3	76.5
4	2HR	372	67.3	49.8	26	100
4	4HR	388	152	113	47.2	199
4	6HR	404	114	75.4	27.2	110
4	8HR	382	103	66.6	33.9	129
4	12HR	407	136	76.7	37.8	132
5	PRE	385	40.9	22.4	26.9	115
6	PRE	385	51.8	25.1	31.8	139
7	PRE	387	74.3	41.7	46	245
7	2HR	398	94.6	63	46.3	205
7	4HR	409	132	85.4	61.4	310
7	6HR	394	142	83.8	74.1	351
7	8HR	398	136	79.3	59.9	296
7	12HR	384	111	62.1	54.2	286
8	PRE	402	63.1	31.7	38.4	211
9	PRE	417	101	53.4	59	283
10	PRE	390	76.4	40.8	65	363
11	PRE			and the second s		
12	PRE			**		
13	PRE					
14	PRE					
14	2HR					
14	4HR					
14	6HR					
14 14	8HR					
14	12HR					

Table 13f-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 08

Day	<u>Time</u>	QTc	<u>Halo +</u>	<u> Halo -</u>	Metab +	Metab -
15	PRE					
16	PRE					
17	PRE	_				
18	PRE	•				
19	PRE		,			
20	PRE	•				
21	PRE					
21	2HR			.,		
21	4HR					
21	6HR					
21	8HR					
21 v	12HR					
22	PRE		1			
25	PRE					
29	PRE					
32	PRE					
33	PRE					
36	PRE					
39	PRE					
42	PRE					
42	.5HR					
42	1HR					
42 42	2HR 3HR					
42 42	4HR					
42	6HR					
42	8HR					
42	10HR					
42	12HR					
43	AM			. * *		
44	AM			مينين. مار		
45	AM					
48	AM					
51	AM					
54	AM					
57	AM					
72	AM					
180	AM					

Table 13g-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 09

<u>Day</u>	<u>Time</u>	QTc	Halo +	Halo -	Metab +	<u>Metab -</u>
1	PRE	395			•	
1	.5HR	374	,			
1	1HR	375		•		
1.	2HR	359	12.6	11.2		
1	3HR		70.9	61.8		
1	4HR	386	152	132		20.4
1	6HR	401	122	102		24.3
1	8HR	391	103	81.4		27.6
1	10HR	381	65	47		26.6
1	12HR	391	53.8	37.4		23
2	PRE	368	21	15.2		24
3、	PRE	393	20.6	13.4		33.2
4	PRE	416	24.2	16.5		44.1
4	2HR	384	42.8	29.5		51.7
4	4HR	403	109	73.3	23.1	78.5
4	6HR	391	95.8	63.6	15.2	64.3
4	8HR	385	60.5	42.5	16.6	55
4	12HR	409	38.6	24.1	15.7	44.1
5	PRE	384	27	17.5	17.8	85.8
6	PRE	397	36.7	20.5	15.2	62.6
7	PRE	372	40.9	23.4	21.7	111
7	2HR	358	36.1	21.4	18.7	79.8
7	4HR	389	122	86.7	41.5	194
7	6HR	407	122	87	33.2	176
7	8HR	396	94.1	60.8	28.5	125
7	12HR	406	64.8	43.5	35.3	164
8	PRE	399	44.6	28	29.1	158
9	PRE	428	57.4	35.1	29.7	138
10	PRE	411	51.6	29	25.5	153
11	PRE	391	60.3	36.9	45.3	240
12	PRE	413	65.4	43.4	36.8	228
13	PRE	423	58.9	33.1	29.1	180
14	PRE	398	53.1	30	27.3	174
14	2HR	412	74.7	49	27	176
14	4HR	406	166	124	56.9	382
14	6HR	393	162	119	51.9	337
14	8HR	411	166	130	73.2	423
14	12HR	417	132	92.1	63.7	400

Table 13g-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 09

Day	Time	QTc	Halo +	<u>Halo -</u>	Metab +	<u>Metab -</u>
15	PRE	374	59.6	35.5	34.4	252
16	PRE	421	62.3	37.8	42.1	289
17	PRE	368	68.6	41.2	31.7	264
18	PRE	427	81.9 .	54.1	39.1	300
19	PRE	· 427	164	120	53.3	386
20	PRE	440	234	166	47.7	312
21	PRE	433	221	155	66.4	384
21	2HR	416	111	73.3	59.8	386
21	4HR	438	91.2	55.6	54.5	393
21	6HR	438	42.5	25.4	45.6	313
21	8HR	410	58.1	36.8	42.4	364
21、	12HR	409	86.4	60.2	42.4	282
22`	PRE					,
25	PRE	432	42	20.6	30.2	227
29	PRE	419	58.4	32.8	44.8	263
32	PRE	415	56.5	34.3	35	251
33	PRE	470	54.9	29.4	19.9	147
36	PRE	387	46	29.9	19	126
39	PRE	391	104	68.9	30.8	227
42	PRE	417	81	50.9	36.8	255
42	.5HR	413	88	52.6	19.3	139
42	1HR	413	120	73.2	37.1	256
42	2HR	419	90.9	49.6	35	181
42	3HR	424	72.9	43.2	32	207
42	4HR	420	70.8	40.4	32.3	217
42	6HR	418	54.9	29.4	30.5	222
42	8HR	413	37.3	21.1	28.2	205
42	10HR					
42	12HR	404	25.8	15		113
43	AM	454	17.8	process.		73.5
44	AM	384	22	. 12.2		73.5
45	AM	433	20,1	10.7		42.2
48	AM	367	13.2	56.5		22
51	AM	388		44.8	•	
54	AM					
57	AM					
72	AM					
180	AM					

Table 13h-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 10

Day	<u>Time</u>	QTc	Halo +	<u>Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	398				
1	.5HR	392		•		
1	1HR	400				
1	2HR	402	19.6	28.8		
1	3HR	409	63.2	72.8		29.3
1	4HR	399	103	88.5	15.1	31
1	6HR	395	86.9	66	16.5	-33.7
1	8HR	396	75.5	61.7	16.7	33.7
1	10HR	406	58.1	56.2		32.2
1	12HR	400	43.5	47.6		23
2	PRE	377	23.3	21.4		20.4
3、	PRE	404	20	12.4		33.5
4	PRE	404	28.4	23.3	18.4	45.9
4	2HR	413	32.9	30	19.2	51.8
4	4HR	412	70.9	56.9	19.4	70.1
4	6HR	405	63.2	46.7	20.2	66.8
4	8HR	412	49.2	37.1	24.8	73.1
4	12HR	414	34.1	23	24.2	68.7
5	PRE	412	24.3	15.4	21.7	71.4
6	PRE	409	20.5	16.5	19.2	71
7	PRE	410	19.8	14.2		51
7	· 2HR	419	43.5	37.5		60
7	4HR	405	63.3	54.6	19	79
7	6HR	399	65.4	63.9	18.8	70.3
7	8HR	418	51.7	43.9	16.5	67.4
7	12HR	406	31.4	25.1		54.3
8	PRE	414	29.1	21.4	15.3	61.1
9	PRE .	414	81.7	50.4	28.8	104
10	PRE	438	62	45.4	22.1	103
11	PRE	420	45.1	32.1	33.5	137
12	PRE	418	58.1	34.7	22.1	90.6
13	PRE	406	47.6	28	20.3	81.9
14	PRE	402	56.2	45.2	18	73.7
14	2HR	406	167	140	20.9	96.9
14	4HR	442	334	359	36.8	132
14	6HR	439	259	192	40.8	150
14	8HR	450	283	196	48.3	156
14	12HR	420	178	109	40.2	152

Table 13h-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 10

Day	<u>Time</u>	QTc	Halo +	<u>Halo -</u>	Metab +	<u>Metab</u> -
15	PRE	440	98.6	57.7	45.3	207
16	PRE	420	83.6	45.4	41.4	202
17	PRE	415	65.9	37.4	33.5	200
18	PRE	403	224	200	43.7	245
19	PRE	433	359	333	47.4	209
20	PRE	451	278	192	55.5	213
21	PRE	429	254	172	61.1	255
21	2HR	446	173	109	44.7	200
21	4HR	416	95.1	51.1	38.5	212
21	6HR	405	98.4	62.7	46.4	232
21	8HR	432	87.9	53.5	36	216
21 、	12HR	414	136	82.1	43.5	215
22	PRE		,			
25	PRE	377	118	64.5	57.4	287
29	PRE	414	94.6	47.4	50.3	301
32	PRE	413	67.8	35.6	26.1	178
33	PRE	373	83.7	44	31.7	236
36	PRE	392	54.5	37.8	19.8	151
39	PRE	379	165	124	54.9	403
42	PRE	445	435	468	44.1	481
42	.5HR	436	318	261	48.7	324
42	1HR	411	303	234	68.2	431
42	2HR	410	204	150	47.4	326
42	3HR	419	259	184	55.9	340
42	4HR	418	203	128	56.3	314
42	6HR	430	127	80.5	60.3	420
42	8HR	415	58.9	33.3	31.5	255
42	10HR					
42	12HR	406	43.2	37		198
43	AM	411	36.1	.30.9		168
44	AM	404	24.7	23.4		106
45	AM		and the second			
48	AM					
51	AM					
54	AM					
57	AM					
72	AM					
400						

AM

180

Table 13I-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 11

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	<u> Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	412				
1	.5HR	421				
1	1HR	414	17.9	16.9		
1	2HR	409	34.8	27.4		
1	3HR	455	31.2	23		
1	4HR	474	80	50.9	24.2	45.7
1	6HR	414	42.2	24.8		20.8
1	8HR	414	41	22.9	17.2	31
1	10HR	415	39.9	23	16.9	31.3
1	12HR	416	28.4	16.5	17.9	35.7
2	PRE	423	17.1		16.2	31.5
3、	PRE	444	83.1	47.5	44	100
4	PRE	435	44.8	22.1	40.9	96.3
4	2HR	425	63.4	44.6	41.4	95
4	4HR	437	134	96.9	59.7	164
4	6HR	416	103	69.9	53.8	137
4	8HR	448	99.4	65.6	51.9	137
4	12HR	439	79.3	48.7	45.1	125
5	PRE	439	48.5	29.5	41,6	103
6	PRÉ	444	57.6	34.4	46.8	139
7	PRE	421	32.5	21.6	29.8	84.8
7	2HR	434	55.4	42.4	30.6	101
7	4HR	424	109	79.1	47.5	142
7	6HR	429	85.8	56.7	36.2	103
7	8HR	437	75	49.1	33.6	94.8
7	12HR	410	59.3	37.5	32.9	93.4
8	PRE	424	33.3	20	32	96.9
9	PRE	423	43.5	25.8	35.7	126
10	PRE	430	34.1	21.1	25.6	86.6
11	PRE	427	41.7	26.2	26.6	97.4
12	PRE	412	41.3	23.7	27.7	102
13	PRE	407	58.5	36.4	42.1	167
14	PRE	438	43.9	31.3	32	135
14	2HR	409	67.2	52.7	25.9	102
14	4HR	447	216	205	41.1	157
14	6HR	436	302	264	47.5	167
14	8HR	439	324	269	41.8	133
14	12HR	452	187	159	50.3	155

Table 13I-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 11

Day	Time	QTc	<u>Halo +</u>	Halo -	Metab +	Metab -
15	PRE	431	73.9	41.7	44.4	193
16	PRE	458	60.5	30.9	33.6	137
17	PRE .	451	65.6	34.6	27.7	130
18	PRE	454	67.1	40.4	31.3	118
19	PRE	441	86.2	58.9	27	98.7
20	PRE	450	127	87.4	39.3	195
21	PRE	483	96.8	65.6	32.7	131
21	. 2HR	438	81.4	50.8	39.3	176
21	4HR	440	56.1	29.9	27.5	120
21	6HR	474	54.1	29.1	32.9	125
21	8HR	441	46.4	25.8	28.9	150
21、	12HR	438	63.4	37.8	35.7	154
22	PRE		,			
25	PRE		Ź			
29	PRE	452	72.3	42	58.1	201
32	PRE	473	54.5	30.1	39.5	201
33	PRE	434	49.4	27.3	39.7	166
36	PRE	418	60.3	39.6	48.2	203
39	PRE	451	142	115	66.1	319
42	PRE	491	176	127	65.6	307
42	.5HR	476	205	147	74	390
42	1HR	478	135	93.6	49.8	233
42	2HR	471	111	67.8	51.9	230
42	3HR	425	155	98.2	77.6	367
42	4HR	450	92.9	55.2	46.8	251
42	6HR	434	54.2	31.5	45.4	225
42	8HR	427	43.6	24.3	35.7	204
42	10HR	463	38.5	22.3	24.4	162
42	12HR					
43	AM			garan. Gara		
44	ΑM			•		
45	AM		e de la companya de la companya de la companya de la companya de la companya de la companya de la companya de			
48	AM					
51	AM					
54	AM					
57	AM					
72	AM					
180	AM					

Table 13j-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 14

<u>Day</u>	Time	QTc	Halo +	<u> Halo -</u>	Metab +	<u>Metab</u> -
1	PRE	403				
1	.5HR	406				
1	1HR	399			•	
1	2HR	421	11.2			
1	3HR	416	24.8	13.7		
1	4HR	389	44	19.5		17.1
1	6HR	385	49.2	22.3		15.6
1	8HR	426	50.4	20.7		19.1
1	10HR	419	50.7	19.7		22.6
1	12HR	426	34.5	12.7		22.3
2	PRE	420	18.9	•		18.8
3、	PRE	403	16.9			19.4
4	PRE	408	28.4			33.3
4	2HR	412	39.8	19.2		38.6
4	4HR	410	48.7	23.7	15.8	59.8
4	6HR	403	68	29.1	15.8	59.5
4	8HR	407	44.8	15		33.6
4	12HR	398	38.6	13.2		45.8
5	PRE	404	28.7	10.3		29.6
6	PRE	419	47.1	17.3		83.3
7	PRE	412	52.5	17.6		53.4
7	2HR	413	40.9	23.9		59.2
7	4HR	416	66	27		70.5
7	6HR	412	73.3	29.6	18.2	84.7
7	8HR	420	53.3	19.9		63
7	12HR	420	45.6	13.6		51.1
8	PRE	413	39.2	12.9		55.1
9	PRE	413	50.3	16.9	15.6	72
10	PRE	424	96.8	33.6	26.5	116
11	PRE	428	99.7	33.3	20.5	97.8
12	PRE	421	99.5	30	28.6	155
13	PRE	418	71.6	23.9	25.2	196
14	PRE	413	73.3	22.8	28.4	195
14	2HR	419	99.8	40.4	34.4	298
14	4HR	413	168	82.6	50	320
14	6HR	413	176	87.9	44	317
14	8HR	405	182	84	55.5	374
14	12HR	417	104	42	39.6	299

180

ΑM

Table 13j-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 14

<u>Day</u>	<u>Time</u>	QTc	Halo +	<u>Halo -</u>	Metab +	<u>Metab -</u>
15	PRE	422	91.6	29.1	35.2	320
16	PRE	421	90	27.6	31.2	303
17	PRE	421	60.4	18.4	20	199
18	PRE	415	156	69.5	37.8	336
19	PRE	413	154	65.1	31.2	233
20	PRE	420	140	62.2	29.9	244
21	PRE	414	99.8	40.9	23.1	176
21	2HR	421	86.2	29.1	22.1	161
21	4HR	416	74.7	22.6	29.4	292
21	6HR	444	126	38.3	32.8	339
21	8HR	450	272	91.3	56.3	460
21、	12HR	430	215	72.6	38	311
22`	PRE		,			
25	PRE	448	206	61.6	48.5	401
29	PRE	438	223	70.6	54.5	405
32	PRE					
33	PRE					
36	PRE					
39	PRE					
42	PRE					
42	.5HR					
42	1HR					
42	2HR					
42	3HR					
42	4HR					
42	6HR					
42	8HR					
42	10HR					
42	12HR					
43	AM					
44	AM					
45	AM					
48	AM					
51	AM					
54	AM					
57 70	AM					
72	AM					

Table 13k-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 15

<u>Day</u>	<u>Time</u>	QTc	<u> Halo +</u>	<u>Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	401			,	
1	.5HR	388	•			
1	1HR	349				
1	2HR	395	23.9	19.6		
1	3HR	374	28.6	19.9		
1	4HR	395	44	26.9		15.7
1	6HR	397	43.7	23.9		
1	8HR	392	38.6	20.7		
1	10HR	388	31.9	14.1		
1	12HR	388	22.3			
2	PRE	399	13			
3 \	PRE	405	39.1	18.8		23.9
. 4	PRE	381	33.7	14		50.3
4	2HR	416	61.1	37.1		58.1
4	4HR	396	70.6	39.7	18	88.6
4	6HR	383	70.2	36.5	22.3	108
4	8HR	401	59.7	28.3	20.9	89.7
4	12HR	381	47.3	. 21		68.8
5	PRE	388	33.2	12.2		41
6	PRE	404	35.1	13	16.9	89
7	PRE	398	34.6	12.2	16.3	97.5
7	2HR	383	58.5	33.8	15.3	87.9
7	4HR	395	100	57.7	20.9	149
7	6HR	365	98.2	54.4	20	112
7	8HR	394	72.6	36.9		53.8
7	12HR	371	68.8	27.5		49.2
8	PRE	397	34.8	14.4		83.6
9	PRE	396	30.4	13.3		55.1
10	PRE	401	47.1	22.1	20	120
11	PRE	404	50.4	23.7	16.7	102
12	PRE	388	49.7	22.8	20.2	135
13	PRE	401	35.1	17.7	16.9	110
14	PRE	396	53.1	24.8	19.8	154
14	2HR	398	94.8	61.6	27.5	186
14	4HR	430	107	65.2	36.2	221
14	6HR	410	138	75.5	22.3	137
14	8HR	409	121	64.9	30.8	180
14	12HR	398	91.5	41.1	24.4	169

Table 13k-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 15

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	<u> Halo -</u>	<u>Metab +</u>	<u>Metab</u> -
15	PRE	409	51.6	23.1	21.3	167
16	PRE	397	53.8	29.5	21.3	188
17	PRE	392	38.2	17		137
18	PRE	401	85.4	49.4	20.7	180
19	PRE	435	142	94.3	31.8	250
20	PRE	416	145	92.5	22.3	173
21 -	PRE	409	125	76.3	31.2	251
21	2HR	403	89.6	50.1	20.9	178
21	4HR	394	49.7	24.8	28.7	221
21	6HR	423	40.1	18.5	22.9	161
21	8HR	418	86.2	43.9	42	319
21 \	12HR	402	94.5	48.7	42	346
. 22	PRE		/			
25	PRE	407	77.9	34.5	33.1	332
29	PRE	404	75.4	36.5	36.4	342
32	PRE	406	76.1	35.8		182
33	PRE	393	90.5	44.8	20.2	242
36	PRE	410	100	54.1	31.2	375
39	PRE	392	108	56.8	18.8	199
42	PRE	414	151	86	52.3	514
42	.5HR	389	138	73.5	39.1	372
42	1HR	408	123	64.4	19.6	163
42	2HR	404	124	66.2	26.7	270
42	3HR	402	114	58.1	29.1	284
42	4HR	420	128	66.9	38.3	326
42	6HR	415	89.1	42.7	34.3	406
42	8HR	401	65.8	32	20.9	270
42	10HR	395	46.2	22.1	17.3	272
42	12HR	389	33	12.8		188
43	AM	399	26.2	e de la companya de la companya de la companya de la companya de la companya de la companya de la companya de La companya de la co		106
44	AM	347	31.5	12.4		72.2
45	AM	383	20.2			26.9
48	AM	432	22.1			
51	AM	397				
54	AM					
57	AM					
72	AM					
180	AM					

Table 13L-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 16

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	<u>Halo</u> -	Metab +	<u>Metab</u> -
1	PRE	380				
1	.5HR	396				
1	1HR	393				
1	2HR	390	18.1	12.9		
1	3HR	400	38.7	25.9		
1	4HR	400	40.3	24.4		
1	6HR	394	21.7	11.1		
1	8HR	374	19.8			
1	10HR	400	20.1	10.2		16.6
1	12HR	400	20.6			19.5
2	PRE	392	11		•	18.5
3 、	PRE	382	18.9			49.1
4	PRE	399	28.5	13.6		78.1
4	2HR	395	51.2	30.4		85.1
4	4HR	396	94.1	54.3	18.7	132
4	6HR	399	68.6	37.2	18.2	99.5
4	8HR	401	55.7	28.6		77.5
4	12HR	401	46.9	23.4	22.7	128
5	PRE	403	35.2	16.6	17.6	123
6	PRE	404	42.7	20.7	29.3	200
7	PRE	405	53.1	24.1	36.7	267
7	2HR	404	83.3	50.3	35.6	238
7	4HR	401	153	87.3	24.7	157
7	6HR	400	189	105	20.7	146
7	8HR	399	128	66.8	34.7	214
7	12HR	407	87.3	43.7	35.6	254
8	PRE	406	49.1	23.4	27.6	226
9	PRE	405	57.5	26.1	32.7	256
10	PRE	400	55.4	24.9	41.6	335
11	PRE	408	58.5	27.9	31.6	292
12	PRE	397	57.1	28.7	31.6	290
13	PRE	411	67.5	29.4	33.3	317
14	PRE	402	64.8	27.9	32.5	334
14	2HR	416	73.8	38.7	36.5	354
14	4HR	403	107	57.6	52.2	462
14	6HR	404	132	68.9	55.9	473
14	8HR	403	90.9	46.8	48.7	430
14	12HR	400	101	44.2	48.7	430

Table 13L-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 16

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	<u> Halo -</u>	Metab +	<u>Metab -</u>
15	PRE	403	81.8	35.1	49.6	
16	PRE	411	94	40.9	51.9	561
17	PRE	404	97.7	38.6	43.3	588 534
18	PRE	391	110	58.3	43.9	521 507
19	PRE	421	219	125	45.9 45	587 549
20	PRE	414	215	120	45.6	548 533
21	PRE	410	152	80.8	68.7	532
21	2HR	411	151	69.6	51.6	715
21	4HR	400	91.5	39.2	37.6	492
21	6HR	420	85.9	36.1	44.2	552 560
21	8HR	426	69.8	30.7	34.7	569
21 \	12HR	434	138	66.9	41.6	393
22	PRE			00.0	41.0	510
25	PRE	424	152	68.4	47.9	497
29	PRE	427	242	115	73	594
32	PRE	438	87.7	39.7	28.2	335
33	PRE	420	108	47.8	31.9	375
36	PRE	407	90.5	41.2	32.2	344
39	PRE	403	120	63.3	32.2	381
42	PRE	433	208	114	47.9	524
42	.5HR	408	242	137	43.3	480
42	1HR	416	183	96.5	28.2	383
42	2HR	414	143	71.4	33	363
42	3HR	410	178	86.3	42.7	484
42	4HR	415	119	57.8	33.3	368
42	6HR	419	114	49.6	28.5	377
42	8HR	422	114	46.6	41	563
42	10HR					
42	12HR			•		
43	AM			and the second second		
44	AM		armin .	. • • •		
45	AM		. **			·
48	AM	399	21.1			38.9
51	AM	416				33.0
54	AM					
57	AM					
72	AM					
180	AM -					

Table 13m-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 18

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	Halo -	Metab +	<u>Metab</u> -
1	PRE	403				
1	.5HR	394				
1	1HR	400				
1	2HR	409	24.1	20.5	28.4	
1	3HR	403	82.5	75.1	16.5	22.6
1	4HR	403	147	128	15.5	22.6
1	6HR	402	105	83.2	. 16.3	23.3
1	8HR	403	85.9	58.9	18.5	31.3
1	10HR	409	76.2	49.3	15.5	32.7
1	12HR	402	61.2	38.3	16.3	28.9
2	PRE	409	60.6	26.6	20.4	95.7
3	PRE	411	29.3	15		24.8
4	PRE	416	67.1	31.1	23.4	124
4	2HR	412	74.3	42.3	19.5	116
4	4HR	413	116	74.2	25.4	138
4	6HR	441	156	94.3	23.2	126
4	8HR	411	114	64.4	19.5	91.6
4	12HR	415	95.9	48	18.9	96.8
5	PRE	422	60.5	27.8	25.6	135
6	PRE	415	66	32.3	31.2	190
7	PRE	421	114	56.4	27.2	182
7	2HR	410	82.4	45.2	26	153
7	4HR	438	224	158	33.4	213
7	6HR	435	226	153	28.2	191
7	8HR	422	87.4	41.9	24.8	207
7	12HR	421	141	78.4	26	153
8	PRE	418	87.9	41	28.6	204
9	PRE	451	82.2	35.8	27	235
10	PRE	422	91.2	41.2	32.8	235
11	PRE	416	85.4	37.1	39	239
12	PRE	419	103	43.4	38.2	299
13	PRE	440	85	37.1	26.4	265
14	PRE	430	87.9	36.8	28.4	267
14	2HR	425	171	102	35	222
14	4HR	428	166	107	37.6	293
14	6HR	425	149	95.6	30.2	306
14	8HR	420	118	67.1	26.4	267
14	12HR	428	125	62.6	33.8	218

Table 13m-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 18

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	<u>Halo -</u>	Metab +	<u>Metab -</u>
15	PRE	452	86.5	35.4	28.4	216
16	PRE	432	81.3	33.9	28.2	219
17	PRE	426	90.8	36.8	27.8	202
18	PRE	414	113	57.9	31.8	254
19	PRE	437	147	82.6	23.4	245
20	PRE	446	186	102	31.4	227
21	PRE	428	166	83.1	30.8	253
21	2HR	428	116	52.7	23.2	211
21	4HR	431	93	37.1	27.6	197
21	6HR	450	56.7	24.7	17.7	212
21	8HR	426	70.1	32.7	19.7	182
21、	12HR	453	157	87.4	29.8	173
22 `	PRE					
25	PRE					
29	PRE					
32	PRE	475	213	112	39.2	384
33	PRE	462	215	127	37.8	389
36	PRE	456	201	117	37.8	377
39	PRE	434	209	159	38.4	438
42	PRE	464	219	157	33.8	394
42	.5HR	454	293	204	33.6	393
42	1HR	420	311	198	43.3	402
42	2HR	415	260	166	37.8	352
42	3HR	426	237	133	45.3	335
42	4HR	428	247	128	32.8	353
42	6HR	423	165	80	31.8	294
42	8HR	445				
42	10HR	440	110	47.3	18.1	273
42	12HR		54.8	20.7	17.7	291
43	AM	424	58.9	21.7		215
44	AM	419	42.3	20.2	•	141
45	AM	415	42.7	17.3		73.2
48	AM	416	. 27.7	14		43.3
51	AM					
54	AM					
57	AM					
72	AM					
180	AM					

Table 13n-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 19

<u>Day</u>	Time	QTc	Halo +	<u>Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	395				
1	.5HR	377				
1	1HR	366	26.6	23.2		
1	2HR	389	40.7	34.7	18.4	
1	3HR	404	48	34.5	15.8	•
1	4HR	418	40.9	27.8		
1	6HR	402	60.4	37.4		17.2
1	8HR	402	37.8	20.8		15.3
1	10HR	405	45.2	24.7		15.3
1	12HR	404	34.3	19.2	•	20.1
2	PRE	402	26.6	13.4	22	16.4
3 、	PRE-	422	44.7	26.9		33.6
4 `	PRE	410	50.4	29	15.5	40.2
4	2HR	404	65	43.1	23.1	60
4	4HR	409	151	115	23.6	62.2
4	6HR	410	145	107		65.6
4	8HR	418	110	77.9	23.1	77
4	12HR	404	66	44.2		58.5
5	PRE	404	50.5	31.4		66.9
6	PRE	404	52.5	31.6	15.5	88.6
7	PRE	403	53.6	27.8	15.8	99.5
7	2HR		104	78.8		116
7	4HR	403	155	121	17.2	115
7	6HR	413	130	99.7		107
7	8HR	421	87.8	67.9		49.5
7	12HR	408	81.9	53		68
8	PRE	403	61	46.6	15.3	120
9	PRE	409	44.5	32.1	15.5	119
10	PRE	406	64	45.2	27.7	157
11	PRE	407	57.5	37.7	20.5	147
12	PRE	408	60.9	44.1	25.3	187
13	PRE	393	57.8	37.7	22.2	176
14	PRE	416	59.9	35.7	23.9	222
14	2HR		98.1	68.9	26	242
14	4HR		210	131	17.7	223
14	6HR		197	120	18.9	151
14	8HR		164	103	24.8	179
14	12HR		121	65.7		110

Table 13n-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 19


<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	<u> Halo -</u>	Metab +	<u>Metab -</u>
15	PRE	. 411	86.7	45.6		136
16	PRE	408	110	59.5		127
17	PRE	396	89.9	66.8	20.1	183
18	PRE	404	51.1	41.9		138
19	PRE	407	123	88.8		109
20	PRE	405	76.3	73.7	26.2	248
21	PRE	405	77.9	59.4	34.3	285
21	2HR	405	43.4	32.9	17	166
21	4HR	410	33	22.6	19.8	186
21	6HR	408	29.6	17.8		188
21	8HR	411	37.3	24.9	17.4	231
21 、	12HR	442	40.1	27.1	18.9	217
22 `	PRE		52	33.7	21.7	278
25	PRE	420	49.6	32.4	21.2	231
29	PRE	401	55.2	35.5	29.3	309
32	PRE	440	44.9	30		179
33	PRE	409	45.9	29		200
36	PRE	398	56.4	38.1	21.7	253
39	PRE	405	74.2	55	19.3	259
42	PRE	416	105	77	28.1	298
42	.5HR	406	106	70.3	23.9	278
42	1HR	403	149	87.6	33.1	293
42	2HR	410	101	63.5	33.8	271
42	3HR	403	82.2	51.4	28.4	286
42	4HR	410	80.6	46.3	23.1	268
42	6HR	406	61.5	35.8	19.1	247
42	8HR	398	40.8	22.1	16.7	214
42	10HR	393	32	17.6	18.6	236
42	12HR	406	27.8	11.8		72.5
43	AM	415	19.5	10.5		97.6
44	AM	367	15.8	10.2		50
45	AM	401	13,1	11		28
48	AM	403				
51	AM					
54	AM					
57	AM					
72	AM					
180	AM					

Table 13o-1: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 20

<u>Day</u>	Time	QTc	Halo +	<u>Halo -</u>	Metab +	<u>Metab -</u>
1	PRE	422				
1	.5HR	392				
1	1HR	415				
1	2HR	404				
1	3HR	402	14.8	13.8		18.2
1	4HR	402	24.2	18.1		24.6
1	6HR	398	19.5	12.9		29.4
1	8HR	398	12.7			29
1	10HR	392				30.3
1	12HR	402				31.7
2	PRE	4368			47.5	48.7
3	PRE	383				48
4	PRE	397	15	11.5	23.6	105
4	2HR	422	22.3	20.2	24	92.7
4	4HR	404				106
4	6HR	403				26
4	8HR	413	36	26	32.3	139
4	12HR	416	30.2	23.4	26	108
5	PRE	378	17.6	12.1	23.1	113
6	PRE	411	19.2	15.8	28.7	128
7	PRE	407	20.1	15.4	22.1	147
7	2HR	411	30	23.9	29.1	159
7	4HR	413	82.2	68.7	181	201
7	6HR	408	39.5	32.9	28.5	155
7	8HR	400	38.2	28.7	31.4	159
7	12HR	405	30	17.7	25.8	131
8	PRE	411	24.2	20.5	28.7	169
9	PRE	407	23.2	20	29.4	169
10	PRE	413	28.2	17.9	_ 26	184
11	PRE	409	23.1	17.9	31.8	184
12	PRE	425	20.4	14.7	29.4	183
13	PRE	415	29.3	23	34.1	190
14	PRE	411	29.7	22	26.9	183
14	2HR	405	28.2	20.5	22.5	178
14	4HR	410	47.1	36.9	40.7	176
14	6HR	410	40.5	29	37	205
14	8HR	426	55.2	42.1	36	209
14	12HR	424	50	30.8	26.5	171

Table 13o-2: QTc Intervals and Halofantrine / Metabolite Concentrations for Subject 20

<u>Day</u>	<u>Time</u>	QTc	<u>Halo +</u>	Halo -	Metab +	<u> Metab -</u>
15	PRE	402				20
16	PRE	409	32.9	23.2	21.1	162
17	PRE	410	36.5	20.4	21.9	134
18	PRE	411	41.6	33.8	27.9	176
19	PRE	417	83.8	59.7	33.3	192
20	PRE	417	51.7	34.8	26.5	163
21	PRE	432	56	37.3	25.6	170
21	2HR	416	45.6	30.4	31.	154
21	4HR	424	19.2	13.1	20.7	153
21	6HR	415	40.8	24.6	18.6	115
21	8HR	448	78.4	57.1	39.1	201
21、	12HR	426	41.1	26	49	329
22 `	PRE		35.9	22.5	42	264
25	PRE	427	36.9	18.1	53.1	420
29	PRE	421	22.4	14.4	43	385
32	PRE	438	33.8	17	28.5	304
33	PRE	437	27	17.2	33	330
36	PRE	425	40.8	24.8	40.9	389
39	PRE	428	35.7	26.4	38.7	346
42	PRE	442	71	57.5	49.3	424
42	.5HR	442	66.1	50.2	45.9	416
42	1HR	435	80.3	53.4	41.1	386
42	2HR	420	63.6	42.8	45.9	429
42	3HR	416	57.3	37.3	42.7	383
42	4HR	425	49.5	37.7	41.6	304
42	6HR	414	34.3	22.3	33.2	309
42	8HR	411	21.7	14.2	31.4	283
42	10HR	411	17.4		24.2	309
42	12HR	412				159
43	AM	414		, de Late		117
44	AM	407	a se anima e	**		
45	AM	382			34.8	51.9
48	AM	409	18.9		31.9	48.8
51	AM		12.9		29.4	64
54	AM					
57	AM					
72	AM					
180	AM					







Figure 55a: Halofantrine and Metabolite Concentrations for Subject 01



200 → Metab (+) -0- Metab (-) ← Halo (+) → Halo (-) 180 Figure 55b: Halofantrine and Metabolite Concentrations for Subject 02 160 140 120 100 80 9 40 ∞ 20 1000 10 100 Concentration (ng/mL)

Dec. 17, 1998

200 ● Metab (+) -0- Metab (-) → Halo (+) →- Halo (-) 180 Figure 55c: Halofantrine and Metabolite Concentrations for Subject 04 160 140 120 Time (days) 100 80 9 40 20 10 100 1000 Concentration (ng/mL)

Page 212

200 — Metab (+) -O- Metab (-) ← Halo (+) -->-- Halo (-) 180 Figure 55d: Halofantrine and Metabolite Concentrations for Subject 05 160 140 120 100 80 9 0 40 20 10 1000 100 Concentration (ng/mL)


Dec. 17, 1998

Time (days)

200 -o- Metab (-) ► Halo (+) --<-- Halo (-) 180 Figure 55e: Halofantrine and Metabolite Concentrations for Subject 07 160 140 120 100 80 60 40 20 0 10 100 Concentration (ng/mL)

Dec. 17, 1998

Time (days)




200 ——— Metab (+) -0- Metab (-) – Halo (+) -->-- Halo (-) 180 Figure 55g: Halofantrine and Metabolite Concentrations for Subject 09 160 140 120 Time (days) 100 80 60 40 20 1000 100 Concentration (ng/mL)

200 —●— Metab (+) -o- Metab (-) – Halo (+) -->- Halo (-) 180 Figure 55h: Halofantrine and Metabolite Concentrations for Subject 10 160 140 120 Time (days) 100 80 9 40 20 10 1000 100 Concentration (ng/mL)

Dec. 17, 1998

Figure 55I: Halofantrine and Metabolite Concentrations for Subject 11



200 —●– Metab (+) -o- Metab (-) —◆– Halo (+) -->- Halo (-) 180 Figure 55j: Halofantrine and Metabolite Concentrations for Subject 14 160 140 120 100 80 9 40 20 0 100 1000 Concentration (ng/mL)

Dec. 17, 1998


Time (days)

200 -o- Metab (-) – Halo (+) --<-- Halo (-) 180 Figure 55k: Halofantrine and Metabolite Concentrations for Subject 15 160 140 120 Time (days) 100 80 60 \Diamond 40 20 0 10 1000 100 Concentration (ng/mL)

Dec. 17, 1998

200 → Metab (+) -o- Metab (-) -- Halo (+) ->- Halo (-) 180 Figure 55L: Halofantrine and Metabolite Concentrations for Subject 16 160 140 120 Time (days) 100 80 0 9 40 20 0 1000 100 Concentration (ng/mL)

Dec. 17, 1998



200 ——— Metab (+) -- O-- Metab (-) -->-- Halo (-) – Halo (+) 180 Figure 55n: Halofantrine and Metabolite Concentrations for Subject 19 160 140 120 100 80 9 40 20 0 19 1000 100 Concentration (ng/mL)

Time (days)

Figure 550: Halofantrine and Metabolite Concentrations for Subject 20






Figure 56a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 01



QTc = 392.1 + 0.1281 * Halo(+)

Correlation Coeficient (r) = 0.361

Figure 56b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 01




QTc = 394.2 + 0.1979 * Halo(-)

Correlation Coeficient (r) = 0.308


Page 226

Figure 57a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 02




$$QTc = 412.2 + 0.1748 * Halo(+)$$

Figure 57b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 02



$$QTc = 417.2 + 0.1904 * Halo(-)$$

Figure 58a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 04




QTc = 398.2 + 0.0318 * Halo(+)

Correlation Coeficient (r) = 0.334

Page 229


Figure 58b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 04



QTc = 400.6 + 0.0287 * Halo(-)

Correlation Coeficient (r) = 0.272


Figure 59a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 05



QTc = 395.3 + 0.0119 * Halo(+)

Correlation Coeficient (r) = 0.021


Figure 59b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 05



QTc = 397.5 + -0.0663 * Halo(-)


Correlation Coeficient (r) = -0.067

Figure 60a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 07




Page 233

Figure 60b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 07



$$QTc = 415.8 + 0.0301 * Halo(-)$$


Figure 61a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 08



QTc = 373.9 + 0.1718 * Halo(+)

Correlation Coeficient (r) = 0.569


Figure 61b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 08



QTc = 378.2 + 0.1927 * Halo(-)

Correlation Coeficient (r) = 0.429


Figure 62a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 09



QTc = 397.1 + 0.1109 * Halo(+)

Correlation Coeficient (r) = 0.238


Figure 62b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 09



QTc = 398.6 + 0.1130 * Halo(-)

Correlation Coeficient (r) = 0.189


Figure 63a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 10



QTc = 403.6 + 0.0903 * Halo(+)

Correlation Coeficient (r) = 0.525


Figure 63b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 10



QTc = 405.9 + 0.0920 * Halo(-)

Correlation Coeficient (r) = 0.487


Figure 64a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 11



QTc = 429.4 + 0.1126 * Halo(+)

Correlation Coeficient (r) = 0.339


Figure 64b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 11



QTc = 433.0 + 0.1025 * Halo(-)

Correlation Coeficient (r) = 0.268


Figure 65a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 14



QTc = 407.0 + 0.1075 * Halo(+)


Correlation Coeficient (r) = 0.522

Figure 65b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 14



$$QTc = 409.9 + 0.1938 * Halo(-)$$


Figure 66a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 15



QTc = 387.9 + 0.1539 * Halo(+)


Correlation Coeficient (r) = 0.379

Figure 66b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 15




$$QTc = 386.2 + 0.3180 * Halo(-)$$

Figure 67a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 16



QTc = 395.7 + 0.1125 * Halo(+)

Figure 67b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 16




QTc = 400.4 + 0.1452 * Halo(-)

Correlation Coeficient (r) = 0.415


Page 248

Figure 68a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 18



$$QTc = 412.8 + 0.1112 * Halo(+)$$


Figure 68b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 18



QTc = 418.1 + 0.1203 * Halo(-)

Correlation Coeficient (r) = 0.349


Figure 69a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 19



QTc = 402.6 + 0.0566 * Halo(+)


Correlation Coeficient (r) = 0.168

Figure 69b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 19




$$QTc = 403.8 + 0.0583 * Halo(-)$$

Figure 70a: QTc Intervals vs. Halofantrine (+) Concentration for Subject 20



$$QTc = 401.6 + 0.3849 * Halo(+)$$

Figure 70b: QTc Intervals vs. Halofantrine (-) Concentration for Subject 20



$$QTc = 404.0 + 0.4512 * Halo(-)$$